<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>MedRise Board Review</title><link>https://med-rise.com/board-review</link><description>Step 2 CK and shelf exam review: next-step algorithms, mind maps, comparisons and test-day strategy, organized by rotation.</description><language>en-us</language><copyright>&#169; 2026 ViaAI LLC</copyright><lastBuildDate>Fri, 20 Nov 2026 05:59:16 -0600</lastBuildDate><atom:link href="https://med-rise.com/board-review/feed.xml" rel="self" type="application/rss+xml"/><image><url>https://med-rise.com/images/icons/icon-512.png</url><title>MedRise Board Review</title><link>https://med-rise.com/board-review</link></image><item><title>Acute Coronary Syndrome Algorithm for the Medicine Shelf: From the First ECG to Reperfusion</title><link>https://med-rise.com/board-review/acute-coronary-syndrome-algorithm-medicine-shelf</link><guid isPermaLink="true">https://med-rise.com/board-review/acute-coronary-syndrome-algorithm-medicine-shelf</guid><pubDate>Fri, 20 Nov 2026 05:59:16 -0600</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Study guide</category><category>Board Review</category><description>Work up acute coronary syndrome step by step for the medicine shelf: the 10-minute ECG, PCI vs fibrinolysis timing, cardiogenic shock and NSTE-ACS risk.</description><content:encoded><![CDATA[<p>On the medicine shelf, an acute coronary syndrome question pairs chest pressure with an ECG and a clock: how long since the pain began, how far away the cath lab is, or whether a troponin is rising. It tests the order of decisions: read the ECG first, then match the patient to primary PCI, fibrinolysis and transfer, emergency revascularization for shock, or risk-based timing for NSTE-ACS.</p>

<h2>The algorithm</h2>
<p>The first ECG splits the pathway. Steps 2 to 7 are the STEMI branch, step 8 is NSTE-ACS, and step 9 applies to every patient with ACS.</p>
<ol class="sp-flow"><li><span>ECG within 10 minutes<small>Acquire and read a 12-lead ECG within 10 minutes of first medical contact. New ST elevation of 1 mm or more in 2 contiguous leads (in V2–V3: 2 mm in men 40 and older, 2.5 mm in men under 40, 1.5 mm in women) means STEMI: go to step 2 and do not wait for a troponin. No ST elevation points to NSTE-ACS (step 8); repeat the ECG if symptoms continue.</small></span></li><li><span>Look for the hidden patterns<small>Inferior STEMI: get right-sided leads to look for right ventricular involvement. Isolated ST depression of 0.5 mm or more in V1–V3: get posterior leads V7–V9, because this can be a posterior STEMI from a circumflex occlusion. A presumably new left bundle branch block on its own does not diagnose MI.</small></span></li><li><span>Give what does not delay reperfusion<small>Chewed aspirin 162–325 mg. Oxygen only if SpO2 is below 90%. Nitroglycerin only if systolic pressure is 90 mm Hg or more, with no suspected RV infarct and no sildenafil in the past 24 hours or tadalafil in the past 48 hours. No NSAIDs.</small></span></li><li><span>Pick reperfusion by the clock<small>Symptoms under 12 hours: primary PCI with a first-contact-to-device goal of 90 minutes or less, or 120 minutes or less when transfer is needed. Expected delay to PCI over 120 minutes and no contraindication: start a fibrinolytic within 30 minutes of arrival. Onset 12 to 24 hours: primary PCI is reasonable. Over 24 hours and stable with no ongoing ischemia: no PCI of the occluded artery.</small></span></li><li><span>Screen for fibrinolysis contraindications<small>Absolute: any prior intracranial hemorrhage, a known cerebral vascular lesion or intracranial cancer, ischemic stroke within 3 months, suspected aortic dissection, active bleeding (not menses), significant head or facial trauma within 3 months, intracranial or spinal surgery within 2 months, and blood pressure above 180/110 mm Hg despite treatment. Any of these: transfer for PCI even if it takes longer.</small></span></li><li><span>After fibrinolysis, transfer anyway<small>Transfer to a PCI center right after the drug, with clopidogrel and an anticoagulant. Reperfused: angiography between 2 and 24 hours. Failed reperfusion (ongoing pain, less than 50% ST resolution in the anterior leads or less than 70% in the inferior leads, or instability) or shock: immediate angiography and rescue PCI.</small></span></li><li><span>Cardiogenic shock overrides the clock<small>ACS with shock or hemodynamic instability: emergency revascularization of the culprit vessel by PCI or CABG, whatever the time from onset. Treat only the culprit artery at that procedure.</small></span></li><li><span>NSTE-ACS: troponin, then risk<small>Check a high-sensitivity troponin now and again at 1 to 2 hours. Give aspirin and IV heparin. Refractory angina or hemodynamic or electrical instability: immediate invasive strategy. High risk: angiography within 24 hours is reasonable. Intermediate or high risk: an invasive strategy during the admission. Low risk: routine or selective invasive approach.</small></span></li><li><span>Lock in secondary prevention<small>For PCI, ticagrelor or prasugrel over clopidogrel (no prasugrel after a stroke or TIA), with dual antiplatelet therapy for at least 12 months unless bleeding risk is high. Oral beta-blocker within 24 hours unless there are signs of heart failure, low output, risk of shock or another contraindication. High-intensity statin for everyone; add a nonstatin drug if LDL-C stays at 70 mg/dL or more on the maximum tolerated statin.</small></span></li></ol>
<p>Thresholds follow the 2025 ACC/AHA guideline; the 30-minute lytic target in step 4 comes from StatPearls and the 2025 Australian ACS guideline.</p>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Chest pressure for 1 hour, 3-mm ST elevation in V2–V4, cath lab on site</td><td>Anterior STEMI</td><td>Primary PCI, first contact to device in 90 minutes or less</td></tr>
<tr><td>ST elevation in II, III and aVF; blood pressure falls after nitroglycerin; neck veins distended; lungs clear</td><td>Right ventricular infarct</td><td>Right-sided leads, IV fluid bolus, no more nitrates, primary PCI</td></tr>
<tr><td>STEMI for 3 hours, nearest PCI center more than 2 hours away, no contraindications</td><td>PCI delay over 120 minutes</td><td>Fibrinolytic within 30 minutes of arrival, then transfer</td></tr>
<tr><td>90 minutes after tenecteplase: still in pain, ST elevation barely changed</td><td>Failed reperfusion</td><td>Immediate angiography and rescue PCI</td></tr>
<tr><td>STEMI, hemorrhagic stroke 2 years ago, PCI 3 hours away</td><td>Absolute contraindication to fibrinolysis</td><td>Transfer for primary PCI</td></tr>
<tr><td>STEMI 30 hours after onset, cold extremities, systolic pressure 78 mm Hg</td><td>Cardiogenic shock</td><td>Emergency culprit-vessel PCI or CABG, regardless of time from onset</td></tr>
<tr><td>NSTEMI with chest pain despite treatment and runs of ventricular tachycardia</td><td>Unstable NSTE-ACS</td><td>Immediate invasive strategy</td></tr>
<tr><td>Took sildenafil last night, now has chest pain from ACS</td><td>Phosphodiesterase-5 inhibitor within 24 hours</td><td>No nitroglycerin</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Waiting for a troponin in STEMI. The ECG makes the diagnosis; reperfusion is not delayed for biomarkers.</li>
<li>Sending every STEMI for PCI. When the expected delay is over 120 minutes, symptoms began less than 12 hours ago and lysis is safe, the fibrinolytic comes first.</li>
<li>Stopping after the fibrinolytic. Every lysed patient is transferred: angiography in 2 to 24 hours if it worked, rescue PCI now if it did not.</li>
<li>Giving a fibrinolytic for ST depression alone. Unless a true posterior STEMI is suspected, lysis for ST depression causes harm through intracranial and other major bleeding.</li>
<li>Choosing nitroglycerin, furosemide or IV metoprolol for a hypotensive inferior MI. A right ventricular infarct needs preload, and IV beta-blockers raise the risk of cardiogenic shock.</li>
</ul>

<h2>Practice question</h2>
<p>A 58-year-old man comes to the emergency department of a hospital with an on-site catheterization laboratory 1 hour after the onset of crushing substernal chest pain. He has hypertension and smokes. He has taken no phosphodiesterase-5 inhibitor. On arrival, blood pressure is 118/74 mm Hg, pulse 64/min, respirations 18/min and SpO2 96% on room air. ECG shows 2-mm ST elevation in leads II, III and aVF. He chews aspirin 325 mg and receives sublingual nitroglycerin 0.4 mg. Ten minutes later he feels lightheaded; blood pressure is 82/50 mm Hg and pulse 66/min. Jugular venous pressure is elevated, the lungs are clear, and there is no new murmur. A right-sided ECG shows 1.5-mm ST elevation in V4R. The cath team will be ready in 20 minutes.</p>
<p>Which of the following is the most appropriate next step while the team prepares?</p>
<ol type="A">
<li>A second dose of sublingual nitroglycerin</li>
<li>IV furosemide</li>
<li>IV normal saline bolus</li>
<li>IV metoprolol</li>
<li>IV tenecteplase</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: C.</strong> An inferior STEMI with hypotension after nitroglycerin, raised jugular venous pressure, clear lungs and ST elevation in V4R points to right ventricular infarction. The infarcted right ventricle depends on preload, so a crystalloid bolus (for example 500 mL) treats the hypotension while primary PCI stays the plan. Persistent hypotension after fluids calls for an inotrope such as dobutamine.</p>
<p><strong>Why the others are wrong.</strong> A: nitrates are avoided in suspected right ventricular infarction and when systolic pressure is below 90 mm Hg. B: a diuretic cuts preload further, and his lungs are clear. D: a beta-blocker is not given to a hypotensive patient at risk of cardiogenic shock. E: the cath lab is minutes away, so primary PCI is preferred; lysis is for an expected PCI delay over 120 minutes.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>First-contact-to-device goal for primary PCI</strong> 90 minutes or less, or 120 minutes or less with transfer.</li><li><strong>When a fibrinolytic comes before PCI</strong> Onset under 12 hours, expected PCI delay over 120 minutes and no contraindication.</li><li><strong>Angiography timing after successful fibrinolysis</strong> Between 2 and 24 hours.</li><li><strong>Bedside triad of right ventricular infarction</strong> Hypotension, raised jugular venous pressure and clear lungs.</li><li><strong>Revascularization in cardiogenic shock</strong> Emergency culprit-vessel PCI or CABG, regardless of time from onset.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review <a href="https://med-rise.com/board-review/cabgvspci">CABG vs PCI</a>, present a chest pain case with <a href="https://med-rise.com/viva/">MedRise Viva</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>. Test yourself with today's Daily Case on Instagram @medrise_ at 7:30 PM Central, and hear it worked through on the <a href="https://med-rise.com/podcast/">MedRise Podcast</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1016/j.jacc.2024.11.009">Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. J Am Coll Cardiol, 2025 (PubMed)</a></li>
<li><a href="https://professional.heart.org/en/science-news/2025-guideline-for-the-management-of-patients-with-acute-coronary-syndromes/top-things-to-know">American Heart Association. Top things to know: 2025 guideline for acute coronary syndromes, 2025</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/books/NBK532281/">Akbar H, Sharma S. Acute ST-segment elevation myocardial infarction (STEMI). StatPearls, NCBI Bookshelf, updated 2024</a></li>
<li><a href="https://www.statpearls.com/point-of-care/28600">Right ventricular myocardial infarction. StatPearls, updated 2026</a></li>
<li><a href="https://assets.contentstack.io/v3/assets/blt8a393bb3b76c0ede/bltd864bf83673e6b61/ACS-Guideline-summary-for-healthcare-professionals.pdf">National Heart Foundation of Australia, CSANZ. Australian clinical guideline for diagnosing and managing acute coronary syndromes: summary, 2025</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/acute-coronary-syndrome-algorithm-medicine-shelf.jpg" medium="image" type="image/jpeg"/></item><item><title>SIADH Management on Step 2 CK: Why Normal Saline Can Push the Sodium Lower</title><link>https://med-rise.com/board-review/siadh-management-step-2-ck</link><guid isPermaLink="true">https://med-rise.com/board-review/siadh-management-step-2-ck</guid><pubDate>Thu, 19 Nov 2026 14:54:54 -0600</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Guide</category><category>Board Review</category><description>SIADH management for Step 2 CK: why normal saline can lower sodium, when fluid restriction will fail, safe correction limits and a clue-to-next-step table.</description><content:encoded><![CDATA[<p>In SIADH, when the urine osmolality is 600 mOsm/kg, a liter of normal saline delivers about 308 mOsm of solute that the kidney can excrete in roughly half a liter of urine. The other half liter of water stays in the patient.</p>
<p>That is why the most active-looking order on a SIADH question can lower the sodium. A 1997 <a href="https://doi.org/10.7326/0003-4819-126-1-199701010-00003">Annals of Internal Medicine study</a> watched this happen: after surgery with only near-isotonic fluids, plasma sodium fell in 21 of 22 women, by a mean of 4.2 mmol/L in 24 hours, because their urine stayed concentrated.</p>
<p>The first-line fix in both major guidelines is slower than most students expect. In a 2020 <a href="https://doi.org/10.1210/clinem/dgaa619">randomized trial of fluid restriction</a>, limiting fluids to 1 L a day raised sodium by a median of only 3 mmol/L in 3 days. Below is how SIADH management decisions actually run on Step 2 CK, on the shelf and on the wards: who gets 3% saline, who gets restriction, how to predict that restriction will fail, and the speed limit that protects the brain.</p>

<h2>The saline math: concentrated urine turns salt water into free water</h2>
<p>SIADH keeps the collecting duct open to water while sodium handling stays roughly intact. Whatever salt you infuse leaves in urine as concentrated as the ADH allows, and the water you gave with it can stay behind.</p>
<p>Run the numbers yourself, using simplified round figures:</p>
<div class="table-wrap"><table class="sp-table">
<caption>What 1 liter of fluid does when urine osmolality is fixed at 600 mOsm/kg (simplified)</caption>
<thead><tr><th>Fluid</th><th>Solute delivered</th><th>Urine needed to excrete it</th><th>Net water effect</th></tr></thead>
<tbody>
<tr><td>0.9% saline (154 mmol/L NaCl)</td><td>about 308 mOsm</td><td>about 510 mL</td><td>about 490 mL of water retained</td></tr>
<tr><td>3% saline (513 mmol/L NaCl)</td><td>about 1,026 mOsm</td><td>about 1,710 mL</td><td>about 710 mL of water removed</td></tr>
</tbody>
</table></div>
<p>The rule that falls out of the table is the one <a href="https://www.ncbi.nlm.nih.gov/books/NBK507777/">StatPearls</a> states: a fluid only raises the sodium in SIADH if its osmolality is higher than the urine's. Normal saline at about 308 mOsm/L loses to urine at 500 or 600.</p>
<p>The 2013 US expert panel put it bluntly: <a href="https://doi.org/10.1016/j.amjmed.2013.07.006">isotonic saline</a> "is not an effective therapy for hyponatremia resulting from SIADH." It adds that saline can worsen the sodium when urine sodium plus potassium exceeds serum sodium, a ratio you will use again below.</p>

<h2>Seizure, coma or vomiting: 3% saline in boluses, before any workup</h2>
<p>Severe symptoms flip the priority. Brain swelling is the immediate threat, so hypertonic saline comes first and the diagnostic workup follows.</p>
<ul>
<li><strong>US expert panel (2013):</strong> 100 mL of 3% NaCl IV over 10 minutes, repeated up to 3 times as needed.</li>
<li><strong><a href="https://doi.org/10.1530/EJE-13-1020">European guideline (2014)</a>:</strong> 150 mL of 3% saline over 20 minutes, recheck the sodium, and repeat up to twice more or until the sodium has risen 5 mmol/L.</li>
<li><strong>Target:</strong> a quick rise of about 4 to 6 mmol/L; the European guideline sets 5 mmol/L in the first hour.</li>
</ul>
<p>Boluses also beat a slow drip on safety. In the <a href="https://doi.org/10.1001/jamainternmed.2020.5519">SALSA randomized trial</a> of 178 patients with symptomatic hyponatremia, overcorrection rates were similar (17.2% with rapid boluses vs 24.2% with continuous infusion, not significant), but the bolus group needed relowering therapy less often: 41.4% vs 57.1%.</p>
<p>What 3% saline is not for: a patient with mild, chronic symptoms such as fatigue or poor appetite. Giving it there trades a slow problem for an overcorrection risk.</p>

<h2>Everyone else: restrict fluids first, and run a 10-second failure test</h2>
<p>For SIADH without severe symptoms, both guidelines start with fluid restriction. StatPearls frames it as oral water intake under 800 mL a day. The US panel aims for 500 mL a day below the 24-hour urine volume, counting all nonfood fluids, not just water.</p>
<p>Restriction works slowly, and not for everyone. In the 2020 trial of 46 patients with chronic SIADH, 61% of the restricted group reached a sodium of 130 or higher after 3 days, so more than a third did not.</p>
<p>The US panel lists four predictors that restriction will fail:</p>
<ol>
<li>Urine osmolality above 500 mOsm/kg.</li>
<li>Urine sodium plus urine potassium higher than the serum sodium.</li>
<li>24-hour urine volume below 1,500 mL.</li>
<li>Serum sodium rising less than 2 mmol/L a day over 24 to 48 hours on a restriction of 1 L a day or less.</li>
</ol>
<p><strong>Worked example (original numbers):</strong> serum sodium 126, urine sodium 104, urine potassium 38. Urine Na + K = 142, which is higher than 126. The urine is saltier than the plasma, so the kidney is not making free water to lose. Restriction alone is unlikely to work, and you should plan a second-line option now instead of on day 3.</p>
<p>Second-line choices are where the guidelines split:</p>
<div class="table-wrap"><table class="sp-table">
<caption>When fluid restriction fails in SIADH: what the sources say</caption>
<thead><tr><th>Option</th><th>US expert panel (2013) and StatPearls</th><th>European guideline (2014)</th></tr></thead>
<tbody>
<tr><td>Oral urea</td><td>15 to 60 g a day, titrated weekly</td><td>0.25 to 0.50 g/kg a day, a second-line choice</td></tr>
<tr><td>Loop diuretic plus oral salt</td><td>StatPearls: furosemide 20 mg twice daily added to salt tablets</td><td>Equal second-line choice with urea</td></tr>
<tr><td>Tolvaptan (vaptan)</td><td>An option; cites the FDA limit of 30 days or less and no use in underlying liver disease</td><td>Not recommended in moderate hyponatremia; recommended against in profound</td></tr>
<tr><td>Demeclocycline</td><td>600 to 1,200 mg a day; StatPearls calls it nephrotoxic, a last resort</td><td>Recommended against, as is lithium</td></tr>
</tbody>
</table></div>
<p>For an exam-style question, the takeaway is the order: restriction first, a second-line agent when restriction fails, and never a vaptan or demeclocycline as the opening move for mild, chronic SIADH.</p>

<h2>The speed limit: 8 mmol/L a day for high-risk patients, and the rescue if you overshoot</h2>
<p>Raising the sodium too fast in chronic hyponatremia can cause osmotic demyelination. <a href="https://www.ncbi.nlm.nih.gov/books/NBK551697/">StatPearls</a> describes dysphagia, dysarthria, spastic quadriparesis and, in the worst cases, locked-in syndrome, with onset days after the correction, not hours.</p>
<div class="table-wrap"><table class="sp-table">
<caption>Correction limits for chronic hyponatremia</caption>
<thead><tr><th>Source</th><th>Maximum rise</th><th>Who counts as high risk</th></tr></thead>
<tbody>
<tr><td>US expert panel (2013)</td><td>10 to 12 mmol/L in any 24 hours and 18 in 48 hours; 8 mmol/L in any 24 hours if high risk</td><td>Sodium 105 mmol/L or lower, low potassium, alcohol use disorder, malnutrition, advanced liver disease</td></tr>
<tr><td>European guideline (2014)</td><td>10 mmol/L in the first 24 hours, then 8 mmol/L in every 24 hours after</td><td>Applies the same cap to all chronic cases</td></tr>
</tbody>
</table></div>
<p>The US panel also sets a floor: aim for at least 4 to 8 mmol/L a day, or 4 to 6 if the demyelination risk is high. Too slow is a failure too.</p>
<p>If the sodium overshoots, the European guideline says to stop active treatment and, with expert input, give 10 mL/kg of electrolyte-free water (such as a glucose solution) over 1 hour and consider IV desmopressin 2 micrograms, repeated no more often than every 8 hours.</p>
<p>The newest evidence pushes against excessive caution. A 2025 <a href="https://doi.org/10.1001/jamainternmed.2024.5981">JAMA Internal Medicine meta-analysis</a> of 16 cohort studies with 11,811 patients found that correcting severe hyponatremia by 8 to 10 mmol/L or more in 24 hours was linked to fewer in-hospital deaths than slower correction (odds ratio 0.67), without a significant rise in osmotic demyelination.</p>
<p>The caveat is strong: every included study was an observational cohort, and the authors rated the evidence moderate certainty at best, so sicker patients may simply have corrected more slowly. The guidelines have not changed their caps, and exam answers follow them.</p>

<h2>How the exam disguises SIADH: clue to next step</h2>
<p>SIADH questions rarely say "euvolemic" or "SIADH." They plant clues. Translate each one into an action:</p>
<div class="table-wrap"><table class="sp-table">
<caption>Clue-to-next-step table for SIADH (original examples)</caption>
<thead><tr><th>Clue in the stem</th><th>What it means</th><th>Next step</th></tr></thead>
<tbody>
<tr><td>Low sodium with a seizure, coma, deep somnolence or repeated vomiting</td><td>Hyponatremic encephalopathy</td><td>3% saline bolus now; workup after</td></tr>
<tr><td>Moist mucosa, no edema, normal blood pressure; serum osm under 275, urine osm over 100, urine sodium over 40; normal TSH and cortisol</td><td>SIADH by the StatPearls criteria</td><td>Fluid restriction and find the cause</td></tr>
<tr><td>Central lung mass in a smoker, recent stroke or meningitis, pneumonia, or a new SSRI, carbamazepine, oxcarbazepine or cyclophosphamide</td><td>The cause the question planted</td><td>Treat or stop the cause alongside restriction</td></tr>
<tr><td>Sodium drifting down after surgery on isotonic fluids only</td><td>ADH-driven desalination</td><td>More normal saline is not the fix</td></tr>
<tr><td>Urine Na + K above serum Na, or urine osm above 500</td><td>Restriction will likely fail</td><td>Plan urea or a loop diuretic with salt</td></tr>
<tr><td>Sodium up 13 mmol/L in the first 24 hours</td><td>Overcorrection</td><td>Stop therapy; free water and desmopressin with expert input</td></tr>
<tr><td>New trouble speaking and swallowing, then weakness, days after a fast correction</td><td>Osmotic demyelination</td><td>The complication the speed limit exists to prevent</td></tr>
</tbody>
</table></div>
<p>One emerging option is not on that table yet. A <a href="https://doi.org/10.1016/j.beem.2025.102055">review published online in October 2025</a> reports that two randomized placebo-controlled trials found the SGLT2 inhibitor empagliflozin raised sodium in inpatients and outpatients with SIADH. Neither 2013-2014 guideline includes it, so treat it as one to watch, not an exam answer.</p>
<p>SIADH rewards restraint: take water away, check the urine before you trust the plan, and let the sodium climb no faster than the brain can follow.</p>

<p><strong>Today's MedRise study set:</strong> fix the habit behind missed sodium questions with <a href="https://med-rise.com/board-review/hyponatremia-questions-step-2-ck">How to Stop Missing Hyponatremia Questions on Step 2 CK</a>, then run the full workup in the <a href="https://med-rise.com/board-review/hyponatremia-algorithm-medicine-shelf">Hyponatremia Algorithm for the Medicine Shelf</a>. Test yourself with today's Daily Case on Instagram @medrise_ at 7:30 PM Central, and practice explaining the saline math out loud in <a href="https://med-rise.com/viva/">MedRise Viva</a>. More exam resources are on the <a href="https://med-rise.com/medicine/students/">MedRise student page</a>.</p>

<h2>60-second recall</h2><ul><li><strong>SIADH lab pattern</strong> Serum osm under 275, urine osm over 100, high urine sodium, euvolemic, normal TSH and cortisol.</li><li><strong>Why normal saline can lower the sodium</strong> The urine is more concentrated than the saline, so the kidney excretes the salt and keeps the water.</li><li><strong>Seizure, coma or repeated vomiting</strong> 3% saline in boluses, before any workup.</li><li><strong>First-line for chronic mild to moderate SIADH</strong> Fluid restriction.</li><li><strong>Speed limit in high-risk patients</strong> A rise of 8 mmol/L or less in 24 hours.</li></ul>

<h2>FAQ</h2>
<h3>What is the first-line treatment for SIADH?</h3>
<p>Fluid restriction, for patients without severe symptoms. Patients with seizures, coma or other severe symptoms get a 3% saline bolus first.</p>
<h3>Why does normal saline not correct SIADH?</h3>
<p>Under ADH the kidney excretes the infused salt in concentrated urine and keeps much of the water. When urine osmolality is higher than about 308 mOsm/kg, normal saline can leave the patient with extra free water and a lower sodium.</p>
<h3>How fast can sodium be corrected in SIADH?</h3>
<p>For chronic hyponatremia, the European guideline caps the rise at 10 mmol/L in the first 24 hours and 8 mmol/L in each 24 hours after. The US panel caps it at 8 mmol/L in any 24 hours for high-risk patients.</p>
<h3>When is tolvaptan used for SIADH?</h3>
<p>The US panel lists it as an option when restriction is not enough, with the FDA limit of 30 days or less and no use in underlying liver disease. The European guideline does not recommend vaptans for moderate hyponatremia and recommends against them for profound hyponatremia.</p>
<h3>What lab pattern defines SIADH?</h3>
<p>Low serum osmolality (under 275), inappropriately concentrated urine (over 100 mOsm/kg), high urine sodium (StatPearls uses over 40 mEq/L), a euvolemic exam, and no hypothyroidism or adrenal insufficiency.</p>

<h2>Sources</h2>
<ol class="refs">
<li>Yasir M, Mechanic OJ. <a href="https://www.ncbi.nlm.nih.gov/books/NBK507777/">Syndrome of Inappropriate Antidiuretic Hormone Secretion</a>. StatPearls, updated March 2023.</li>
<li>Danyalian A, Heller D. <a href="https://www.ncbi.nlm.nih.gov/books/NBK551697/">Central Pontine Myelinolysis</a>. StatPearls, updated August 2023.</li>
<li>Verbalis JG, et al. <a href="https://doi.org/10.1016/j.amjmed.2013.07.006">Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations</a>. Am J Med. 2013;126(10 Suppl 1):S1-S42.</li>
<li>Spasovski G, et al. <a href="https://doi.org/10.1530/EJE-13-1020">Clinical practice guideline on diagnosis and treatment of hyponatraemia</a>. Eur J Endocrinol. 2014;170(3):G1-G47.</li>
<li>Steele A, et al. <a href="https://doi.org/10.7326/0003-4819-126-1-199701010-00003">Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination</a>. Ann Intern Med. 1997;126(1):20-25.</li>
<li>Garrahy A, et al. <a href="https://doi.org/10.1210/clinem/dgaa619">Fluid restriction therapy for chronic SIAD: results of a prospective randomized controlled trial</a>. J Clin Endocrinol Metab. 2020;105(12).</li>
<li>Baek SH, et al. <a href="https://doi.org/10.1001/jamainternmed.2020.5519">Risk of overcorrection in rapid intermittent bolus vs slow continuous infusion therapies of hypertonic saline (SALSA)</a>. JAMA Intern Med. 2021;181(1):81-92.</li>
<li>Ayus JC, et al. <a href="https://doi.org/10.1001/jamainternmed.2024.5981">Correction rates and clinical outcomes in hospitalized adults with severe hyponatremia</a>. JAMA Intern Med. 2025;185(1):38-51.</li>
<li>Monnerat S. <a href="https://doi.org/10.1016/j.beem.2025.102055">New potential treatment options for syndrome of inappropriate antidiuresis</a>. Best Pract Res Clin Endocrinol Metab. 2026;40(1):102055.</li>
</ol>
<p><em>MedRise Perspectives share educational information only. They are not medical, legal or immigration advice. Confirm requirements with the official organization or program.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/siadh-management-step-2-ck-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>How to Stop Missing Hyponatremia Questions on Step 2 CK: Reading Order, Traps and a Review Plan</title><link>https://med-rise.com/board-review/hyponatremia-questions-step-2-ck</link><guid isPermaLink="true">https://med-rise.com/board-review/hyponatremia-questions-step-2-ck</guid><pubDate>Thu, 19 Nov 2026 13:30:41 -0600</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Guide</category><category>Board Review</category><description>The order to read a sodium question, the three traps behind most missed hyponatremia items, three practice stems and a 21-day spaced review plan.</description><content:encoded><![CDATA[<p>Most missed hyponatremia questions on Step 2 CK are not knowledge gaps. The facts about SIADH, diuretics and polydipsia are familiar; the error is reading the labs in the wrong order, or choosing the answer that feels most active. This guide fixes the order, names the three traps, tests it on three stems and ends with a review plan that makes the sequence automatic.</p>

<h2>The reading-order algorithm</h2>
<p>Read every sodium question in this order, before looking at the answer choices. The full workup is in our <a href="https://med-rise.com/board-review/hyponatremia-algorithm-medicine-shelf">hyponatremia algorithm</a>.</p>
<ol class="sp-flow"><li><span>Symptoms first<small>Seizure, coma, repeated vomiting or deep somnolence means severe hyponatremia: a 3% saline bolus comes before any further workup.</small></span></li><li><span>Serum osmolality<small>Above 295 mOsm/kg: hypertonic (hyperglycemia, mannitol). 275 to 295: consider pseudohyponatremia from high lipids or protein. Below 275: true hypotonic hyponatremia; keep going.</small></span></li><li><span>Urine osmolality<small>Below 100 mOsm/kg: ADH is off (primary polydipsia, low solute intake from beer or tea and toast). Above 100: ADH is on; keep going.</small></span></li><li><span>Volume status and urine sodium together<small>Hypovolemic with urine sodium below 30: GI or other extrarenal loss. Hypovolemic with urine sodium above 30: diuretics, adrenal insufficiency. Euvolemic: SIADH, hypothyroidism, glucocorticoid deficiency. Hypervolemic: heart failure, cirrhosis, nephrotic syndrome, kidney failure.</small></span></li><li><span>Treatment and its speed limit<small>Match the treatment to the bucket, then check the rate of correction before you commit.</small></span></li></ol>

<h2>The three traps</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Trap</th><th>Why it catches people</th><th>The correct move</th></tr></thead>
<tbody>
<tr><td>Normal saline in SIADH</td><td>Giving fluid feels like treatment</td><td>When the urine is more concentrated than the infusion, the kidney excretes the salt and keeps the water, and sodium can fall. First-line for chronic, mild to moderate SIADH is fluid restriction, typically under about 800 mL a day</td></tr>
<tr><td>Doing more than the stem needs</td><td>Tolvaptan or demeclocycline looks decisive</td><td>They are second-line, for when restriction fails. Tolvaptan carries a liver injury warning</td></tr>
<tr><td>Ignoring the speed limit</td><td>The number is low, so faster seems better</td><td>In chronic hyponatremia, keep the rise to 8 mEq/L or less in 24 hours in high-risk patients (alcohol use disorder, malnutrition, hypokalemia, liver disease, sodium 105 or lower). Overcorrection risks osmotic demyelination</td></tr>
</tbody>
</table></div>
<p>Severe symptoms override the usual caution: the European guideline gives 150 mL of 3% saline over 20 minutes, repeated as needed, aiming for a rise of about 5 mEq/L in the first hour. US expert panels describe a similar 100 mL bolus approach. After that first rise, the speed limit applies again.</p>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Sodium 124, serum osm 262, urine osm 480, urine Na 50, moist mucosa, normal TSH and cortisol</td><td>SIADH</td><td>Fluid restriction and look for the cause</td></tr>
<tr><td>Same labs, smoker with a central lung mass</td><td>SIADH from small cell lung cancer</td><td>Fluid restriction; work up the mass</td></tr>
<tr><td>Sodium 118 and a generalized seizure</td><td>Severe symptomatic hyponatremia</td><td>3% saline bolus</td></tr>
<tr><td>Sodium 126, urine osm 60, drinks 6 L of water a day</td><td>Primary polydipsia</td><td>Restrict water intake</td></tr>
<tr><td>New thiazide, sodium 125, urine Na 45, dry mucosa</td><td>Diuretic-induced hyponatremia</td><td>Stop the thiazide; isotonic fluid if volume depleted</td></tr>
<tr><td>Hyponatremia with hyperkalemia and hypotension</td><td>Primary adrenal insufficiency</td><td>Cortisol and ACTH; hydrocortisone if unstable</td></tr>
<tr><td>Sodium rose from 110 to 122 in 18 hours</td><td>Overcorrection</td><td>Re-lower with free water (D5W), with or without desmopressin</td></tr>
</tbody>
</table></div>

<h2>Three practice stems</h2>
<p><strong>Stem 1.</strong> A 68-year-old woman is admitted with pneumonia. Sodium is 125 mEq/L, serum osmolality 260 mOsm/kg, urine osmolality 520 mOsm/kg and urine sodium 62 mEq/L. She is alert. Mucous membranes are moist, and there is no edema or jugular venous distension. TSH and morning cortisol are normal. The team starts 0.9% saline at 100 mL/h. Twelve hours later, the sodium is 123 mEq/L.</p>
<p>Which of the following is the most appropriate change in management?</p>
<ol type="A">
<li>Increase the 0.9% saline to 200 mL/h</li>
<li>Stop the saline and restrict fluid intake</li>
<li>Start tolvaptan</li>
<li>Give a 3% saline bolus</li>
<li>Start furosemide alone</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: B.</strong> This is SIADH from pneumonia: hypotonic, urine osmolality far above 100, high urine sodium, euvolemic, with normal thyroid and adrenal function. Her urine is more concentrated than the saline, so the infusion makes the sodium fall. Stop it and restrict fluids.</p>
<p><strong>Why the others are wrong.</strong> A: more saline worsens the hyponatremia. C: tolvaptan is second-line after restriction fails. D: she has no severe symptoms. E: a loop diuretic is sometimes added with salt in refractory SIADH, but not as first-line therapy on its own.</p>
</details>

<p><strong>Stem 2.</strong> A 45-year-old man with alcohol use disorder is brought in after drinking about 12 beers a day for 2 weeks with little food. Sodium is 112 mEq/L, potassium 2.9 mEq/L and urine osmolality 70 mOsm/kg. He is confused but has had no seizures. After normal saline and potassium replacement, his urine output rises to 400 mL/h.</p>
<p>What is the main risk now?</p>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: too-rapid correction.</strong> Low solute intake with beer drinking suppresses ADH (urine osmolality 70). Once solute arrives, the kidneys excrete large volumes of dilute urine and the sodium can climb quickly. He is high risk (alcohol use, malnutrition, hypokalemia, sodium 112), so the limit is 8 mEq/L in 24 hours. Check sodium often and be ready to give D5W or desmopressin.</p>
</details>

<p><strong>Stem 3.</strong> A 30-year-old woman collapses at a music festival after taking MDMA and drinking large amounts of water. She has a generalized seizure. Sodium is 117 mEq/L.</p>
<p>What is the next step?</p>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: 3% saline bolus now.</strong> Acute severe symptomatic hyponatremia needs hypertonic saline immediately, with repeat boluses until symptoms improve. Acute hyponatremia (under 48 hours) carries a lower risk of osmotic demyelination, but the sodium should still be tracked closely once the seizure stops.</p>
</details>

<h2>Make the fix stick: the 21-day review schedule</h2>
<p>Retrieval beats rereading. In a randomized trial with pediatric and emergency medicine residents, repeated testing with feedback produced final scores of 39% versus 26% for repeated study more than 6 months later. In another trial, third-year students who received weekly emailed case questions retained more clinical knowledge at the end of the year.</p>
<ol class="sp-time"><li><span>Day 1<small>Write the reading order from memory in 3 minutes, check it against the algorithm, then do 10 electrolyte questions and log every miss.</small></span></li><li><span>Day 2<small>Redraw it from memory; say the first treatment for each bucket and the three traps aloud.</small></span></li><li><span>Day 4<small>Ten mixed electrolyte questions, timed at about 90 seconds each.</small></span></li><li><span>Day 7<small>Redraw the tree; reread only your error log, not the textbook.</small></span></li><li><span>Day 14<small>A mixed block that includes sodium questions without warning.</small></span></li><li><span>Day 21<small>Final redraw and one more mixed block. If the same step keeps appearing in your log, that step is your study plan.</small></span></li></ol>
<p>For each miss, write one line: "The key clue was ___. I broke the sequence at symptoms, serum osm, urine osm, volume and urine sodium, treatment, or speed limit. Next time the word that should stop me is ___." After five entries, read them together. If you track misses by knowledge, reasoning and stamina, as in our <a href="https://med-rise.com/resilience/nbme-scores-not-improving">plan for NBME scores that stop improving</a>, sodium misses you "knew" are usually reasoning errors.</p>

<h2>60-second recall</h2><ul><li><strong>Reading order</strong> Symptoms, serum osm, urine osm, volume plus urine sodium, treatment, speed limit.</li><li><strong>Urine osm below 100</strong> ADH off: polydipsia or low solute intake.</li><li><strong>SIADH first-line</strong> Fluid restriction; normal saline can worsen it.</li><li><strong>Severe symptoms</strong> 3% saline bolus, about 5 mEq/L rise first.</li><li><strong>High-risk chronic patient</strong> Rise of 8 mEq/L or less in 24 hours.</li><li><strong>Overcorrection</strong> D5W, with or without desmopressin.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, or read <a href="https://med-rise.com/board-review/siadh-management-step-2-ck">SIADH management on Step 2 CK</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1530/EJE-13-1020">Spasovski G, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol, 2014</a></li>
<li><a href="https://doi.org/10.1016/j.amjmed.2013.07.006">Verbalis JG, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med, 2013 (PubMed 24074529)</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/35852524/">Adrogué HJ, Tucker BM, Madias NE. Diagnosis and management of hyponatremia: a review. JAMA, 2022</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/books/NBK507777/">StatPearls: Syndrome of inappropriate antidiuretic hormone secretion. NCBI Bookshelf</a></li>
<li><a href="https://doi.org/10.1111/j.1365-2923.2009.03518.x">Larsen DP, Butler AC, Roediger HL. Repeated testing improves long-term retention relative to repeated study: a randomised controlled trial. Med Educ, 2009 (PubMed 19930508)</a></li>
<li><a href="https://doi.org/10.1111/j.1365-2929.2006.02644.x">Kerfoot BP, et al. Spaced education improves the retention of clinical knowledge by medical students: a randomised controlled trial. Med Educ, 2007 (PubMed 17209889)</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/hyponatremia-questions-step-2-ck-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>Acute Stroke Algorithm for the Neurology Shelf: Step-by-Step Management</title><link>https://med-rise.com/board-review/acute-stroke-algorithm-neurology-shelf</link><guid isPermaLink="true">https://med-rise.com/board-review/acute-stroke-algorithm-neurology-shelf</guid><pubDate>Thu, 19 Nov 2026 05:56:51 -0600</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Study guide</category><category>Board Review</category><description>Manage acute ischemic stroke step by step for the neurology shelf: glucose and CT first, the 4.5-hour lytic window, thrombectomy criteria and BP limits.</description><content:encoded><![CDATA[<p>On the neurology shelf, an acute stroke question gives a sudden focal deficit, such as right arm weakness with aphasia, the time the patient was last known well, a fingerstick glucose and a head CT result, then asks for the next best step. It tests the order of decisions: exclude a mimic and a bleed, decide whether the deficit is disabling, match the time window to thrombolysis or thrombectomy, and keep blood pressure inside the right limits.</p>

<h2>The algorithm</h2>
<p>Steps 1 to 3 happen in the first minutes. Thrombolysis and the search for a large vessel occlusion then run side by side, not one after the other.</p>
<ol class="sp-flow"><li><span>Set the clock and check glucose<small>Stabilize airway, breathing and circulation, then fix the time last known well; every window counts from it. Check blood glucose before thrombolysis. Treat glucose below 60 mg/dL. If a disabling deficit persists after severe hypo- or hyperglycemia is corrected, thrombolysis is still recommended.</small></span></li><li><span>Image the brain right away<small>Noncontrast CT or MRI excludes hemorrhage. Blood on the scan ends the thrombolysis pathway. Do not hold thrombolysis for coagulation results unless something suggests they will be abnormal, such as anticoagulant use.</small></span></li><li><span>Decide whether the deficit is disabling<small>A disabling deficit is treated whatever the NIHSS score. A mild nondisabling deficit, such as an isolated sensory syndrome, does not get thrombolysis; it has not beaten dual antiplatelet therapy.</small></span></li><li><span>Within 4.5 hours, give a thrombolytic<small>Tenecteplase 0.25 mg/kg (maximum 25 mg) as a single bolus, or alteplase 0.9 mg/kg (maximum 90 mg; 10% as a 1-minute bolus, the rest over 60 minutes). Blood pressure must be below 185/110 mm Hg before it starts. Do not delay it for CTA or perfusion imaging.</small></span></li><li><span>Look for a large vessel occlusion<small>Get urgent vascular imaging (CTA or MRA) within 24 hours of last known well, without waiting for a creatinine. A patient eligible for both treatments gets the thrombolytic and goes for thrombectomy; do not wait to see whether the drug works.</small></span></li><li><span>Apply the thrombectomy criteria<small>ICA or M1 occlusion, NIHSS 6 or more, prestroke mRS 0 to 1: thrombectomy within 6 hours with ASPECTS 3 to 10, and from 6 to 24 hours with ASPECTS 6 or more (ASPECTS 3 to 5 in selected patients under 80 without mass effect). Basilar occlusion with NIHSS 10 or more and PC-ASPECTS 6 or more: thrombectomy within 24 hours. Nondominant M2, distal MCA, ACA and PCA occlusions show no benefit.</small></span></li><li><span>Unknown onset or 4.5 to 9 hours: use advanced imaging<small>Unknown onset, seen within 4.5 hours of noticing symptoms, with a DWI lesion smaller than one-third of the MCA territory and no marked FLAIR change: thrombolysis can be beneficial. Salvageable penumbra on perfusion imaging 4.5 to 9 hours from last known well, or within 9 hours of the midpoint of sleep, makes thrombolysis reasonable.</small></span></li><li><span>Hold the blood pressure limits<small>After thrombolysis, keep it below 180/105 mm Hg for at least 24 hours. No reperfusion and blood pressure below 220/120: starting antihypertensives in the first 48 to 72 hours does not prevent death or dependency. Pushing systolic pressure below 140 mm Hg brings no benefit after thrombolysis and causes harm after successful thrombectomy.</small></span></li><li><span>Start antithrombotics on the right day<small>No thrombolysis: aspirin within 48 hours. Minor noncardioembolic stroke (NIHSS 3 or less) or high-risk TIA (ABCD2 4 or more): aspirin plus clopidogrel started within 24 hours for 21 days, then one agent. After thrombolysis: repeat CT or MRI at 24 hours before any antiplatelet or anticoagulant. Then find the cause with an ECG and telemetry, echocardiography, carotid imaging, lipids and HbA1c.</small></span></li></ol>
<p>Sources differ on exclusions and anticoagulation timing: older references list fixed cutoffs (platelets under 100,000/mm³, INR above 1.7) and wait 7 to 14 days to anticoagulate atrial fibrillation, while the 2026 AHA/ASA guideline grades many exclusions by level of risk and calls early anticoagulation reasonable in selected milder strokes; this post follows the 2026 guideline.</p>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Sudden aphasia and right arm weakness, fingerstick glucose 38 mg/dL</td><td>Hypoglycemia, a stroke mimic</td><td>Treat the glucose; if a disabling deficit persists, continue the stroke pathway</td></tr>
<tr><td>Hyperdense blood in the basal ganglia on noncontrast CT</td><td>Intracerebral hemorrhage</td><td>No thrombolysis; manage as a hemorrhage</td></tr>
<tr><td>Disabling deficit at 2 hours, blood pressure 200/115 mm Hg</td><td>Above the thrombolysis limit</td><td>Lower it below 185/110 mm Hg, then give the thrombolytic</td></tr>
<tr><td>Isolated numbness of one side of the body, NIHSS 1</td><td>Mild nondisabling stroke</td><td>No thrombolysis; aspirin plus clopidogrel for 21 days</td></tr>
<tr><td>NIHSS 14 at 90 minutes, CTA shows an M1 occlusion</td><td>Large vessel occlusion inside the lytic window</td><td>Thrombolytic now and thrombectomy, without waiting for a response</td></tr>
<tr><td>Woke up with hemiparesis, last seen normal 8 hours ago</td><td>Unknown onset</td><td>MRI: DWI-FLAIR mismatch supports thrombolysis</td></tr>
<tr><td>10 hours, ICA occlusion, NIHSS 12, ASPECTS 7</td><td>Late-window anterior large vessel occlusion</td><td>Thrombectomy (allowed up to 24 hours)</td></tr>
<tr><td>Vertigo, dysarthria, then coma; basilar occlusion at 12 hours, NIHSS 22</td><td>Basilar artery occlusion</td><td>Thrombectomy within 24 hours</td></tr>
<tr><td>New headache, vomiting and a worse exam during the alteplase infusion</td><td>Suspected hemorrhage after thrombolysis</td><td>Stop the infusion; emergency head CT</td></tr>
<tr><td>No reperfusion therapy, day 1 blood pressure 190/100 mm Hg</td><td>Permissive hypertension</td><td>Do not lower it now</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Waiting for the INR or platelet count before thrombolysis when nothing suggests a coagulopathy. Glucose is the test that must come first.</li>
<li>Giving a thrombolytic because the patient is inside 4.5 hours when the deficit is mild and nondisabling. The better answer is dual antiplatelet therapy.</li>
<li>Skipping the thrombolytic because thrombectomy is planned, or holding thrombectomy to see whether the thrombolytic works. Eligible patients get both, as fast as possible.</li>
<li>Choosing an intensive blood pressure target. Systolic pressure below 140 mm Hg is not recommended after thrombolysis and is harmful after successful thrombectomy.</li>
<li>Starting antithrombotics too early after thrombolysis. Get the 24-hour scan first, and never give IV aspirin with thrombolysis or within 90 minutes after it starts.</li>
<li>Ordering heparin for an undifferentiated acute stroke. Early anticoagulation does not prevent early neurologic worsening.</li>
</ul>

<h2>Practice question</h2>
<p>A 64-year-old woman comes to the emergency department 2 hours after sudden numbness of the right side of her face, right arm and right leg. She has no weakness, speech difficulty or visual loss, and she can walk and use her hands normally. She has hypertension and hyperlipidemia treated with amlodipine and atorvastatin and takes no antithrombotic drugs. Temperature is 36.9 C, blood pressure 164/90 mm Hg and pulse 78/min and regular. Fingerstick glucose is 112 mg/dL. Pinprick and light touch are decreased over the right face, arm and leg; strength, coordination, language and visual fields are normal. The NIHSS score is 1. ECG shows sinus rhythm. Noncontrast CT of the head shows no hemorrhage, and CT angiography shows no large vessel occlusion.</p>
<p>Which of the following is the most appropriate treatment?</p>
<ol type="A">
<li>IV tenecteplase 0.25 mg/kg</li>
<li>Aspirin plus clopidogrel</li>
<li>IV unfractionated heparin infusion</li>
<li>Mechanical thrombectomy</li>
<li>IV antihypertensive therapy to bring systolic pressure below 140 mm Hg</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: B.</strong> She has a minor, nondisabling ischemic stroke (an isolated sensory syndrome, NIHSS 1) in sinus rhythm and was not given thrombolysis. Aspirin plus clopidogrel started within 24 hours of onset and continued for 21 days, followed by a single antiplatelet drug, lowers the risk of another stroke.</p>
<p><strong>Why the others are wrong.</strong> A: thrombolysis for mild nondisabling deficits has not shown benefit over dual antiplatelet therapy and adds bleeding risk. C: early anticoagulation for an undifferentiated ischemic stroke does not prevent early worsening, and she has no atrial fibrillation. D: there is no large vessel occlusion, and her NIHSS is below 6. E: without reperfusion therapy and with pressure below 220/120 mm Hg, early lowering does not prevent death or dependency.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>The one test needed before thrombolysis in most patients</strong> Blood glucose.</li><li><strong>Blood pressure before and after thrombolysis</strong> Below 185/110 before; below 180/105 for at least 24 hours after.</li><li><strong>Tenecteplase dose</strong> 0.25 mg/kg, maximum 25 mg, single bolus.</li><li><strong>Anterior thrombectomy criteria</strong> ICA or M1 occlusion, NIHSS 6 or more, prestroke mRS 0 to 1, up to 24 hours.</li><li><strong>Dual antiplatelet therapy for minor stroke</strong> NIHSS 3 or less or ABCD2 4 or more, start within 24 hours, 21 days.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review <a href="https://med-rise.com/board-review/anticoagulants-vs-antiplatelets-vs-thrombolytics">anticoagulants vs antiplatelets vs thrombolytics</a> (including how to reverse a thrombolytic bleed), present a stroke case with <a href="https://med-rise.com/viva/">MedRise Viva</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1161/STR.0000000000000513">Prabhakaran S, et al. 2026 Guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association/American Stroke Association. Stroke, 2026 (PubMed)</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/books/NBK499997/">Lui F, Khan Suheb MZ, Patti L. Ischemic stroke. StatPearls, NCBI Bookshelf, updated 2026</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/books/NBK430927/">Khaku AS, Tadi P. Cerebrovascular disease. StatPearls, NCBI Bookshelf, 2026 edition</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/acute-stroke-algorithm-neurology-shelf-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>Depression Treatment Algorithm for the Psychiatry Shelf: First-Line to Next Step</title><link>https://med-rise.com/board-review/depression-treatment-algorithm-psychiatry-shelf</link><guid isPermaLink="true">https://med-rise.com/board-review/depression-treatment-algorithm-psychiatry-shelf</guid><pubDate>Wed, 18 Nov 2026 05:56:43 -0600</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Study guide</category><category>Board Review</category><description>Treat major depression step by step for the psychiatry shelf: rule out bipolar, match CBT or an SSRI to severity, judge at 4 weeks, then switch or augment.</description><content:encoded><![CDATA[<p>On the psychiatry shelf, depression treatment questions describe at least 2 weeks of low mood or lost interest with changes in sleep, energy, appetite and concentration, then ask for the best first treatment or the next step after a drug has not worked. The question tests three decisions: have you ruled out bipolar disorder and danger, does the treatment match the severity, and do you know when to wait, raise the dose, switch or add.</p>

<h2>The algorithm</h2>
<p>Steps 1 to 3 come before any prescription.</p>
<ol class="sp-flow"><li><span>Confirm major depressive disorder<small>Five or more of nine symptoms for at least 2 weeks, one of them depressed mood or loss of interest, with impaired function. Any past manic or hypomanic episode means a bipolar disorder, not MDD, and antidepressant monotherapy should be avoided in bipolar I.</small></span></li><li><span>Rule out medical and substance causes<small>Check a CBC, metabolic panel, TSH with free T4 and a toxicology screen, adding other tests as the history suggests. These exclude medical illness that can look like depression.</small></span></li><li><span>Assess suicide risk and choose the setting<small>Ask directly about ideation, plan and intent. Ideation with intent to act, or psychotic symptoms, often warrants inpatient care.</small></span></li><li><span>Grade severity and pick the first treatment<small>Mild: structured psychotherapy such as CBT is preferred. Moderate: CBT or a second-generation antidepressant (SSRI, SNRI, bupropion, mirtazapine and others) alone, or both together. Severe without psychosis: medication, ideally combined with psychotherapy; psychotherapy alone is not enough.</small></span></li><li><span>Treat psychotic, catatonic or life-threatening features differently<small>Psychotic features: an antidepressant plus an antipsychotic, or ECT; hold structured psychotherapy until the psychosis settles. ECT can be first-line for psychotic or catatonic features, severe suicidal ideation, refusal to eat or drink, or a deteriorating physical condition. Benzodiazepines are the other option for catatonia.</small></span></li><li><span>Choose the drug by side effects and safety<small>SSRIs are the usual first drug; antidepressants work about equally well but differ in side effects. Bupropion, mirtazapine and vortioxetine cause fewer sexual side effects. Mirtazapine adds drowsiness, appetite and weight gain. Bupropion is approved for smoking cessation but is contraindicated with a seizure disorder, bulimia or anorexia. TCAs are second-line and dangerous in overdose; MAOIs are third-line.</small></span></li><li><span>Check early, then decide at 4 weeks<small>Ask about side effects within 2 weeks. Less than 20% improvement in the symptom score by 2 to 4 weeks predicts failure: by 4 weeks, consider raising the dose or switching. Response is a drop of 50% or more; remission is a PHQ-9 score of 4 or less.</small></span></li><li><span>Not better: switch or add<small>No response or poor tolerance: switch to another first-line antidepressant, or to CBT. Partial response that is well tolerated: add an adjunct (first-line aripiprazole or brexpiprazole) or add CBT. Failure of 2 or more adequate trials is treatment-resistant depression: recheck the diagnosis, then consider rTMS, esketamine nasal spray with an oral antidepressant, or ECT.</small></span></li><li><span>After remission, continue, then taper<small>Keep the antidepressant for 6 to 12 months after remission, or 2 years or more with risk factors for recurrence such as residual symptoms, many prior episodes or chronic episodes. Taper over weeks to months; fluoxetine needs no taper, and paroxetine and venlafaxine carry the highest risk of discontinuation symptoms.</small></span></li></ol>
<p>Guidelines differ on step 9: the APA 2010 guideline advises 4 to 9 months of continuation, with maintenance after 3 or more episodes; this post follows the newer CANMAT 2023 range of 6 to 12 months.</p>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Five depressive symptoms for 3 weeks, mild impairment, no suicidal ideation</td><td>Mild MDD</td><td>Psychotherapy such as CBT</td></tr>
<tr><td>Depressed now, but last year a week of little sleep, racing thoughts and overspending</td><td>Bipolar disorder, not MDD</td><td>No antidepressant alone; use mood-stabilizing treatment</td></tr>
<tr><td>Suicidal ideation with a plan and intent to act</td><td>High suicide risk</td><td>Inpatient care</td></tr>
<tr><td>Delusions of guilt, voices saying he deserves to die</td><td>MDD with psychotic features</td><td>Antidepressant plus antipsychotic, or ECT</td></tr>
<tr><td>Mute, posturing, refusing food and fluids</td><td>Catatonic features with physical decline</td><td>ECT, or a benzodiazepine for the catatonia</td></tr>
<tr><td>Sertraline for 4 weeks, symptom score down only 10%</td><td>No early improvement</td><td>Raise the dose, or switch if side effects limit it</td></tr>
<tr><td>Low libido and delayed orgasm on an SSRI</td><td>SSRI sexual side effect</td><td>Switch to an agent with fewer sexual effects, such as bupropion</td></tr>
<tr><td>Partial response at a full dose, no side effects</td><td>Partial response</td><td>Add aripiprazole or brexpiprazole, or add CBT</td></tr>
<tr><td>Insomnia, poor appetite and weight loss</td><td>Symptoms that favor a sedating agent</td><td>Consider mirtazapine</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Starting an SSRI before asking about mania or hypomania. A past manic episode makes it bipolar I, where antidepressant monotherapy should be avoided.</li>
<li>Calling a drug a failure after 1 or 2 weeks. SSRIs may take up to 6 weeks for full effect; the dose-or-switch decision comes at about 4 weeks.</li>
<li>Choosing a TCA for a patient at risk of overdose. TCAs cause altered mental status, cardiac toxicity and seizures in overdose; SSRIs are preferred.</li>
<li>Giving bupropion to a patient with bulimia, anorexia or a seizure disorder. It lowers the seizure threshold.</li>
<li>Stopping the antidepressant as soon as the patient feels well, or stopping it abruptly. Continue for 6 to 12 months after remission, then taper.</li>
<li>Forgetting the boxed warning. Antidepressants carry an FDA warning for suicidality in patients under 25, so monitor them closely after starting.</li>
</ul>

<h2>Practice question</h2>
<p>A 29-year-old woman comes to the clinic with 6 weeks of low mood, loss of interest in her hobbies, poor concentration, fatigue and early morning awakening. She feels worthless but has no thoughts of death or suicide. She has never had a period of elevated mood or decreased need for sleep. She smokes 1 pack of cigarettes daily and wants to quit. During an earlier episode 3 years ago, she stopped an antidepressant because of low libido and weight gain, and she asks for a medicine that avoids both. She has no history of seizures, head injury or an eating disorder and rarely drinks alcohol. Temperature is 36.8 C, blood pressure 118/76 mm Hg, pulse 76/min and BMI 23 kg/m². Examination is normal. Hemoglobin is 13.4 g/dL, TSH 1.9 µU/mL and sodium 139 mEq/L; a urine toxicology screen is negative. Her PHQ-9 score is 16. She is offered CBT but prefers medication.</p>
<p>Which of the following is the most appropriate pharmacotherapy?</p>
<ol type="A">
<li>Bupropion</li>
<li>Mirtazapine</li>
<li>Paroxetine</li>
<li>Amitriptyline</li>
<li>Phenelzine</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: A.</strong> She has MDD with no history of mania and no safety concerns, so a second-generation antidepressant is a first-line choice. Bupropion is one of the few antidepressants without sexual dysfunction, can cause weight loss, and is approved for smoking cessation. She has none of its contraindications: no seizure disorder, no bulimia or anorexia, and no alcohol withdrawal.</p>
<p><strong>Why the others are wrong.</strong> B: mirtazapine has fewer sexual side effects but increases appetite and weight and causes drowsiness. C: paroxetine is an SSRI; sexual dysfunction and weight change are common, and it has a high risk of discontinuation symptoms. D: amitriptyline is a TCA, a second-line choice that is dangerous in overdose. E: phenelzine is an MAOI, a third-line choice with tyramine and drug interactions that can cause hypertensive crisis or serotonin syndrome.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>Time criterion for MDD</strong> At least 2 weeks, with depressed mood or loss of interest among 5 or more symptoms.</li><li><strong>Preferred first treatment for mild MDD</strong> Structured psychotherapy such as CBT.</li><li><strong>No early improvement means</strong> Less than 20% drop in the symptom score by 2 to 4 weeks.</li><li><strong>First-line adjuncts for a partial response (CANMAT)</strong> Aripiprazole or brexpiprazole.</li><li><strong>How long to continue after remission</strong> 6 to 12 months; 2 years or more with risk factors.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review the <a href="https://med-rise.com/board-review/hyponatremia-algorithm-medicine-shelf">hyponatremia algorithm</a> (SSRIs and SNRIs raise the risk of hyponatremia in adults over 65), present a case with <a href="https://med-rise.com/viva/">MedRise Viva</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1177/07067437241245384">Lam RW, et al. CANMAT 2023 update on clinical guidelines for management of major depressive disorder in adults. Can J Psychiatry, 2024 (PubMed)</a></li>
<li><a href="https://doi.org/10.7326/M22-2056">Qaseem A, et al. Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American College of Physicians. Ann Intern Med, 2023</a></li>
<li><a href="https://www.aafp.org/pubs/afp/issues/2011/0515/p1219.html">Armstrong C. APA releases guideline on treatment of patients with major depressive disorder. Am Fam Physician, 2011</a></li>
<li><a href="https://doi.org/10.1176/appi.ajp.2013.13020185">Pacchiarotti I, et al. The ISBD task force report on antidepressant use in bipolar disorders. Am J Psychiatry, 2013 (PubMed)</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/books/NBK559078/">Bains N, Abdijadid S. Major depressive disorder. StatPearls, NCBI Bookshelf, updated 2023</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/books/NBK430847/">Chand SP, Arif H. Depression. StatPearls, NCBI Bookshelf, updated 2023</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/books/NBK554406/">Chu A, Wadhwa R. Selective serotonin reuptake inhibitors. StatPearls, NCBI Bookshelf, updated 2023</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/books/NBK470212/">Huecker MR, et al. Bupropion. StatPearls, NCBI Bookshelf, updated 2024</a></li>
<li><a href="https://www.statpearls.com/point-of-care/25185">Mirtazapine. StatPearls, updated 2024</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t4/">SAMHSA. DSM-IV to DSM-5 major depressive episode/disorder comparison (Table 3.4). NCBI Bookshelf, 2016</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/depression-treatment-algorithm-psychiatry-shelf-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>First-Trimester Bleeding Algorithm for the OB/GYN Shelf: Step-by-Step Workup</title><link>https://med-rise.com/board-review/first-trimester-bleeding-algorithm-obgyn-shelf</link><guid isPermaLink="true">https://med-rise.com/board-review/first-trimester-bleeding-algorithm-obgyn-shelf</guid><pubDate>Tue, 17 Nov 2026 05:57:58 -0600</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Study guide</category><category>Board Review</category><description>Work up first-trimester bleeding step by step for the OB/GYN shelf: the unstable patient, hCG and the discriminatory level, ultrasound criteria, ectopic, loss.</description><content:encoded><![CDATA[<p>On the OB/GYN shelf, first-trimester bleeding arrives as a positive pregnancy test with spotting or cramping, plus vitals, an hCG value and an ultrasound report to read together. The question tests three decisions: is she stable, where is the pregnancy, and is it viable. Ectopic pregnancy is the diagnosis you cannot miss.</p>

<h2>The algorithm</h2>
<p>Step 1 decides whether there is time for the rest.</p>
<ol class="sp-flow"><li><span>Check vitals and the abdomen first<small>Hypotension, tachycardia or peritoneal signs in early pregnancy mean ruptured ectopic until proven otherwise: resuscitate and go to surgery without waiting for a repeat hCG. Substantial free fluid in the cul-de-sac is also an urgent surgical referral.</small></span></li><li><span>Confirm the pregnancy and get baseline labs<small>Quantitative serum hCG, a baseline hemoglobin, and the Rh type if unknown.</small></span></li><li><span>Speculum exam<small>Look for cervicitis, vaginitis or a cervical polyp. Tissue at an open os means an incomplete abortion. Otherwise the os cannot tell you where the pregnancy is, so the next step is transvaginal ultrasound.</small></span></li><li><span>Transvaginal ultrasound: is there an intrauterine pregnancy?<small>An intrauterine pregnancy essentially rules out ectopic, except a heterotopic pregnancy. An adnexal yolk sac or embryo proves ectopic, but most ectopics never show one.</small></span></li><li><span>Empty uterus: compare the hCG with the discriminatory level<small>A sac is usually visible by an hCG of 1,500 to 3,000 mIU/mL; for a desired pregnancy, use a level as high as 3,500 before calling it abnormal. Above it, suspect ectopic. Below it, this is a pregnancy of unknown location: repeat the hCG in 48 hours and review warning signs (pelvic or shoulder pain, dizziness).</small></span></li><li><span>Read the 48-hour hCG trend<small>A viable pregnancy rises at least 49% from a start under 1,500 mIU/mL, 40% from 1,500 to 3,000, and 33% above 3,000; rescan once it passes the discriminatory level. A slower rise or plateau suggests ectopic or failing pregnancy. A fall of at least 21% suggests a failed intrauterine pregnancy; a smaller fall keeps ectopic on the list. If the location was never seen, follow the hCG until undetectable.</small></span></li><li><span>Intrauterine pregnancy: viable or failed?<small>Loss is certain with a crown-rump length (CRL) of 7 mm or more and no heartbeat, a mean sac diameter of 25 mm or more and no embryo, or no embryo with a heartbeat 11 days or more after a sac with a yolk sac. CRL under 7 mm without a heartbeat or a mean sac diameter of 16 to 24 mm is only suspicious: rescan in 7 to 10 days. A live embryo, bleeding and a closed os is a threatened abortion: expectant care (about 11% are still lost).</small></span></li><li><span>Treat early pregnancy loss<small>If stable, expectant care, medication or uterine aspiration are all acceptable. Medication is misoprostol 800 mcg vaginally (one repeat dose if needed), ideally after mifepristone 200 mg orally 24 hours earlier. Choose aspiration for hemorrhage, instability or infection; septic abortion needs IV broad-spectrum antibiotics and prompt evacuation.</small></span></li><li><span>Treat the ectopic pregnancy<small>Methotrexate fits a stable patient with an unruptured ectopic, no cardiac activity, hCG under 5,000 mIU/mL, a mass under 35 mm, normal blood count, kidney and liver tests, and reliable follow-up. Single dose: 50 mg/m² IM, hCG on days 1, 4 and 7; a fall of more than 15% from day 4 to day 7 means it is working, then weekly to undetectable. Cardiac activity, hCG of 5,000 or more, a mass of 35 mm or more, significant pain or a contraindication point to laparoscopic surgery.</small></span></li></ol>
<p>Cutoffs differ: NICE offers methotrexate first-line only below an hCG of 1,500 IU/L, and methotrexate or surgery up to 5,000. On Rh, this post follows ACOG's 2024 update: routine Rh testing and anti-D can be forgone for abortion or pregnancy loss before 12 0/7 weeks. Older questions may expect anti-D after aspiration (ACOG 2018) or ectopic pregnancy (AAFP 2019).</p>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Positive test, BP 84/50 mm Hg, pulse 124/min, rebound</td><td>Ruptured ectopic pregnancy</td><td>Resuscitate and go to surgery</td></tr>
<tr><td>Spotting, closed os, live intrauterine embryo on ultrasound</td><td>Threatened abortion</td><td>Expectant care and return precautions</td></tr>
<tr><td>Tissue at an open os, heavy bleeding, falling blood pressure</td><td>Incomplete abortion with hemorrhage</td><td>Uterine aspiration</td></tr>
<tr><td>Empty uterus, hCG 4,200 mIU/mL</td><td>Above the discriminatory level: likely ectopic</td><td>Manage as an ectopic pregnancy</td></tr>
<tr><td>Empty uterus, hCG 900 mIU/mL, stable</td><td>Pregnancy of unknown location</td><td>Repeat hCG in 48 hours with ectopic precautions</td></tr>
<tr><td>Mean sac diameter 27 mm, no embryo</td><td>Anembryonic gestation (diagnostic of loss)</td><td>Expectant care, mifepristone plus misoprostol, or aspiration</td></tr>
<tr><td>CRL 5 mm, no cardiac activity</td><td>Suspicious, not diagnostic</td><td>Repeat transvaginal ultrasound in 7 to 10 days</td></tr>
<tr><td>Fever, uterine tenderness, foul discharge after a miscarriage</td><td>Septic abortion</td><td>IV broad-spectrum antibiotics and prompt uterine evacuation</td></tr>
<tr><td>Bleeding, hyperemesis, uterus large for dates, "snowstorm" pattern with no fetal parts</td><td>Complete hydatidiform mole</td><td>Suction curettage, then serial hCG until normal</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Sending an unstable patient for a repeat hCG or a formal scan. Instability with a positive test is a surgical problem.</li>
<li>Calling an ectopic after one hCG below the discriminatory level. A normal pregnancy may not be visible yet; repeat the hCG in 48 hours before methotrexate.</li>
<li>Declaring a loss on old cutoffs (CRL 5 mm, mean sac diameter 16 mm). Only CRL 7 mm or more without a heartbeat, or a sac of 25 mm or more without an embryo, is diagnostic.</li>
<li>Giving methotrexate despite cardiac activity, hCG of 5,000 or more, breastfeeding, kidney or liver disease, active peptic ulcer or cytopenias. These point to surgery.</li>
<li>Prescribing bed rest for a threatened abortion. It does not improve outcomes.</li>
</ul>

<h2>Practice question</h2>
<p>A 31-year-old woman, gravida 2, para 1, comes to the emergency department with 2 days of light spotting and mild left lower abdominal cramping. Her last menstrual period was 6 weeks ago. Temperature is 36.9 C, blood pressure 122/74 mm Hg, pulse 84/min and respirations 14/min. The abdomen is soft with mild left lower quadrant tenderness, no rebound or guarding. Speculum exam shows scant blood and a closed os. Serum hCG was 3,800 mIU/mL two days ago and is 3,910 mIU/mL today. Transvaginal ultrasound shows an empty uterus and a 2.4-cm complex left adnexal mass separate from the ovary, with no yolk sac, embryo, cardiac activity or free fluid. Hemoglobin is 12.8 g/dL, leukocyte count 7,200/mm3, platelet count 240,000/mm3, creatinine 0.7 mg/dL and ALT 18 U/L. She is Rh-positive, is not breastfeeding and can return for follow-up.</p>
<p>Which of the following is the most appropriate next step in management?</p>
<ol type="A">
<li>Repeat serum hCG in 48 hours</li>
<li>Intramuscular methotrexate</li>
<li>Emergency laparotomy</li>
<li>Misoprostol 800 mcg vaginally</li>
<li>Expectant management with weekly hCG</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: B.</strong> The hCG is above the 3,500 mIU/mL discriminatory level, the uterus is empty, the hCG has plateaued (3% in 48 hours, against at least 33% expected above 3,000) and there is an adnexal mass: this is an ectopic pregnancy. She meets methotrexate criteria: stable, unruptured, no cardiac activity, hCG under 5,000, mass under 35 mm, normal labs and reliable follow-up. NICE would also offer laparoscopic surgery at this level, but it is not an option here.</p>
<p><strong>Why the others are wrong.</strong> A: she is already above the discriminatory level with a plateau and a mass; waiting delays treatment. C: laparotomy is for the unstable patient. D: misoprostol empties the uterus in early pregnancy loss; it does not treat a tubal pregnancy. E: expectant care is for a low, falling hCG (under 1,000 mIU/mL and decreasing); hers has plateaued near 3,900.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>Discriminatory level for a desired pregnancy</strong> As high as 3,500 mIU/mL.</li><li><strong>Minimum 48-hour hCG rise in a viable pregnancy</strong> 49% (start under 1,500), 40% (1,500 to 3,000), 33% (above 3,000).</li><li><strong>Diagnostic of early pregnancy loss</strong> CRL 7 mm or more without a heartbeat, or mean sac diameter 25 mm or more without an embryo.</li><li><strong>Medication for early pregnancy loss</strong> Mifepristone 200 mg orally, then misoprostol 800 mcg vaginally 24 hours later.</li><li><strong>Single-dose methotrexate is working when</strong> hCG falls more than 15% from day 4 to day 7.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review the <a href="https://med-rise.com/board-review/obgyn-genetic-aneuploidy-screening-timeline">OB/GYN screening timeline</a>, present a case with <a href="https://med-rise.com/viva/">MedRise Viva</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1097/AOG.0000000000002560">ACOG Practice Bulletin No. 193: Tubal ectopic pregnancy. Obstet Gynecol, 2018 (PubMed)</a></li>
<li><a href="https://doi.org/10.1097/AOG.0000000000002900">ACOG Practice Bulletin No. 200: Early pregnancy loss (summary). Obstet Gynecol, 2018 (PubMed)</a></li>
<li><a href="https://doi.org/10.1097/AOG.0000000000005733">ACOG Clinical Practice Update: Rh D immune globulin after abortion or pregnancy loss before 12 weeks. Obstet Gynecol, 2024 (PubMed)</a></li>
<li><a href="https://www.nice.org.uk/guidance/ng126/chapter/management-of-tubal-ectopic-pregnancy">NICE. Ectopic pregnancy and miscarriage (NG126), first published 2019</a></li>
<li><a href="https://aafp.org/pubs/afp/issues/2019/0201/p166.pdf">Hendriks E, et al. First trimester bleeding: evaluation and management. Am Fam Physician, 2019</a></li>
<li><a href="https://www.aafp.org/pubs/afp/issues/2020/0515/p599.html">Hendriks E, et al. Ectopic pregnancy: diagnosis and management. Am Fam Physician, 2020</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/books/NBK560521/">Alves C, et al. Early pregnancy loss (spontaneous abortion). StatPearls, NCBI Bookshelf, updated 2023</a></li>
<li><a href="https://www.ogmagazine.org.au/24/3-24/update-on-gestational-trophoblastic-disease/">Dean J, et al. Update on gestational trophoblastic disease. O&amp;G Magazine (RANZCOG), 2022</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/first-trimester-bleeding-algorithm-obgyn-shelf-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>Neonatal Jaundice Algorithm for the Pediatrics Shelf: Step-by-Step Workup</title><link>https://med-rise.com/board-review/neonatal-jaundice-algorithm-pediatrics-shelf</link><guid isPermaLink="true">https://med-rise.com/board-review/neonatal-jaundice-algorithm-pediatrics-shelf</guid><pubDate>Mon, 16 Nov 2026 05:58:32 -0600</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Study guide</category><category>Board Review</category><description>Work up neonatal jaundice step by step for the pediatrics shelf: day-1 jaundice, AAP 2022 thresholds, hemolysis, escalation, exchange and cholestasis.</description><content:encoded><![CDATA[<p>On the pediatrics shelf, neonatal jaundice arrives as a yellow newborn with a timestamp: hours of life, gestational age, the mother's blood type, feeding and sometimes stool color. The question tests three decisions: is the jaundice too early, is the bilirubin above the hour-specific threshold, and is it conjugated. The 2022 AAP guideline raised the phototherapy thresholds, so older cutoffs may now be wrong.</p>

<h2>The algorithm</h2>
<p>Steps 1 to 8 cover week one; step 9 catches cholestasis.</p>
<ol class="sp-flow"><li><span>Check the hour of onset<small>Jaundice in the first 24 hours most likely means hemolysis: measure a TSB or TcB as soon as possible (NICE: within 2 hours). Onset on days 2 to 5 in a well, feeding infant fits the physiologic rise.</small></span></li><li><span>Get a number, not a skin estimate<small>Every infant at 35 weeks or more gets a TcB or TSB at 24 to 48 hours, or before discharge if earlier. The eye is unreliable, more so in darker skin. Confirm with a TSB any TcB of 15 mg/dL or more, or within 3 mg/dL of the threshold; treatment decisions use the TSB.</small></span></li><li><span>Plot it on the right curve<small>AAP 2022 thresholds rise with gestational age and hours of age, and are lower with any neurotoxicity risk factor: gestational age under 38 weeks, albumin under 3.0 g/dL, isoimmune hemolysis, G6PD deficiency or other hemolysis, sepsis, or significant clinical instability in the past 24 hours. At 40 weeks or more with no risk factors the threshold is 13.3 mg/dL at 24 hours and 21.8 mg/dL at 96 hours.</small></span></li><li><span>Look for hemolysis<small>Send infant blood type and DAT if the mother's antibody screen is positive or unknown, or if an infant needing phototherapy has a group O or Rh(D)-negative mother. A rise of 0.3 mg/dL per hour or more on day 1, or 0.2 mg/dL per hour or more after, suggests hemolysis. Check G6PD activity when unexplained jaundice rises despite intensive phototherapy, rises suddenly or after falling, or needs escalation.</small></span></li><li><span>At or above the phototherapy threshold: treat and keep feeding<small>Start phototherapy and recheck the TSB within 12 hours. Keep feeding; do not give water or dextrose water. With poor intake (over 10% weight loss, few wet or dirty diapers), add lactation support and consider expressed milk, donor milk or formula. Sunlight is not a treatment.</small></span></li><li><span>Within 2 mg/dL of the exchange threshold: escalate<small>Send STAT total and direct bilirubin, CBC, albumin, chemistries and type and crossmatch; give IV fluids and intensive phototherapy; move to a NICU that can do an exchange; repeat the TSB at least every 2 hours. With a positive DAT, IVIG 0.5 to 1 g/kg over 2 hours is an option.</small></span></li><li><span>Exchange transfusion<small>Urgent when the TSB reaches the exchange threshold or for signs of intermediate or advanced acute bilirubin encephalopathy: hypertonia, arching, retrocollis, opisthotonos, high-pitched cry, recurrent apnea. Early signs are quieter: sleepiness, poor suck, hypotonia.</small></span></li><li><span>Stop phototherapy, then check for rebound<small>Stopping is an option once the TSB is at least 2 mg/dL below the threshold at which it started. Started before 48 hours, positive DAT or hemolysis: recheck 6 to 12 hours after stopping and again the next day; otherwise the next day.</small></span></li><li><span>Still yellow at 2 to 4 weeks: fractionate<small>Check total and direct bilirubin if formula-fed and jaundiced at 2 weeks, or breastfed and jaundiced at 3 to 4 weeks. Direct bilirubin above 1.0 mg/dL is abnormal: check stool color (pale stool is a biliary atresia red flag), get a fasting ultrasound, urine culture and thyroid tests, and refer to pediatric GI or hepatology. A thriving breastfed infant with a normal direct level fits breast milk jaundice, which usually clears by 3 months; breastfeeding continues.</small></span></li></ol>
<p>Direct bilirubin cutoffs differ (NASPGHAN/ESPGHAN above 1.0 mg/dL, NICE above 25 micromol/L); pale stool overrides both. This post follows AAP 2022 for unconjugated bilirubin and NASPGHAN/ESPGHAN for cholestasis.</p>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Yellow face and chest at 16 hours of life</td><td>Jaundice before 24 hours, likely hemolysis</td><td>TSB or TcB now, not at the routine screen</td></tr>
<tr><td>Mother's antibody screen positive or never done</td><td>Risk of isoimmune hemolysis</td><td>Infant blood type and DAT (cord or peripheral blood)</td></tr>
<tr><td>DAT-negative boy whose TSB climbs under intensive phototherapy</td><td>Possible G6PD deficiency</td><td>G6PD activity; if normal during hemolysis, retest at 3 months or later</td></tr>
<tr><td>Breastfed, 11% below birth weight, few wet diapers on day 3</td><td>Suboptimal intake</td><td>Lactation support, 8 to 12 feeds a day, consider supplementing; no water or dextrose water</td></tr>
<tr><td>TSB 1.5 mg/dL below the exchange threshold</td><td>Escalation of care</td><td>STAT labs, IV fluids, intensive phototherapy, NICU, TSB every 2 hours</td></tr>
<tr><td>Day-4 infant with arching, retrocollis and a high-pitched cry</td><td>Intermediate or advanced acute bilirubin encephalopathy</td><td>Urgent exchange transfusion</td></tr>
<tr><td>Thriving breastfed 3-week-old, yellow stools, normal direct bilirubin</td><td>Breast milk jaundice</td><td>Reassure, keep breastfeeding, confirm the newborn thyroid screen</td></tr>
<tr><td>4-week-old with pale stools, dark urine, direct bilirubin 2.6 mg/dL</td><td>Cholestasis; biliary atresia until proven otherwise</td><td>Fasting ultrasound and prompt pediatric hepatology referral</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Calling day-1 jaundice physiologic and rechecking in the morning; measure it now.</li>
<li>Choosing the lower curve for the wrong risk factors. Exclusive breastfeeding, a cephalohematoma or a sibling who needed phototherapy make a high level more likely, but only gestational age and the neurotoxicity risk factors pick the curve.</li>
<li>Choosing water, dextrose water or "stop breastfeeding." The AAP recommends against water and dextrose water, and feeding continues during phototherapy and in breast milk jaundice.</li>
<li>Trusting a normal G6PD level during active hemolysis or soon after an exchange. It can be falsely normal; retest at least 3 months later.</li>
<li>Picking a hepatobiliary scan after days of phenobarbital for suspected biliary atresia. Scintigraphy is not a standalone test, and the premedication delays the Kasai. The gold standard is an intraoperative cholangiogram.</li>
</ul>

<h2>Practice question</h2>
<p>A 4-week-old girl is brought to clinic for yellow eyes since age 2 weeks. She was born at 39 weeks and is exclusively breastfed. Over the past week her stools have become pale and putty-colored, and her urine stains the diaper dark yellow. Birth weight was 3.3 kg; today she weighs 3.9 kg. Temperature is 37.0 C, pulse 142/min and respirations 38/min. She has scleral icterus, and the liver edge is palpable 3 cm below the right costal margin. Newborn screening was normal. Total bilirubin is 7.8 mg/dL and direct bilirubin 3.4 mg/dL; ALT is 88 U/L, AST 112 U/L and GGT 410 U/L.</p>
<p>Which of the following is the most appropriate next step in management?</p>
<ol type="A">
<li>Reassure the parents that this is breast milk jaundice and recheck at 2 months</li>
<li>Stop breastfeeding for 48 hours and repeat the bilirubin</li>
<li>Start home phototherapy</li>
<li>Fasting abdominal ultrasound and prompt referral to pediatric gastroenterology or hepatology</li>
<li>Hepatobiliary scintigraphy after 5 days of phenobarbital</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: D.</strong> A direct bilirubin of 3.4 mg/dL is well above 1.0 mg/dL, so this is cholestasis, and pale stools with dark urine make biliary atresia the first diagnosis to exclude; the high GGT fits. Get a fasting ultrasound and refer promptly: about 70% of infants regain bile flow when the Kasai is done within 60 days of life, and fewer than 25% after 90 days. She is 28 days old.</p>
<p><strong>Why the others are wrong.</strong> A: breast milk jaundice is unconjugated with normal stools, and waiting could close the Kasai window. B: stopping breastfeeding does nothing for cholestasis. C: phototherapy acts on unconjugated bilirubin. E: scintigraphy is not a standalone test, and phenobarbital premedication delays the diagnosis.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>Jaundice in the first 24 hours</strong> Measure TSB or TcB as soon as possible; think hemolysis.</li><li><strong>When a TcB needs a confirmatory TSB</strong> TcB 15 mg/dL or more, or within 3 mg/dL of the phototherapy threshold.</li><li><strong>AAP 2022 neurotoxicity risk factors</strong> Gestational age under 38 weeks, albumin under 3.0 g/dL, hemolysis (isoimmune, G6PD or other), sepsis, recent significant instability.</li><li><strong>When escalation of care starts</strong> TSB within 2 mg/dL of the exchange threshold.</li><li><strong>Abnormal direct bilirubin at any age</strong> Above 1.0 mg/dL; with pale stools, start the biliary atresia workup now.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review <a href="https://med-rise.com/board-review/-clinical-pearls-initial-vs-best-diagnostic-test-high-yield-summary">initial vs best diagnostic tests</a>, present a newborn case with <a href="https://med-rise.com/viva/">MedRise Viva</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1542/peds.2022-058859">Kemper AR, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation (AAP). Pediatrics, 2022</a></li>
<li><a href="https://doi.org/10.1097/MPG.0000000000001334">Fawaz R, et al. Guideline for the evaluation of cholestatic jaundice in infants (NASPGHAN/ESPGHAN). J Pediatr Gastroenterol Nutr, 2017</a></li>
<li><a href="https://www.nice.org.uk/guidance/CG98/chapter/Recommendations">NICE. Jaundice in newborn babies under 28 days (CG98), 2010, updated 2023</a></li>
<li><a href="https://www.aafp.org/afp/2023/0500/neonatal-hyperbilirubinemia">Par EJ, et al. Neonatal hyperbilirubinemia: evaluation and treatment. Am Fam Physician, 2023</a></li>
<li><a href="https://doi.org/10.1097/01.JAA.0000000000000120">Chastain AP, et al. Managing neonatal hyperbilirubinemia: an updated guideline. JAAPA, 2024 (PubMed)</a></li>
<li><a href="https://doi.org/10.3390/nu15102261">Gao C, et al. Breast milk constituents and breast milk jaundice: a systematic review. Nutrients, 2023 (PubMed)</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/neonatal-jaundice-algorithm-pediatrics-shelf-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>Trauma Primary Survey Algorithm for the Surgery Shelf: xABCDE Step by Step</title><link>https://med-rise.com/board-review/trauma-primary-survey-algorithm-surgery-shelf</link><guid isPermaLink="true">https://med-rise.com/board-review/trauma-primary-survey-algorithm-surgery-shelf</guid><pubDate>Sun, 15 Nov 2026 06:09:41 -0600</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Study guide</category><category>Board Review</category><description>Run the trauma primary survey step by step for the surgery shelf: stop exsanguinating bleeding, then airway, chest killers, shock, disability and exposure.</description><content:encoded><![CDATA[<p>On the surgery shelf, the primary survey arrives as a hypotensive patient after a crash, a fall or a stab wound, with several abnormal findings and five sensible-looking actions. The question is almost always about order: which threat kills first, and what you fix before anyone goes to the scanner. The 11th edition of ATLS (2025) changed the sequence to xABCDE, so exsanguinating external bleeding now comes before the airway.</p>

<h2>The algorithm</h2>
<p>Fix each problem as you find it, then move to the next letter.</p>
<ol class="sp-flow"><li><span>x: stop exsanguinating bleeding<small>Pumping external bleeding is controlled before the airway. Use direct pressure or wound packing; on a limb, place a tourniquet if pressure fails. No catastrophic bleeding: move to the airway.</small></span></li><li><span>A: airway with spinal motion restriction<small>Obstruction, hypoventilation, hypoxia or a GCS of 8 or less calls for a definitive airway by rapid sequence intubation. ATLS 11 prefers video laryngoscopy and asks you to treat shock first, because induction can cause collapse. If intubation fails, perform a surgical cricothyroidotomy. Restrict spinal motion selectively; rigid collars matter less than before.</small></span></li><li><span>B: find the chest killers<small>Shock with absent breath sounds and a hyperresonant side is tension pneumothorax: decompress at once at the 4th or 5th intercostal space at or just in front of the midaxillary line (finger thoracostomy or needle), then place a chest tube. A sucking wound is an open pneumothorax: occlusive dressing, then a chest tube away from the wound. A dull, silent side with shock is massive hemothorax: a 28 to 32 Fr chest tube; more than 1,500 mL out means thoracotomy is likely.</small></span></li><li><span>C: resuscitate with blood, not liters of saline<small>Activate the massive transfusion protocol early and give balanced products (1:1:1, or whole blood where available), keeping crystalloid to a short bridge. Until bleeding is controlled and if there is no brain injury, accept a systolic pressure of 80 to 90 mm Hg. Give tranexamic acid within 3 hours of injury: 1 g over 10 minutes, then 1 g over 8 hours. Keep ionized calcium normal. If a pelvic fracture may be bleeding, apply a pelvic binder.</small></span></li><li><span>Decide where the bleeding gets fixed<small>Use eFAST and bedside chest and pelvic films. Unstable with free fluid on FAST: the abdomen is the likely source, so the patient goes to the operating room, not to CT. Unstable with a disrupted pelvic ring: close and stabilize the pelvis early, then angioembolization or extraperitoneal packing if bleeding continues. Stable: contrast whole-body CT. A negative FAST does not exclude bleeding.</small></span></li><li><span>D: disability<small>Check GCS, pupils and glucose. A GCS of 8 or less is severe traumatic brain injury, which needs a definitive airway. Unequal or unreactive pupils suggest raised intracranial pressure. With brain injury, the permissive low blood pressure no longer applies.</small></span></li><li><span>E: exposure and temperature<small>Undress the patient fully and log-roll to examine the back. Then prevent hypothermia with warm blankets, warmed fluids and a warm room.</small></span></li><li><span>Adjuncts, then reassess<small>Blood at the urethral meatus is the cardinal sign of urethral injury: get a retrograde urethrogram and never force a catheter. A possible base of skull fracture makes a nasogastric tube relatively contraindicated, so use an orogastric tube. If anything changes, return to x.</small></span></li><li><span>Secondary survey last<small>Only when the primary survey is complete, take a SAMPLE history and examine head to toe.</small></span></li></ol>
<p>Sources differ in places: NICE prefers finger thoracostomy to a needle in hospital; with brain injury the European guideline targets a mean arterial pressure of 80 mm Hg or more and ATLS 11 a systolic above 100 to 110 mm Hg by age; the 2023 EAU guideline allows a gentle catheter attempt by experienced staff, then a suprapubic catheter if it fails. This post follows ATLS 11 for the order and the European guideline for targets.</p>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Arterial bleeding from a thigh wound that soaks through direct pressure</td><td>Exsanguinating external hemorrhage</td><td>Tourniquet now, before the airway</td></tr>
<tr><td>GCS 7 with snoring respirations after a fall</td><td>Severe brain injury, unprotected airway</td><td>Rapid sequence intubation with spinal motion restriction</td></tr>
<tr><td>Hypotension, tachypnea, absent breath sounds and hyperresonance on one side, trachea shifted away</td><td>Tension pneumothorax</td><td>Immediate decompression, then chest tube; no x-ray first</td></tr>
<tr><td>Bubbling chest wall wound</td><td>Open pneumothorax</td><td>Occlusive dressing, then chest tube away from the wound</td></tr>
<tr><td>Shock, dull silent hemithorax, 1,600 mL from the chest tube</td><td>Massive hemothorax</td><td>Blood products and thoracotomy</td></tr>
<tr><td>Stab wound to the chest, hypotension, raised JVP, muffled heart sounds</td><td>Cardiac tamponade</td><td>Ultrasound, then operative repair; pericardiocentesis only as a bridge</td></tr>
<tr><td>Hypotension after a high-energy crash, free fluid in Morison's pouch on FAST</td><td>Intra-abdominal hemorrhage in an unstable patient</td><td>Laparotomy, not CT</td></tr>
<tr><td>Hypotension, pelvic ring fracture, negative FAST</td><td>Pelvic bleeding</td><td>Pelvic binder, then angioembolization or extraperitoneal packing</td></tr>
<tr><td>Normal vital signs after a high-speed crash with several injuries</td><td>Stable blunt polytrauma</td><td>Contrast whole-body CT</td></tr>
<tr><td>Pelvic fracture with blood at the urethral meatus</td><td>Urethral injury</td><td>Retrograde urethrogram; do not force a Foley</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Choosing intubation first while a limb wound is pumping blood. In ATLS 11, exsanguinating external bleeding comes before the airway.</li>
<li>Ordering a chest x-ray to confirm a tension pneumothorax in a crashing patient. It is a clinical diagnosis: decompress when you suspect it and the patient is unstable.</li>
<li>Sending an unstable patient to CT. Unstable patients get bleeding control; stable patients get the scan.</li>
<li>Pouring in liters of crystalloid. Current teaching keeps crystalloid to a short bridge and moves early to blood products.</li>
<li>Reading a negative FAST as "no bleeding." It does not exclude intraperitoneal or retroperitoneal hemorrhage.</li>
<li>Forcing a Foley past resistance when there is blood at the meatus.</li>
</ul>

<h2>Practice question</h2>
<p>A 27-year-old man is brought to the emergency department 20 minutes after a high-speed motorcycle crash. He is anxious and speaks in short phrases. There is no external bleeding. Temperature is 36.4 C, blood pressure 82/54 mm Hg, pulse 134/min, respirations 34/min and oxygen saturation 85% on a non-rebreather mask. The trachea is shifted to the right and the neck veins are distended. Breath sounds are absent on the left, and the left chest is hyperresonant to percussion. Heart sounds are clearly audible. GCS is 14. Point-of-care glucose is 118 mg/dL and venous lactate is 4.2 mmol/L.</p>
<p>Which of the following is the most appropriate next step in management?</p>
<ol type="A">
<li>Portable chest x-ray to confirm the diagnosis</li>
<li>Pericardiocentesis</li>
<li>Immediate decompression of the left chest</li>
<li>Rapid sequence intubation</li>
<li>CT of the chest with intravenous contrast</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: C.</strong> There is no exsanguinating bleeding and he is talking, so the next threat is breathing. Hypotension, hypoxia, an absent and hyperresonant left chest and a trachea pushed to the right make this a tension pneumothorax. Decompress the left chest now (finger thoracostomy or needle at the 4th or 5th intercostal space near the midaxillary line), then place a chest tube and move on to circulation.</p>
<p><strong>Why the others are wrong.</strong> A: in an unstable patient this is a clinical diagnosis; a film only delays the fix. B: tamponade also causes hypotension and distended neck veins, but the heart sounds are muffled and both lungs are aerated; here the heart sounds are clear and the left chest is silent. D: intubation does not relieve the tension, and inducing a patient in shock risks collapse; fix the chest first. E: an unstable patient should not leave the resuscitation bay for CT.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>Order of the primary survey in ATLS 11</strong> xABCDE: exsanguinating bleeding, airway with spinal motion restriction, breathing, circulation, disability, exposure.</li><li><strong>GCS that calls for a definitive airway</strong> 8 or less.</li><li><strong>Chest tube output that makes thoracotomy likely in massive hemothorax</strong> More than 1,500 mL.</li><li><strong>Tranexamic acid dose and time window</strong> 1 g over 10 minutes, then 1 g over 8 hours, within 3 hours of injury.</li><li><strong>Systolic target while bleeding, with no brain injury</strong> 80 to 90 mm Hg until major bleeding is controlled.</li></ul>

<p>Keep going: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review <a href="https://med-rise.com/board-review/-clinical-pearls-initial-vs-best-diagnostic-test-high-yield-summary">initial vs best diagnostic tests</a>, run a trauma case out loud with <a href="https://med-rise.com/viva/">MedRise Viva</a>, or find more study resources on <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://pubmed.ncbi.nlm.nih.gov/41671886/">Ramasamy A. Advanced trauma life support 2025: a brief review of updates. Injury, 2026</a></li>
<li><a href="https://journalfeed.org/article-a-day/2026/new-atls-update-what-you-need-to-know/">JournalFeed. New ATLS update: what you need to know (summary of the Injury review), 2026</a></li>
<li><a href="https://www.mayoclinic.org/medical-professionals/trauma/news/atls-update-what-trauma-professionals-need-to-know/mac-20602992">Mayo Clinic. ATLS update: what trauma professionals need to know, 2026</a></li>
<li><a href="https://doi.org/10.1186/s13054-023-04327-7">Rossaint R, et al. The European guideline on management of major bleeding and coagulopathy following trauma, sixth edition. Crit Care, 2023</a></li>
<li><a href="https://www.nice.org.uk/guidance/NG39/chapter/Recommendations">NICE. Major trauma: assessment and initial management (NG39), 2016</a></li>
<li>Victorian State Trauma System. Major trauma guidelines, 2024: <a href="https://trauma.reach.vic.gov.au/specialist/thoracic-trauma/immediately-life-threatening-injuries/">immediately life-threatening chest injuries</a>, <a href="https://trauma.reach.vic.gov.au/specialist/early-trauma-care/early-management/">early trauma care</a> and <a href="https://trauma.reach.vic.gov.au/specialist/traumatic-brain-injury/primary-survey/">traumatic brain injury primary survey</a></li>
<li><a href="https://www.aast.org/Assets/e60726c6-9bb6-41ec-9eda-69e34a6510d2/638783533948300000/eau-guidelines-on-urological-trauma-2023-pdf">European Association of Urology. Guidelines on urological trauma, limited update, 2023</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/books/NBK547757/">StatPearls: Trauma care principles. NCBI Bookshelf, updated 2023</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/trauma-primary-survey-algorithm-surgery-shelf-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>Hyponatremia Algorithm for the Medicine Shelf: Step-by-Step Workup</title><link>https://med-rise.com/board-review/hyponatremia-algorithm-medicine-shelf</link><guid isPermaLink="true">https://med-rise.com/board-review/hyponatremia-algorithm-medicine-shelf</guid><pubDate>Sat, 14 Nov 2026 13:15:43 -0600</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Study guide</category><category>Board Review</category><description>Work up hyponatremia step by step for the medicine shelf: serum and urine osmolality, urine sodium, volume status, SIADH and safe correction limits.</description><content:encoded><![CDATA[<p>On the medicine shelf, hyponatremia usually arrives as an older patient who is confused, has fallen or has just had a seizure, with a sodium in the 110s or 120s and a medication list that includes an SSRI, a thiazide or carbamazepine. The diagnosis is rarely the hard part. The question tests whether you treat severe symptoms first, read serum osmolality, urine osmolality and urine sodium in the right order, and raise the sodium without overshooting.</p>

<h2>The algorithm</h2>
<p>Work through the steps in order. Severe symptoms jump the queue; everything else follows the labs.</p>
<ol class="sp-flow"><li><span>Screen for severe symptoms<small>Vomiting, seizures, deep somnolence, coma or cardiorespiratory distress mean hyponatremic encephalopathy. Give a 3% saline bolus now, aiming for a 4 to 6 mEq/L rise within 1 to 2 hours, then finish the workup. No severe symptoms: go to step 2.</small></span></li><li><span>Confirm it is hypotonic<small>Serum osmolality below 275 mOsm/kg is true hypotonic hyponatremia. Normal osmolality with very high triglycerides or protein is pseudohyponatremia. High osmolality points to glucose or mannitol; add about 2.4 mEq/L to the sodium for every 100 mg/dL of glucose above 100.</small></span></li><li><span>Decide acute or chronic<small>Documented for under 48 hours is acute. If you cannot tell, treat it as chronic, which makes overcorrection the main danger.</small></span></li><li><span>Read urine osmolality<small>100 mOsm/kg or less means ADH is switched off: primary polydipsia, beer potomania or a tea-and-toast diet. Above 100 means ADH is active, so keep going.</small></span></li><li><span>Examine volume status<small>Edema, ascites or a raised JVP point to heart failure, cirrhosis, nephrotic syndrome or kidney failure. Dry mucosa and orthostasis point to volume loss. Neither means the patient is euvolemic.</small></span></li><li><span>Check urine sodium<small>In a dry patient, 30 mEq/L or less suggests extrarenal loss (vomiting, diarrhea, third spacing), and above 30 suggests renal loss (diuretics, primary adrenal insufficiency, cerebral salt wasting). In a euvolemic patient, above 30 fits SIADH.</small></span></li><li><span>Exclude the SIADH mimics<small>Check TSH and cortisol and review the drug list before you call it SIADH. Hypothyroidism, adrenal insufficiency and diuretics, especially thiazides, can produce the same labs.</small></span></li><li><span>Treat by category at a safe rate<small>Hypovolemic: isotonic saline. SIADH: fluid restriction first. Hypervolemic: fluid restriction and treat the cause. In chronic hyponatremia, keep the rise to 10 mEq/L or less in the first 24 hours, and 8 or less if the risk of osmotic demyelination is high.</small></span></li></ol>
<p>Sources differ on details. The European guideline gives 150 mL of 3% saline over 20 minutes and the US expert panel 100 mL over 10 minutes; both allow up to three boluses. The US panel allows 10 to 12 mEq/L in 24 hours at normal risk, while the more recent European guideline caps the rise at 10 in the first 24 hours and 8 in each 24 hours after that. This post uses the European limits.</p>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Seizure, vomiting or coma with a low sodium</td><td>Severe hyponatremic encephalopathy</td><td>3% saline bolus now; recheck sodium after each bolus</td></tr>
<tr><td>Sodium 128 mEq/L with glucose 600 mg/dL</td><td>Hypertonic hyponatremia from glucose (corrects to about 140)</td><td>Treat the hyperglycemia, not the sodium</td></tr>
<tr><td>Normal serum osmolality, lipemic sample or very high protein</td><td>Pseudohyponatremia</td><td>No sodium treatment; address the lipid or protein problem</td></tr>
<tr><td>Urine osmolality under 100 in a heavy beer drinker or a patient drinking large volumes of water</td><td>Low solute intake or primary polydipsia</td><td>Limit water, raise dietary solute such as protein and recheck sodium often</td></tr>
<tr><td>Vomiting or diarrhea, orthostasis, urine sodium 30 or less</td><td>Hypovolemic, extrarenal loss</td><td>Isotonic saline or a balanced crystalloid</td></tr>
<tr><td>Recently started thiazide, urine sodium above 30</td><td>Diuretic-induced hyponatremia</td><td>Stop the thiazide, replace sodium and potassium, do not restart it</td></tr>
<tr><td>Euvolemic, urine osmolality above 100, urine sodium above 30, on an SSRI or carbamazepine or with small cell lung cancer</td><td>SIADH</td><td>Check TSH and cortisol, then restrict fluid</td></tr>
<tr><td>Urine osmolality above 500, or urine sodium plus potassium higher than serum sodium</td><td>Fluid restriction is likely to fail</td><td>Move to urea, or a low-dose loop diuretic with oral salt</td></tr>
<tr><td>Edema, ascites or a raised JVP</td><td>Hypervolemic hyponatremia (heart failure, cirrhosis, nephrotic syndrome)</td><td>Fluid restriction and treat the underlying disease</td></tr>
<tr><td>Sodium up 12 mEq/L in 18 hours in a malnourished patient with alcohol use disorder</td><td>Overcorrection with high osmotic demyelination risk</td><td>Stop active treatment; re-lower with D5W and desmopressin with expert input</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Sending a seizing or vomiting patient for a head CT or a full workup first. Severe symptoms are an emergency: bolus first, investigate after.</li>
<li>Correcting chronic hyponatremia too fast. Osmotic demyelination shows up a few days later as quadriparesis, parkinsonism or a locked-in state. Risk is highest with sodium 105 or lower, hypokalemia, alcohol use disorder, malnutrition or advanced liver disease.</li>
<li>Choosing 0.9% saline for a euvolemic patient with SIADH. Isotonic saline is for volume depletion. In SIADH it often fails to raise the sodium, and the European guideline treats that failure as a supporting clue for the diagnosis.</li>
<li>Forgetting the glucose. A sodium of 128 with a glucose of 600 mg/dL corrects to about 140, so the sodium is not the problem.</li>
<li>Labeling SIADH without checking thyroid and adrenal function and the medication list. Secondary adrenal insufficiency and hypothyroidism are classic look-alikes.</li>
<li>Missing the rebound. Once volume is restored or a thiazide is stopped, a brisk water diuresis can push the sodium up fast, so recheck it often.</li>
</ul>

<h2>Practice question</h2>
<p>A 76-year-old woman is brought to the emergency department after a generalized tonic-clonic seizure at home that stopped on its own after 2 minutes. Her daughter says she has had headaches and worsening confusion for 3 days. Sertraline was started 4 weeks ago for depression, and she takes no diuretics. Temperature is 37.0 C, blood pressure 132/78 mm Hg, pulse 88/min and respirations 16/min. She is drowsy but rousable and vomits twice during the exam. Mucous membranes are moist, there is no edema and the JVP is normal. Labs: sodium 114 mEq/L, potassium 4.1 mEq/L, glucose 96 mg/dL, creatinine 0.8 mg/dL, serum osmolality 238 mOsm/kg, urine osmolality 460 mOsm/kg and urine sodium 58 mEq/L.</p>
<p>Which of the following is the most appropriate next step in management?</p>
<ol type="A">
<li>Restrict free water intake to less than 1 L per day</li>
<li>Infuse 0.9% saline at 125 mL/h</li>
<li>Give a bolus of 3% saline and recheck the sodium shortly afterward</li>
<li>Start oral tolvaptan</li>
<li>Send TSH and a morning cortisol and wait for the results before treating</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: C.</strong> A seizure, drowsiness and repeated vomiting are severe symptoms, so she needs hypertonic saline now, repeated up to three times if symptoms persist, until the sodium has risen about 4 to 6 mEq/L. The duration is unknown, so treat it as chronic: once symptoms settle, keep the total rise to 10 mEq/L or less in the first 24 hours. Her labs fit SIADH from sertraline: hypotonic serum, urine osmolality above 100, urine sodium above 30 and a euvolemic exam.</p>
<p><strong>Why the others are wrong.</strong> A: fluid restriction is first-line for chronic SIADH without severe symptoms, but it raises the sodium far too slowly to treat cerebral edema. B: isotonic saline is for volume depletion; she is euvolemic, and in SIADH it often fails to raise the sodium. D: tolvaptan is started in hospital at a low dose and titrated over days, so it cannot treat a seizure, and the European guideline recommends against vaptans in profound hyponatremia. E: thyroid and adrenal testing is needed before you confirm SIADH, but it should never delay emergency treatment.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>Serum osmolality that confirms hypotonic hyponatremia</strong> Below 275 mOsm/kg.</li><li><strong>Urine osmolality that means ADH is suppressed</strong> 100 mOsm/kg or less (primary polydipsia, beer potomania, tea-and-toast diet).</li><li><strong>Urine sodium cutoff in the European algorithm</strong> 30 mEq/L.</li><li><strong>Maximum rise in the first 24 hours of chronic hyponatremia</strong> 10 mEq/L, or 8 if osmotic demyelination risk is high.</li><li><strong>First-line treatment for chronic SIADH, and the second line</strong> Fluid restriction; then urea or a low-dose loop diuretic with oral salt.</li></ul>

<p>Keep going: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review <a href="https://med-rise.com/board-review/-clinical-pearls-initial-vs-best-diagnostic-test-high-yield-summary">initial vs best diagnostic tests</a>, talk a case through out loud with <a href="https://med-rise.com/viva/">MedRise Viva</a>, or find more study resources on <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1530/EJE-13-1020">Spasovski G, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia (European Society of Endocrinology, ESICM and ERBP). Eur J Endocrinol, 2014</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/24074529/">Verbalis JG, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med, 2013</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/35852524/">Adrogué HJ, Tucker BM, Madias NE. Diagnosis and management of hyponatremia: a review. JAMA, 2022</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/books/NBK470386/">StatPearls: Hyponatremia. NCBI Bookshelf, updated 2023</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/hyponatremia-algorithm-medicine-shelf-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>Prenatal Aneuploidy Screening Timeline: Which Test at Which Week (OB-GYN Shelf)</title><link>https://med-rise.com/board-review/obgyn-genetic-aneuploidy-screening-timeline</link><guid isPermaLink="true">https://med-rise.com/board-review/obgyn-genetic-aneuploidy-screening-timeline</guid><pubDate>Sat, 13 Sep 2025 15:59:00 -0500</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Guide</category><category>Board Review</category><description>Which prenatal screen or diagnostic test fits each gestational week, what a positive result means, and the next best step after cfDNA, NT or a quad screen.</description><content:encoded><![CDATA[<p>On the OB-GYN shelf, a prenatal genetics question gives a gestational age and a result (a cell-free DNA report, a nuchal translucency measurement or a quad screen pattern) and asks for the next best step. It tests two things: which test is available at that week, and whether the result in hand is a screen or a diagnosis.</p>

<h2>The screening timeline</h2>
<p>ACOG recommends offering every pregnant patient both aneuploidy screening and diagnostic testing, whatever her age or risk. Testing is a choice, and declining all of it is also acceptable.</p>
<ol class="sp-time"><li><span>From 10 weeks: cell-free DNA<small>A maternal blood test that analyzes placental DNA fragments. It is the most sensitive and specific screen for trisomies 21, 18 and 13, and can be drawn any time after 10 weeks. It is still a screen.</small></span></li><li><span>10 to 13 weeks: chorionic villus sampling<small>Diagnostic. Placental tissue is sampled transcervically or transabdominally. It gives the earliest definitive answer.</small></span></li><li><span>10 to 13 6/7 weeks: first-trimester combined screen<small>Nuchal translucency on ultrasound plus serum PAPP-A and hCG. Trisomy 21 pattern: thick NT, low PAPP-A, high hCG.</small></span></li><li><span>15 to 22 6/7 weeks: quad screen<small>Serum AFP, hCG, estriol and inhibin A. Trisomy 21 pattern: low AFP, high hCG, low estriol, high inhibin A. Trisomy 18: AFP, hCG and estriol all low.</small></span></li><li><span>From 15 weeks: amniocentesis<small>Diagnostic. Amniocytes are cultured for karyotype or chromosomal microarray. Amniotic fluid AFP and acetylcholinesterase confirm an open neural tube defect.</small></span></li><li><span>15 to 22 weeks: maternal serum AFP<small>Screens for open neural tube defects. Offer it (or rely on the anatomy scan) even when cfDNA was the aneuploidy screen, because cfDNA does not screen for neural tube defects.</small></span></li><li><span>18 to 22 weeks: anatomy ultrasound<small>The detailed fetal survey. Structural anomalies found here, or an earlier NT of 3.0 mm or more, raise the risk of aneuploidy and change the next step.</small></span></li></ol>

<h2>Screen or diagnosis: the line the exam draws</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Test</th><th>Type</th><th>Window</th><th>What it can tell you</th></tr></thead>
<tbody>
<tr><td>Cell-free DNA</td><td>Screen</td><td>10 weeks onward</td><td>Risk of trisomy 21, 18, 13 and sex chromosome aneuploidy; no information on neural tube defects</td></tr>
<tr><td>First-trimester combined screen</td><td>Screen</td><td>10 to 13 6/7 weeks</td><td>Risk of trisomy 21 and 18; a thick NT also flags cardiac defects</td></tr>
<tr><td>Quad screen</td><td>Screen</td><td>15 to 22 6/7 weeks</td><td>Risk of trisomy 21 and 18, plus neural tube defect risk from the AFP</td></tr>
<tr><td>Chorionic villus sampling</td><td>Diagnostic</td><td>10 to 13 weeks</td><td>Fetal karyotype or microarray; cannot measure amniotic fluid AFP</td></tr>
<tr><td>Amniocentesis</td><td>Diagnostic</td><td>15 weeks onward</td><td>Karyotype or microarray, plus amniotic fluid AFP and acetylcholinesterase</td></tr>
</tbody>
</table></div>
<p>A positive screen is never treated as a diagnosis. No irreversible decision, including termination, rests on a cfDNA, combined or quad screen result alone.</p>

<h2>The algorithm after an abnormal result</h2>
<ol class="sp-flow"><li><span>Confirm what kind of result it is<small>A screen gives a risk. Only CVS or amniocentesis gives a fetal diagnosis.</small></span></li><li><span>Offer genetic counseling<small>Explain the positive predictive value, which depends on the prior risk: a positive cfDNA in a 25-year-old is less likely to be a true positive than the same result in a 40-year-old.</small></span></li><li><span>Offer a diagnostic test by gestational age<small>CVS at 10 to 13 weeks, or amniocentesis from 15 weeks. Do not repeat the screen or add a second screen to settle the question.</small></span></li><li><span>Elevated maternal serum AFP: ultrasound first<small>Wrong dates, multiple gestation and fetal demise raise AFP too. Ultrasound confirms dating and looks for an open neural tube or abdominal wall defect before amniocentesis.</small></span></li><li><span>NT of 3.0 mm or more: three referrals<small>Offer diagnostic testing, a detailed anatomy ultrasound and fetal echocardiography, even if the aneuploidy screen comes back low risk.</small></span></li><li><span>Anomaly on ultrasound: order chromosomal microarray<small>When a structural anomaly is seen, microarray on the diagnostic sample is preferred over a karyotype because it detects smaller deletions and duplications.</small></span></li></ol>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>11 weeks, cfDNA high risk for trisomy 21</td><td>Positive screen</td><td>Genetic counseling and CVS (or amniocentesis from 15 weeks)</td></tr>
<tr><td>cfDNA returns "no call"</td><td>Failed screen, linked to higher aneuploidy risk</td><td>Counseling, detailed ultrasound and an offer of diagnostic testing; do not simply reassure</td></tr>
<tr><td>17 weeks, MSAFP 3.1 MoM</td><td>Elevated AFP</td><td>Ultrasound to confirm dates and look for defects</td></tr>
<tr><td>Quad screen: low AFP, high hCG, low estriol, high inhibin A</td><td>Trisomy 21 pattern</td><td>Counseling and amniocentesis</td></tr>
<tr><td>Quad screen: AFP, hCG and estriol all low</td><td>Trisomy 18 pattern</td><td>Counseling and amniocentesis</td></tr>
<tr><td>12 weeks, NT 3.5 mm</td><td>Thick nuchal translucency</td><td>Diagnostic testing, detailed anatomy scan, fetal echocardiography</td></tr>
<tr><td>9 weeks, patient wants a diagnostic test now</td><td>Too early for CVS</td><td>Wait until 10 weeks; CVS before 10 weeks is linked to limb reduction defects</td></tr>
<tr><td>CVS result shows mosaicism</td><td>Possible confined placental mosaicism</td><td>Amniocentesis to test the fetus</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Treating cfDNA as diagnostic. It is the best screen, not a diagnosis, and its positive predictive value falls in low-risk patients.</li>
<li>Ordering amniocentesis for an elevated MSAFP before an ultrasound. Dating error is the most common cause of an abnormal AFP.</li>
<li>Choosing amniocentesis at 12 weeks. Amniocentesis before 15 weeks carries higher loss rates and a risk of talipes; CVS is the first-trimester diagnostic test.</li>
<li>Assuming a normal cfDNA rules out a neural tube defect. It does not; that is the job of MSAFP or the anatomy scan.</li>
<li>Running two aneuploidy screens at the same time. Parallel screening raises false positives without improving detection.</li>
<li>Limiting the offer of diagnostic testing to patients 35 and older. Every patient is offered both screening and diagnostic testing.</li>
</ul>

<h2>Practice question</h2>
<p>A 29-year-old woman, gravida 1, para 0, at 11 weeks of gestation comes for a follow-up visit. Her pregnancy has been uncomplicated, and dating was confirmed by a crown-rump length at 8 weeks. She chose cell-free DNA screening at her first visit; the report shows a high risk for trisomy 21. She is distressed and says she would consider ending the pregnancy if the fetus has Down syndrome. Vital signs are normal. Ultrasound today shows a single live intrauterine fetus with a crown-rump length consistent with 11 weeks.</p>
<p>Which of the following is the most appropriate next step in management?</p>
<ol type="A">
<li>Repeat cell-free DNA screening in 2 weeks</li>
<li>Quad screen at 16 weeks</li>
<li>Genetic counseling and chorionic villus sampling</li>
<li>Counseling about termination based on the cfDNA result</li>
<li>Reassurance, because she is younger than 35</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: C.</strong> A high-risk cfDNA result is a positive screen. It needs confirmation with a diagnostic test before any irreversible decision. At 11 weeks, CVS is available now and gives a fetal karyotype or microarray; amniocentesis from 15 weeks is the alternative if she prefers to wait.</p>
<p><strong>Why the others are wrong.</strong> A and B: repeating the screen or adding a second screen cannot confirm or exclude the diagnosis. D: decisions about the pregnancy should not rest on a screening result, which can be a false positive, especially at lower prior risk. E: age does not make a positive result reassuring, and every patient is offered diagnostic testing.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>Earliest aneuploidy screen</strong> cfDNA, from 10 weeks.</li><li><strong>First-trimester combined screen</strong> NT plus PAPP-A and hCG, 10 to 13 6/7 weeks.</li><li><strong>Quad screen in trisomy 21</strong> AFP low, hCG high, estriol low, inhibin A high.</li><li><strong>Diagnostic windows</strong> CVS 10 to 13 weeks; amniocentesis from 15 weeks.</li><li><strong>Elevated MSAFP</strong> Ultrasound first, to check dates and look for defects.</li><li><strong>NT 3.0 mm or more</strong> Diagnostic testing, detailed anatomy scan and fetal echocardiography.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review the <a href="https://med-rise.com/board-review/first-trimester-bleeding-algorithm-obgyn-shelf">first-trimester bleeding algorithm</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1097/AOG.0000000000004084">American College of Obstetricians and Gynecologists. Screening for fetal chromosomal abnormalities. Practice Bulletin No. 226. Obstet Gynecol, 2020 (PubMed 32804883)</a></li>
<li><a href="https://doi.org/10.1097/AOG.0000000000001405">American College of Obstetricians and Gynecologists. Prenatal diagnostic testing for genetic disorders. Practice Bulletin No. 162. Obstet Gynecol, 2016 (PubMed 26938573)</a></li>
<li><a href="https://www.aafp.org/pubs/afp/issues/2020/0415/p481.html">LeFevre NM, Sundermeyer RL. Fetal aneuploidy: screening and diagnostic testing. Am Fam Physician, 2020;101(8):481-488</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/9lrde3bz3ln38ez81m82tlqonf0zft-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>Endometrial Cancer for the OB-GYN Shelf: Risk Factors, the Bleeding Workup and FIGO 2023</title><link>https://med-rise.com/board-review/endometrial-cancer-mind-map-for-ob-gyn-shelf</link><guid isPermaLink="true">https://med-rise.com/board-review/endometrial-cancer-mind-map-for-ob-gyn-shelf</guid><pubDate>Sat, 23 Aug 2025 13:26:52 -0500</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Study guide</category><category>Board Review</category><description>Unopposed estrogen, the 2026 ACOG postmenopausal bleeding workup, hyperplasia management, Lynch syndrome and FIGO 2023 staging for the OB-GYN shelf.</description><content:encoded><![CDATA[<p>Endometrial cancer questions on the OB-GYN shelf almost always begin with bleeding: a postmenopausal woman with spotting, an obese woman with irregular heavy periods, or a patient on tamoxifen. The question is rarely the diagnosis. It is the next step in the workup, or the treatment of what the biopsy shows.</p>

<h2>The progression from unopposed estrogen to cancer</h2>
<ol class="sp-path"><li><span>Unopposed estrogen<small>Obesity, anovulation, estrogen-only therapy, tamoxifen</small></span></li><li><span>Hyperplasia without atypia<small>Low cancer risk; progestin</small></span></li><li><span>Atypical hyperplasia (EIN)<small>Precancer; hysterectomy</small></span></li><li><span>Endometrioid carcinoma<small>Usually low grade and early stage</small></span></li></ol>
<p>This is the classic estrogen-driven (type I) path, behind most endometrial cancers. The second group, the non-endometrioid or type II cancers (serous and clear cell carcinoma), arises in atrophic endometrium in older women, is often p53-abnormal, and spreads early.</p>

<h2>Risk factors and protective factors</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Raises risk</th><th>Why</th><th>Lowers risk</th></tr></thead>
<tbody>
<tr><td>Obesity</td><td>Adipose tissue converts androgens to estrone</td><td>Combined hormonal contraception</td></tr>
<tr><td>Chronic anovulation, including PCOS</td><td>Estrogen without cyclic progesterone</td><td>Progestin therapy, including the levonorgestrel IUD</td></tr>
<tr><td>Estrogen-only therapy with an intact uterus</td><td>Unopposed estrogen</td><td>Adding a progestin to menopausal estrogen</td></tr>
<tr><td>Tamoxifen</td><td>Estrogen agonist in the endometrium</td><td>Parity</td></tr>
<tr><td>Early menarche, late menopause, nulliparity</td><td>Longer estrogen exposure</td><td></td></tr>
<tr><td>Lynch syndrome</td><td>Mismatch repair deficiency</td><td></td></tr>
<tr><td>Diabetes, older age</td><td>Associated factors</td><td></td></tr>
</tbody>
</table></div>

<h2>The postmenopausal bleeding work-up</h2>
<p>About 90% of patients with endometrial cancer present with abnormal bleeding, so any postmenopausal bleeding is evaluated.</p>
<ol class="sp-flow"><li><span>Take every episode seriously<small>One episode of spotting after menopause is enough to start the workup.</small></span></li><li><span>Transvaginal ultrasound and endometrial sampling together<small>In April 2026, ACOG updated its guidance: for most patients, the initial evaluation combines transvaginal ultrasound with endometrial tissue sampling, usually an office biopsy.</small></span></li><li><span>Do not let a thin stripe close the case<small>An endometrial thickness of 4 mm or less is no longer enough on its own to exclude cancer in most patients. Aggressive non-endometrioid cancers may not thicken the stripe, and fibroids often make the endometrium hard to see.</small></span></li><li><span>Persistent bleeding or a nondiagnostic biopsy<small>Hysteroscopy with directed biopsy, or dilation and curettage.</small></span></li><li><span>Treat by the pathology<small>Hyperplasia, atypical hyperplasia or cancer, as below.</small></span></li></ol>
<p>Sources differ here: older question banks and the 2018 ACOG opinion allowed ultrasound alone, with no biopsy, when the endometrium measured 4 mm or less. The 2026 update replaced that triage rule for most patients. If an exam question offers both, the safest answer is the one that gets tissue.</p>

<h2>Management by biopsy result</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Biopsy shows</th><th>Management</th></tr></thead>
<tbody>
<tr><td>Hyperplasia without atypia</td><td>Progestin (levonorgestrel IUD or oral), remove the estrogen source, repeat sampling</td></tr>
<tr><td>Atypical hyperplasia (endometrial intraepithelial neoplasia)</td><td>Total hysterectomy; a concurrent cancer is often present. Progestin is the alternative for patients who want fertility or cannot have surgery</td></tr>
<tr><td>Endometrial carcinoma</td><td>Surgical staging: total hysterectomy, bilateral salpingo-oophorectomy and sentinel lymph node mapping, often minimally invasive. Test every tumor for mismatch repair status</td></tr>
</tbody>
</table></div>

<h2>FIGO 2023 staging in brief</h2>
<ul>
<li><strong>Stage I</strong>: confined to the uterine corpus. Aggressive histology (serous, clear cell, high-grade endometrioid, carcinosarcoma) without myometrial invasion is IC.</li>
<li><strong>Stage II</strong>: cervical stromal invasion, substantial lymphovascular invasion in a non-aggressive type, or an aggressive type with any myometrial invasion (IIC).</li>
<li><strong>Stage III</strong>: local or regional spread: adnexa or serosa, vagina or parametria, pelvic or para-aortic nodes.</li>
<li><strong>Stage IV</strong>: bladder or bowel mucosa, extrapelvic peritoneum, or distant metastasis.</li>
<li><strong>Molecular class</strong>: FIGO encourages POLE, mismatch repair, p53 and NSMP classification for all tumors. In stage I and II, a POLE mutation downstages to IAm, and p53-abnormal tumors with myometrial invasion are upstaged to IICm.</li>
</ul>

<h2>Lynch syndrome and endometrial cancer</h2>
<p>Endometrial cancer is often the first cancer in women with Lynch syndrome. Mismatch repair testing of every endometrial cancer finds these families. For known carriers, the ACG suggests offering endometrial cancer screening with endometrial sampling from age 30 to 35, and discussing risk-reducing hysterectomy with bilateral salpingo-oophorectomy once childbearing is complete.</p>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>64-year-old with one episode of spotting, BMI 37</td><td>Postmenopausal bleeding</td><td>Transvaginal ultrasound and endometrial biopsy</td></tr>
<tr><td>Woman on tamoxifen for breast cancer with new bleeding</td><td>Tamoxifen-related endometrial pathology</td><td>Endometrial sampling</td></tr>
<tr><td>35-year-old with PCOS, irregular heavy bleeding, BMI 34</td><td>Chronic anovulation with unopposed estrogen</td><td>Endometrial biopsy; age alone does not exclude it</td></tr>
<tr><td>Biopsy shows atypical hyperplasia, childbearing complete</td><td>Precancer with a high rate of concurrent cancer</td><td>Total hysterectomy</td></tr>
<tr><td>Atypical hyperplasia, 29 years old, wants pregnancy</td><td>Fertility-sparing case</td><td>High-dose progestin (often a levonorgestrel IUD) with repeat sampling</td></tr>
<tr><td>Endometrial cancer at 44, father had colon cancer at 46</td><td>Lynch syndrome</td><td>Mismatch repair testing and genetic counseling</td></tr>
<tr><td>Nondiagnostic office biopsy, bleeding continues</td><td>Inadequate sample</td><td>Hysteroscopy with directed biopsy</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Reassuring a patient with postmenopausal bleeding because the stripe is 4 mm or less. Under the 2026 ACOG update, most patients get tissue sampling as well.</li>
<li>Waiting for a second episode of postmenopausal bleeding before evaluating.</li>
<li>Skipping the biopsy in a premenopausal patient under 45 who has years of unopposed estrogen.</li>
<li>Treating atypical hyperplasia with observation, or treating hyperplasia without atypia with hysterectomy as the default.</li>
<li>Ordering Pap testing or CA-125 to diagnose endometrial cancer. Neither replaces endometrial sampling.</li>
<li>Forgetting mismatch repair testing, which identifies Lynch syndrome in the patient's family.</li>
</ul>

<h2>Practice question</h2>
<p>A 61-year-old woman comes to the office because of vaginal spotting on three occasions over the past 2 months. Menopause occurred at age 52. She takes no hormone therapy. She has type 2 diabetes and hypertension, and her BMI is 36 kg/m². Pelvic examination shows a normal cervix and a normal-sized uterus. A cervical screening test 1 year ago was normal. Transvaginal ultrasound shows an endometrial thickness of 3 mm.</p>
<p>Which of the following is the most appropriate next step?</p>
<ol type="A">
<li>Reassurance and follow-up in 6 months</li>
<li>Endometrial biopsy</li>
<li>Serum CA-125</li>
<li>Vaginal estrogen cream</li>
<li>Total hysterectomy</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: B.</strong> She has recurrent postmenopausal bleeding and risk factors for endometrial cancer. Recurrent bleeding has always called for tissue sampling regardless of endometrial thickness, and the 2026 ACOG update now pairs ultrasound with tissue sampling for most patients at the first evaluation.</p>
<p><strong>Why the others are wrong.</strong> A: a thin endometrium does not exclude cancer, especially with persistent bleeding. C: CA-125 is not a diagnostic test for endometrial cancer. D: treating presumed atrophy without tissue risks missing a cancer. E: hysterectomy is not done before a tissue diagnosis.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>Most common presenting sign</strong> Abnormal or postmenopausal bleeding (about 90%).</li><li><strong>2026 ACOG workup</strong> Transvaginal ultrasound plus endometrial sampling for most patients.</li><li><strong>Hyperplasia without atypia</strong> Progestin.</li><li><strong>Atypical hyperplasia (EIN)</strong> Hysterectomy.</li><li><strong>Type II tumors</strong> Serous or clear cell, atrophic endometrium, p53-abnormal, aggressive.</li><li><strong>FIGO 2023</strong> Molecular class can downstage (POLE) or upstage (p53-abnormal).</li><li><strong>Every endometrial cancer</strong> Mismatch repair testing.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review the <a href="https://med-rise.com/board-review/cervical-cancer-shelf-study-guide">cervical cancer study guide</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1097/AOG.0000000000006275">American College of Obstetricians and Gynecologists. Updated guidance regarding the role of transvaginal ultrasonography in evaluating the endometrium of individuals with postmenopausal bleeding. Clinical Practice Update. Obstet Gynecol, 2026 (PubMed 41990335)</a></li>
<li><a href="https://consultqd.clevelandclinic.org/new-guidance-supports-dual-assessment-methods-for-postmenopausal-bleeding">Cleveland Clinic Consult QD. New guidance supports dual assessment methods for postmenopausal bleeding, 2026</a></li>
<li><a href="https://doi.org/10.1097/01.AOG.0000465189.50026.20">American College of Obstetricians and Gynecologists. Endometrial intraepithelial neoplasia. Committee Opinion No. 631. Obstet Gynecol, 2015 (PubMed 25932867)</a></li>
<li><a href="https://doi.org/10.1002/ijgo.14923">Berek JS, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet, 2023 (PubMed 37337978)</a></li>
<li><a href="https://doi.org/10.1038/ajg.2014.435">Syngal S, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol, 2015 (PubMed 25645574)</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/articles/og/endometrial-cancer-mind-map-for-ob-gyn-shelf-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>Cervical Cancer for the OB-GYN Shelf: 2026 Screening Rules, Abnormal Results and FIGO Staging</title><link>https://med-rise.com/board-review/cervical-cancer-shelf-study-guide</link><guid isPermaLink="true">https://med-rise.com/board-review/cervical-cancer-shelf-study-guide</guid><pubDate>Sat, 23 Aug 2025 13:23:45 -0500</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Study guide</category><category>Board Review</category><description>Who gets cytology, primary HPV or self-collection in 2026, what to do with an abnormal result, HPV vaccine timing and the FIGO 2018 stages for the OB-GYN shelf.</description><content:encoded><![CDATA[<p>Cervical cancer on the OB-GYN shelf is mostly a screening topic. A question gives an age, a test result and sometimes a pregnancy, and asks what happens next: routine screening, a repeat test, colposcopy or treatment. Staging appears less often, usually as one finding (hydronephrosis, parametrial spread) that sets the stage.</p>

<h2>The screening timeline</h2>
<p>For average-risk patients with a cervix, following ACOG guidance updated in 2026.</p>
<ol class="sp-time"><li><span>Under 21: no screening<small>Regardless of sexual activity. HPV infection at this age usually clears.</small></span></li><li><span>21 to 29: cytology every 3 years<small>HPV testing is not used for routine screening under 30 in this schedule. The American Cancer Society instead starts at 25 with primary HPV testing every 5 years.</small></span></li><li><span>30 to 65: primary high-risk HPV testing every 5 years, preferred<small>Clinician-collected samples are preferred. Self-collected vaginal HPV testing with an FDA-approved device is an acceptable option; after a negative self-collected test, ACS and the Enduring Consensus guidelines repeat in 3 years. Cotesting every 5 years or cytology every 3 years remains acceptable.</small></span></li><li><span>Over 65: stop after adequate negative screening<small>ACS now asks for negative HPV-based tests at 60 and 65 before exit. Patients with a history of CIN2 or worse continue for at least 25 years after treatment.</small></span></li><li><span>After hysterectomy: usually stop<small>If the cervix was removed for a benign reason and there is no history of CIN2 or worse, screening ends.</small></span></li></ol>
<p>Sources differ on the details: the USPSTF's December 2024 draft also prefers primary HPV testing from 30 to 65 and includes self-collection, but on a 5-year interval. Exams follow the core schedule above, which all groups share.</p>

<h2>HPV vaccination</h2>
<ul>
<li>Routine at 11 to 12 years; it can start at 9.</li>
<li>Catch-up through 26 years for anyone not adequately vaccinated.</li>
<li>27 to 45 years: shared clinical decision-making, not routine.</li>
<li>Two doses (0 and 6 to 12 months) if started before the 15th birthday; three doses if started at 15 or later or if immunocompromised.</li>
<li>Vaccinated patients follow the same screening schedule.</li>
</ul>

<h2>The approach to an abnormal result</h2>
<p>The 2019 ASCCP guidelines manage by risk: the test result plus prior history estimate the immediate risk of CIN3 or worse, and that risk sets the next step.</p>
<ol class="sp-flow"><li><span>HPV 16 or 18 positive<small>Colposcopy, whatever the cytology shows.</small></span></li><li><span>Other high-risk HPV types positive<small>Reflex cytology on the same sample decides: normal cytology usually means repeat HPV testing in 1 year; ASC-US or worse means colposcopy.</small></span></li><li><span>ASC-US with a negative HPV test<small>Repeat HPV-based testing in 3 years.</small></span></li><li><span>LSIL, or ASC-US that is HPV positive<small>Colposcopy for most patients 25 and older.</small></span></li><li><span>HSIL<small>Colposcopy, or expedited excision (LEEP) without colposcopy in nonpregnant patients 25 or older when the risk is high, such as HSIL with HPV 16.</small></span></li><li><span>Atypical glandular cells<small>Colposcopy with endocervical sampling, plus endometrial sampling if 35 or older or at risk for endometrial cancer.</small></span></li><li><span>CIN2 or CIN3 on biopsy<small>Excision, usually LEEP. Observation is an option for CIN2 in patients concerned about future pregnancy.</small></span></li></ol>
<p>Patients 21 to 24 are managed more conservatively: ASC-US or LSIL means repeat cytology in 1 year rather than colposcopy. In pregnancy, colposcopy is safe, endocervical curettage is avoided, and treatment of CIN waits until after delivery unless invasive cancer is suspected.</p>

<h2>FIGO 2018 staging</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Stage</th><th>Extent</th><th>The detail that gets tested</th></tr></thead>
<tbody>
<tr><td>IA1</td><td>Microscopic, stromal invasion 3 mm or less</td><td>Lateral width no longer counts</td></tr>
<tr><td>IA2</td><td>Stromal invasion more than 3 mm and up to 5 mm</td><td>Still microscopic</td></tr>
<tr><td>IB1 to IB3</td><td>Confined to the cervix, split by size: 2 cm or less, 2 to 4 cm, more than 4 cm</td><td>IB3 is treated as locally advanced</td></tr>
<tr><td>IIA</td><td>Upper two-thirds of the vagina, no parametrial invasion</td><td></td></tr>
<tr><td>IIB</td><td>Parametrial invasion, not to the pelvic wall</td><td></td></tr>
<tr><td>IIIA to IIIB</td><td>Lower third of the vagina, or pelvic wall, or hydronephrosis or a nonfunctioning kidney</td><td>Hydronephrosis means at least IIIB</td></tr>
<tr><td>IIIC1 and IIIC2</td><td>Pelvic or para-aortic lymph node metastasis</td><td>Imaging or pathology can assign it</td></tr>
<tr><td>IVA and IVB</td><td>Bladder or rectal mucosa, or distant metastasis</td><td></td></tr>
</tbody>
</table></div>
<p>In broad terms, early disease is treated surgically (conization or simple hysterectomy for IA1, radical hysterectomy with nodal assessment for small IB tumors), and locally advanced disease (IB3 and higher) with concurrent cisplatin-based chemoradiation and brachytherapy.</p>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>19-year-old, sexually active, asks for a Pap test</td><td>Below screening age</td><td>No cervical screening; offer HPV vaccine and STI testing</td></tr>
<tr><td>26-year-old, normal cytology 3 years ago</td><td>Due for routine screening</td><td>Cytology (or primary HPV at 25 or older under ACS)</td></tr>
<tr><td>35-year-old, primary HPV positive for HPV 16</td><td>High immediate risk</td><td>Colposcopy</td></tr>
<tr><td>40-year-old, HPV positive (not 16 or 18), reflex cytology normal</td><td>Lower risk</td><td>Repeat HPV testing in 1 year</td></tr>
<tr><td>23-year-old with LSIL</td><td>Young patient, likely to clear</td><td>Repeat cytology in 1 year</td></tr>
<tr><td>Pregnant at 14 weeks with HSIL</td><td>Abnormal screen in pregnancy</td><td>Colposcopy without endocervical curettage; defer treatment unless cancer suspected</td></tr>
<tr><td>Cervical mass and new bilateral hydronephrosis</td><td>Pelvic wall or ureteral involvement</td><td>Stage at least IIIB; chemoradiation</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Screening a 19-year-old because she is sexually active, or adding HPV testing at 21 to 24.</li>
<li>Repeating cytology for an HPV 16 positive result. It goes to colposcopy.</li>
<li>Sending a 22-year-old with LSIL to colposcopy.</li>
<li>Performing endocervical curettage, or treating CIN, during pregnancy.</li>
<li>Stopping screening at 65 without confirming adequate prior negative results.</li>
<li>Using the old 7 mm width criterion for stage IA. FIGO 2018 removed it.</li>
<li>Telling a vaccinated patient she can skip screening.</li>
</ul>

<h2>Practice question</h2>
<p>A 34-year-old woman, gravida 2, para 2, comes for a routine visit. Her last screening was 5 years ago with a negative primary HPV test. She has no symptoms. She uses a levonorgestrel IUD and has had one sexual partner for 8 years. Pelvic examination is normal. A clinician-collected primary HPV test is positive for HPV 16.</p>
<p>Which of the following is the most appropriate next step in management?</p>
<ol type="A">
<li>Repeat HPV testing in 1 year</li>
<li>Repeat HPV testing in 3 years</li>
<li>Colposcopy</li>
<li>Loop electrosurgical excision procedure</li>
<li>Routine screening in 5 years</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: C.</strong> Under the 2019 ASCCP risk-based guidelines, a positive test for HPV 16 or 18 carries enough immediate risk of CIN3 or worse to require colposcopy, regardless of the cytology result.</p>
<p><strong>Why the others are wrong.</strong> A and B: surveillance intervals apply to lower-risk results, such as HPV positivity for other types with normal cytology. D: expedited excision without colposcopy is reserved for very high-risk results, such as HSIL with HPV 16. E: a positive high-risk HPV result ends routine screening until it is worked up.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>21 to 29</strong> Cytology every 3 years.</li><li><strong>30 to 65</strong> Primary HPV every 5 years preferred; self-collection is an option (repeat in 3 years after a negative self-collected test under ACS).</li><li><strong>HPV 16 or 18 positive</strong> Colposcopy.</li><li><strong>Ages 21 to 24 with ASC-US or LSIL</strong> Repeat cytology in 1 year.</li><li><strong>HPV vaccine</strong> Routine at 11 to 12, catch-up to 26, two doses if started before 15.</li><li><strong>Hydronephrosis</strong> Stage IIIB at least.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review <a href="https://med-rise.com/board-review/endometrial-cancer-mind-map-for-ob-gyn-shelf">endometrial cancer for the OB-GYN shelf</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://www.healio.com/news/womens-health-ob-gyn/20260424/acog-updates-cervical-cancer-screening-guidance-to-include-selfcollection-option">Healio. ACOG updates cervical cancer screening guidance to include self-collection option. April 24, 2026</a></li>
<li><a href="https://www.guidelinecentral.com/guideline/5213580/">American College of Obstetricians and Gynecologists. Cervical cancer screening guidance, 2026 (Guideline Central summary)</a></li>
<li><a href="https://doi.org/10.3322/caac.70041">Perkins RB, et al. Self-collected vaginal specimens for HPV testing and guidance on screening exit: an update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin, 2026 (PubMed 41342729)</a></li>
<li><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening-adults-adolescents">US Preventive Services Task Force. Cervical cancer: screening (including the December 2024 draft update)</a></li>
<li><a href="https://doi.org/10.1097/LGT.0000000000000525">Perkins RB, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis, 2020 (PubMed 32243307)</a></li>
<li><a href="https://doi.org/10.15585/mmwr.mm6832a3">Meites E, et al. Human papillomavirus vaccination for adults: updated recommendations of the ACIP. MMWR, 2019 (PubMed 31415491)</a></li>
<li><a href="https://doi.org/10.1002/ijgo.12749">Bhatla N, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet, 2019 (PubMed 30656645)</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/articles/og/cervical-cancer-shelf-study-guide-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>How to Reset Mental Fatigue During an NBME or Step 2 CK Block: Six In-Seat Techniques</title><link>https://med-rise.com/board-review/how-to-reset-mental-fatigue-during-the-nbme-6-proven-focus-hacks-you-can-do-without-leaving-your-seat</link><guid isPermaLink="true">https://med-rise.com/board-review/how-to-reset-mental-fatigue-during-the-nbme-6-proven-focus-hacks-you-can-do-without-leaving-your-seat</guid><pubDate>Sun, 20 Jul 2025 16:19:43 -0500</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Guide</category><category>Board Review</category><description>How to notice and reset mental fatigue mid-block on a shelf exam or the new 16-block Step 2 CK, with timing math, a 60-second reset and a break plan.</description><content:encoded><![CDATA[<p>Late in a shelf exam or a Step 2 CK day, fatigue rarely feels like tiredness. It shows up as rereading the same stem, second-guessing an answer you knew, or drifting for half a minute before you notice. Those lost minutes and points are recoverable if you catch the signal early and have a reset ready that works without leaving your seat.</p>

<h2>What changed for Step 2 CK in 2026</h2>
<p>For exams taken on or after May 7, 2026, Step 2 CK runs as sixteen 30-minute blocks instead of eight 60-minute blocks. Each block has up to 20 items (USMLE describes 18 to 20 per block), and the total item count and the 9-hour day did not change. You get at least 55 minutes of break time and an optional 5-minute tutorial; finishing the tutorial or a block early can add to your break time. USMLE asks examinees testing after May 7 to practice with the new Step 2 testing experience at starttest.com.</p>
<p>Shorter blocks mean more transitions, more chances to reset, and more chances to lose minutes walking in and out. The pacing math also changed:</p>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Format</th><th>Block length</th><th>Items per block</th><th>Time per item</th></tr></thead>
<tbody>
<tr><td>Step 2 CK from May 7, 2026</td><td>30 minutes</td><td>18 to 20</td><td>About 90 to 100 seconds</td></tr>
<tr><td>Step 2 CK before May 2026</td><td>60 minutes</td><td>Up to 40</td><td>About 90 seconds</td></tr>
</tbody>
</table></div>

<h2>The 60-second reset, step by step</h2>
<p>Use it the moment you notice a fatigue signal, not at the end of the block.</p>
<ol class="sp-flow"><li><span>Name the signal<small>Rereading, drifting, or changing a confident answer. Naming it turns a vague feeling into a cue to act.</small></span></li><li><span>Look away from the screen<small>Ten to 20 seconds at a far point in the room. The clock keeps running, so keep it short.</small></span></li><li><span>Breathe slowly<small>Four or five slow breaths, a long exhale each time, at roughly 6 breaths a minute. Slow-breathing techniques are linked to calmer arousal and better attention in small studies.</small></span></li><li><span>Release one muscle group<small>Drop your shoulders, unclench your jaw, loosen your grip on the mouse.</small></span></li><li><span>Re-enter through the question<small>Read the last line first, then the stem. A fresh entry point beats rereading from the top.</small></span></li><li><span>Apply the time cap<small>If the item has passed about 2 minutes, pick the best answer, flag it and move on.</small></span></li></ol>

<h2>Six in-seat techniques</h2>
<ul>
<li><strong>Slow breathing.</strong> About 6 breaths a minute for one minute. A 2018 systematic review linked slow breathing to higher heart rate variability, more relaxation and better alertness, though the studies were small.</li>
<li><strong>Micro-breaks.</strong> Short pauses of under 10 minutes improved vigor and reduced fatigue in a 2022 meta-analysis; effects on task performance were smaller and less consistent. Use them between blocks, not in the middle of one.</li>
<li><strong>A pacing checkpoint.</strong> In a 30-minute block, check the clock once at the halfway point: about 10 items done at 15 minutes. One check prevents both rushing and drifting.</li>
<li><strong>The flag-and-move rule.</strong> Decide in advance that no item gets more than about 2 minutes on the first pass. Fatigue makes stuck questions stickier.</li>
<li><strong>A fixed reading routine.</strong> Last line, then the stem, then the options. A routine you have drilled carries you when concentration dips.</li>
<li><strong>A physical reset at every transition.</strong> Stand, stretch or roll your shoulders between blocks even if you do not leave the room. Short blocks give you 15 natural reset points.</li>
</ul>

<h2>A sample break schedule</h2>
<p>One way to split about 55 minutes across sixteen 30-minute blocks. Adjust it in practice tests, not on test day.</p>
<ol class="sp-time"><li><span>After blocks 2 and 4: 5 minutes each<small>Water, a short walk, the bathroom.</small></span></li><li><span>After block 6: 5 minutes<small>A small snack.</small></span></li><li><span>After block 8: 20 minutes<small>Real food; the middle of the day is where focus usually drops.</small></span></li><li><span>After blocks 10, 12 and 14: 5 minutes each<small>Short resets for the late blocks, where fatigue errors cluster.</small></span></li><li><span>Keep the rest as a buffer<small>Check-in and walking between the room and your locker use break time too.</small></span></li></ol>

<h2>Signal, meaning, reset</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Signal</th><th>What it usually means</th><th>Reset</th></tr></thead>
<tbody>
<tr><td>Rereading a stem two or three times</td><td>Working memory is overloaded</td><td>60-second reset, then last line first</td></tr>
<tr><td>Changing an answer without a new clue</td><td>Anxiety, not reasoning</td><td>Keep the first answer unless you found a specific fact you missed</td></tr>
<tr><td>Two minutes gone on one item</td><td>Stuck on a hard question</td><td>Best answer, flag, move on</td></tr>
<tr><td>Halfway checkpoint shows 7 items done</td><td>Drifting or overreading</td><td>Tighten the time cap for the next five items</td></tr>
<tr><td>Headache or hunger by mid-day</td><td>Physical fatigue</td><td>Use the long break for food and water</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Pushing through obvious fatigue and spending 4 minutes on one item instead of resetting for one.</li>
<li>Taking long breaks early and having nothing left for the late blocks.</li>
<li>Practicing only untimed questions, so the pace feels new on test day.</li>
<li>Replaying earlier questions in your head during breaks instead of resting. Those items are done.</li>
<li>Testing in the new format without ever practicing a full day of 30-minute blocks.</li>
</ul>

<h2>Scenario: what is the best move?</h2>
<p>You are in block 11 of Step 2 CK. You have read the same 9-line stem three times and still cannot say what it is asking. The block clock shows 13 minutes left with 10 items remaining, and you have 25 minutes of break time banked.</p>
<p>Which response is best?</p>
<ol type="A">
<li>Keep rereading until the question makes sense</li>
<li>Skip all remaining hard items and return at the end</li>
<li>Do a 60-second reset, read the last line first, answer within the time cap and flag</li>
<li>End the block early to take a break, leaving items unanswered</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: C.</strong> Ten items in 13 minutes is about 78 seconds each, so you can afford one minute to reset but not three more rereads. A short reset restores enough focus for the remaining items, the last-line-first entry gives you a new way into the stem, and the flag lets you return if time allows.</p>
<p><strong>Why the others are wrong.</strong> A: rereading while fatigued rarely works and burns the time the other items need. B: skipping several items risks leaving them blank when the clock runs out. D: unanswered items score as wrong; a banked break helps only after the block ends.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>Step 2 CK from May 7, 2026</strong> Sixteen 30-minute blocks, up to 20 items each, same 9-hour day.</li><li><strong>Pace</strong> About 90 to 100 seconds per item; halfway check at 15 minutes.</li><li><strong>Reset</strong> Look away, slow breaths, release tension, re-enter through the last line.</li><li><strong>Time cap</strong> About 2 minutes, then answer and flag.</li><li><strong>Breaks</strong> At least 55 minutes; save some for the late blocks.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, read <a href="https://med-rise.com/resilience/nbme-scores-not-improving">what to do when NBME scores stop improving</a>, or see <a href="https://med-rise.com/medical-news/best-usmle-prep-resources-2025-ai-tools-step2-ck-highyield-img-residency-tips">our guide to Step 2 CK prep resources</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://usmle.org/test-delivery-software-updates-step-2-ck-and-step-1-coming-may-2026">USMLE. Test delivery software updates for Step 2 CK and Step 1 coming May 2026</a></li>
<li><a href="https://www.usmle.org/step-exams/step-2-ck">USMLE. Step 2 CK: test format and break time</a></li>
<li><a href="https://doi.org/10.3389/fnhum.2018.00353">Zaccaro A, et al. How breath-control can change your life: a systematic review on psycho-physiological correlates of slow breathing. Front Hum Neurosci, 2018 (PubMed 30245619)</a></li>
<li><a href="https://doi.org/10.1371/journal.pone.0272460">Albulescu P, et al. "Give me a break!" A systematic review and meta-analysis on the efficacy of micro-breaks for increasing well-being and performance. PLoS One, 2022 (PubMed 36044424)</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace your school's or the testing program's official instructions.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/articles/og/how-to-reset-mental-fatigue-during-the-nbme-6-proven-focus-h-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>GI Cancer Progression Pathways for the Medicine Shelf: Colon, Barrett, H. pylori, Liver</title><link>https://med-rise.com/board-review/-gi-cancer-pathways-medicine-shelf-step-2-ck</link><guid isPermaLink="true">https://med-rise.com/board-review/-gi-cancer-pathways-medicine-shelf-step-2-ck</guid><pubDate>Thu, 03 Apr 2025 23:56:26 -0500</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Guide</category><category>Board Review</category><description>The adenoma-carcinoma sequence, Barrett esophagus, the H. pylori cascade, cirrhosis to HCC and PSC, with the surveillance interval at each step.</description><content:encoded><![CDATA[<p>On the medicine shelf, a GI cancer question rarely asks you to stage a tumor. It describes a patient somewhere on a known path to cancer (a polyp, a segment of Barrett esophagus, an H. pylori infection, cirrhosis) and asks what happens next: the surveillance interval, the test that catches progression, or the treatment that interrupts it. Know where the patient sits on the pathway and the answer follows.</p>

<h2>The adenoma-carcinoma sequence</h2>
<p>Most colorectal cancers follow this chromosomal instability pathway, usually over about 10 years. That decade is the reason screening works.</p>
<ol class="sp-path"><li><span>Normal mucosa<small>APC loss starts the process</small></span></li><li><span>Early adenoma<small>APC lost; crypts proliferate</small></span></li><li><span>Larger adenoma<small>KRAS mutation drives growth</small></span></li><li><span>Advanced adenoma<small>18q loss (DCC, SMAD4)</small></span></li><li><span>Carcinoma<small>TP53 loss allows invasion</small></span></li></ol>
<p>A second route, the microsatellite instability pathway, runs through defective mismatch repair. About 15% of colorectal cancers are MSI-high, but most of those are sporadic (MLH1 promoter hypermethylation, often through sessile serrated lesions with BRAF mutations). Lynch syndrome, the germline form, causes about 3%.</p>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Pathway</th><th>Key genes</th><th>Clinical picture</th><th>What the exam wants</th></tr></thead>
<tbody>
<tr><td>Sporadic adenoma-carcinoma</td><td>APC, KRAS, TP53</td><td>Older adult, often left-sided</td><td>Average-risk screening from age 45</td></tr>
<tr><td>Familial adenomatous polyposis</td><td>Germline APC</td><td>Hundreds to thousands of polyps in adolescence</td><td>Yearly endoscopy from about age 10 to 12; colectomy</td></tr>
<tr><td>Lynch syndrome</td><td>MLH1, MSH2, MSH6, PMS2, EPCAM</td><td>Young patient, right-sided tumor, endometrial cancer in the family</td><td>Colonoscopy every 1 to 2 years from age 20 to 25</td></tr>
<tr><td>Serrated pathway</td><td>BRAF, CpG island methylation</td><td>Flat right-sided sessile serrated lesions</td><td>Complete removal; these are the lesions colonoscopy misses</td></tr>
</tbody>
</table></div>
<p>For average-risk adults, the USPSTF recommends screening from 45 to 75 years, with selective screening from 76 to 85. Options include colonoscopy every 10 years, FIT every year, stool DNA-FIT every 1 to 3 years, and CT colonography or flexible sigmoidoscopy every 5 years. Any positive noninvasive test is followed by colonoscopy.</p>

<h2>The Barrett progression</h2>
<p>Chronic reflux replaces the squamous lining of the distal esophagus with intestinal-type columnar epithelium. Adenocarcinoma of the distal third is the end point.</p>
<ol class="sp-path"><li><span>Chronic GERD<small>Acid and bile injure squamous mucosa</small></span></li><li><span>Barrett, no dysplasia<small>Intestinal metaplasia; PPI and surveillance</small></span></li><li><span>Low-grade dysplasia<small>Confirm with an expert GI pathologist</small></span></li><li><span>High-grade dysplasia<small>Endoscopic eradication therapy</small></span></li><li><span>Esophageal cancer<small>Distal third, glandular</small></span></li></ol>
<p>The ACG suggests a single screening endoscopy for patients with chronic GERD plus three or more risk factors: male sex, age over 50, White race, smoking, obesity, or a first-degree relative with Barrett esophagus or esophageal adenocarcinoma. Surveillance for nondysplastic Barrett: every 5 years if the segment is under 3 cm, every 3 years if it is 3 cm or longer. Confirmed low-grade dysplasia: endoscopic eradication therapy is suggested, with yearly surveillance as an alternative. High-grade dysplasia: endoscopic resection of any visible lesion, then ablation. Esophagectomy is no longer the default answer for dysplasia.</p>
<p>Squamous cell carcinoma follows a different road: smoking, heavy alcohol use, achalasia and caustic injury, with tumors in the upper and middle esophagus.</p>

<h2>The Correa cascade: H. pylori to gastric cancer</h2>
<ol class="sp-path"><li><span>H. pylori infection<small>Chronic active gastritis</small></span></li><li><span>Atrophic gastritis<small>Loss of glands and acid</small></span></li><li><span>Intestinal metaplasia<small>Goblet cells in the stomach</small></span></li><li><span>Dysplasia<small>Precursor lesion</small></span></li><li><span>Gastric cancer<small>Intestinal type</small></span></li></ol>
<p>H. pylori is also the cause of most gastric MALT lymphomas, and low-grade gastric MALT lymphoma often regresses with eradication alone. When susceptibility is unknown, the 2024 ACG guideline recommends 14 days of optimized bismuth quadruple therapy (PPI, bismuth, tetracycline, metronidazole) for treatment-naive patients. Clarithromycin triple therapy is used only when the strain is known to be clarithromycin-susceptible. Confirm eradication at least 4 weeks after treatment with a urea breath test, stool antigen or biopsy, after holding the PPI for 2 weeks.</p>

<h2>The cirrhosis-to-HCC pathway</h2>
<ol class="sp-path"><li><span>Chronic liver injury<small>HBV, HCV, alcohol, MASLD</small></span></li><li><span>Cirrhosis<small>Regenerative nodules and fibrosis</small></span></li><li><span>Dysplastic nodule<small>Premalignant</small></span></li><li><span>Hepatocellular carcinoma<small>Arterial enhancement, washout</small></span></li></ol>
<p>Hepatitis B can cause HCC without cirrhosis, so selected noncirrhotic HBV carriers are screened too. AASLD recommends surveillance with ultrasound, with or without AFP, every 6 months in cirrhosis. A new nodule of 1 cm or more goes to multiphase CT or MRI; arterial-phase hyperenhancement with washout in a cirrhotic liver is diagnostic, so a biopsy is not needed.</p>
<p>Primary sclerosing cholangitis is the biliary version of this story. It carries risk of cholangiocarcinoma, gallbladder cancer and, with coexisting inflammatory bowel disease, colorectal cancer. AASLD guidance: MRI with MRCP, with or without CA 19-9, every year, and colonoscopy every year in patients who also have IBD.</p>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Positive FIT in a 52-year-old</td><td>Possible advanced adenoma or cancer</td><td>Colonoscopy</td></tr>
<tr><td>Colon cancer at 38, mother with endometrial cancer at 45</td><td>Lynch syndrome</td><td>Tumor MMR or MSI testing, genetic counseling, colonoscopy every 1 to 2 years for relatives at risk</td></tr>
<tr><td>Teenager with hundreds of colonic polyps</td><td>Familial adenomatous polyposis</td><td>Genetic testing; plan prophylactic colectomy</td></tr>
<tr><td>4 cm Barrett segment, no dysplasia</td><td>Long-segment nondysplastic Barrett</td><td>PPI and surveillance endoscopy in 3 years</td></tr>
<tr><td>Barrett with high-grade dysplasia</td><td>One step from cancer</td><td>Endoscopic resection and ablation</td></tr>
<tr><td>Dyspepsia, positive stool antigen, no prior treatment</td><td>H. pylori</td><td>14 days of bismuth quadruple therapy, then confirm eradication</td></tr>
<tr><td>Low-grade gastric MALT lymphoma, H. pylori positive</td><td>Antigen-driven lymphoma</td><td>Eradicate H. pylori</td></tr>
<tr><td>Cirrhosis, new 2 cm nodule with arterial enhancement and washout</td><td>Hepatocellular carcinoma</td><td>Diagnosis made on imaging; stage and treat, no biopsy needed</td></tr>
<tr><td>Ulcerative colitis, rising alkaline phosphatase, beaded ducts on MRCP</td><td>Primary sclerosing cholangitis</td><td>Yearly MRCP and yearly colonoscopy</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Calling every MSI-high tumor Lynch syndrome. Most are sporadic; Lynch syndrome accounts for about 3% of colorectal cancers.</li>
<li>Sending Barrett with dysplasia to esophagectomy. Endoscopic eradication therapy is first-line for dysplasia and many early cancers.</li>
<li>Repeating endoscopy for nondysplastic Barrett every year. The interval is 3 or 5 years, set by segment length.</li>
<li>Choosing clarithromycin triple therapy without knowing susceptibility. Bismuth quadruple therapy is the default first-line regimen.</li>
<li>Skipping the eradication test after H. pylori treatment, or testing while the patient is still on a PPI.</li>
<li>Biopsying a classic HCC on multiphase imaging. In cirrhosis, the imaging pattern is enough.</li>
<li>Forgetting the colon in PSC. With coexisting IBD, colorectal cancer surveillance is yearly.</li>
</ul>

<h2>Practice question</h2>
<p>A 58-year-old man comes to the office to discuss the results of an upper endoscopy. He has had heartburn several times a week for 15 years and takes omeprazole daily. He smokes 1 pack of cigarettes daily and has a BMI of 33 kg/m². Endoscopy showed salmon-colored mucosa extending 4 cm above the gastroesophageal junction, with no nodules or ulceration. Biopsies show intestinal metaplasia with goblet cells and no dysplasia.</p>
<p>In addition to continuing the proton pump inhibitor, which of the following is the most appropriate management?</p>
<ol type="A">
<li>Repeat endoscopy in 6 months</li>
<li>Repeat endoscopy in 3 years</li>
<li>Repeat endoscopy in 5 years</li>
<li>Radiofrequency ablation</li>
<li>Esophagectomy</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: B.</strong> He has nondysplastic Barrett esophagus with a segment of 3 cm or longer. The ACG recommends surveillance endoscopy every 3 years for this group, along with long-term acid suppression.</p>
<p><strong>Why the others are wrong.</strong> A: a short interval is used to recheck indefinite or newly found dysplasia, not nondysplastic Barrett. C: 5 years is the interval for segments shorter than 3 cm. D: ablation is for confirmed dysplasia, not nondysplastic Barrett. E: esophagectomy is reserved for cancers that cannot be managed endoscopically.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>Adenoma-carcinoma sequence</strong> APC, then KRAS, then 18q (DCC, SMAD4), then TP53.</li><li><strong>Average-risk colorectal screening</strong> Ages 45 to 75; colonoscopy every 10 years or FIT yearly.</li><li><strong>Lynch surveillance</strong> Colonoscopy every 1 to 2 years from age 20 to 25.</li><li><strong>Nondysplastic Barrett</strong> Every 5 years if under 3 cm, every 3 years if 3 cm or longer.</li><li><strong>H. pylori first-line</strong> Bismuth quadruple therapy for 14 days, then confirm eradication.</li><li><strong>HCC surveillance in cirrhosis</strong> Ultrasound with or without AFP every 6 months.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review <a href="https://med-rise.com/board-review/-gi-cancers-mind-map">GI cancers by organ</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1016/0092-8674(90)90186-I">Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell, 1990 (PubMed 2188735)</a></li>
<li><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening">US Preventive Services Task Force. Colorectal cancer: screening. Final recommendation statement, 2021</a></li>
<li><a href="https://doi.org/10.1038/ajg.2014.435">Syngal S, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol, 2015 (PubMed 25645574)</a></li>
<li><a href="https://doi.org/10.14309/ajg.0000000000001680">Shaheen NJ, et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. Am J Gastroenterol, 2022 (PubMed 35354777)</a></li>
<li><a href="https://doi.org/10.14309/ajg.0000000000002968">Chey WD, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol, 2024 (PubMed 39626064)</a></li>
<li><a href="https://doi.org/10.1097/HEP.0000000000000466">Singal AG, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology, 2023 (PubMed 37199193)</a></li>
<li><a href="https://doi.org/10.1002/hep.32771">Bowlus CL, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2023 (PubMed 36083140)</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/gi-cancer-pathways-medicine-shelf-step-2-ck-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>GI Cancers by Organ for the Medicine Shelf: Risk Factors, Classic Stems and First Tests</title><link>https://med-rise.com/board-review/-gi-cancers-mind-map</link><guid isPermaLink="true">https://med-rise.com/board-review/-gi-cancers-mind-map</guid><pubDate>Thu, 03 Apr 2025 23:19:17 -0500</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Guide</category><category>Board Review</category><description>Esophageal, gastric, pancreatic, liver, biliary and colorectal cancer in one table, plus the workup for painless jaundice and iron deficiency anemia.</description><content:encoded><![CDATA[<p>On the medicine shelf, a GI cancer question usually hands you a risk factor and one physical finding (a smoker with painless jaundice, a man with iron deficiency anemia, a patient with cirrhosis and a new liver nodule) and asks for the first test. The cancer is rarely in doubt. The order of tests is what gets scored.</p>

<h2>GI cancers at a glance</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Cancer</th><th>Biggest risk factors</th><th>Classic stem</th><th>First diagnostic test</th><th>Pearl</th></tr></thead>
<tbody>
<tr><td>Esophageal adenocarcinoma</td><td>Chronic GERD, Barrett esophagus, obesity, smoking</td><td>Older man, progressive dysphagia to solids then liquids, weight loss</td><td>Upper endoscopy with biopsy</td><td>Distal third of the esophagus</td></tr>
<tr><td>Esophageal squamous cell carcinoma</td><td>Smoking, heavy alcohol use, achalasia, caustic injury</td><td>Same dysphagia pattern, upper or middle esophagus</td><td>Upper endoscopy with biopsy</td><td>The most common type worldwide</td></tr>
<tr><td>Gastric adenocarcinoma</td><td>H. pylori, smoked and salted foods, smoking, germline CDH1 (diffuse type)</td><td>Early satiety, weight loss, left supraclavicular node, periumbilical nodule</td><td>Upper endoscopy with biopsy</td><td>Diffuse type: signet ring cells, linitis plastica</td></tr>
<tr><td>Pancreatic adenocarcinoma</td><td>Smoking, chronic pancreatitis, obesity, diabetes, family history, BRCA variants</td><td>Painless jaundice, weight loss, palpable nontender gallbladder, migratory thrombophlebitis</td><td>Pancreatic-protocol (multiphase) CT</td><td>CA 19-9 tracks the disease; it does not make the diagnosis</td></tr>
<tr><td>Hepatocellular carcinoma</td><td>Cirrhosis from any cause, hepatitis B even without cirrhosis, hepatitis C, alcohol, MASLD</td><td>Patient with cirrhosis who decompensates, or a new nodule on surveillance ultrasound</td><td>Multiphase CT or MRI</td><td>Arterial enhancement with washout is diagnostic without biopsy</td></tr>
<tr><td>Cholangiocarcinoma</td><td>Primary sclerosing cholangitis, liver flukes, choledochal cyst</td><td>Painless jaundice with a hilar stricture, often in a patient with ulcerative colitis</td><td>MRI with MRCP</td><td>ERCP with brushings gives tissue and drainage</td></tr>
<tr><td>Gallbladder carcinoma</td><td>Gallstones, porcelain gallbladder, large polyps, PSC</td><td>Found at cholecystectomy, or RUQ pain with weight loss</td><td>Ultrasound, then CT</td><td>In PSC, a gallbladder polyp larger than 8 mm goes to cholecystectomy</td></tr>
<tr><td>Colorectal adenocarcinoma</td><td>Age, adenomas, inflammatory bowel disease, Lynch syndrome, FAP</td><td>Right side: iron deficiency anemia. Left side: hematochezia, narrow stools, obstruction</td><td>Colonoscopy with biopsy</td><td>Streptococcus gallolyticus bacteremia calls for a colonoscopy</td></tr>
</tbody>
</table></div>

<h2>The approach to painless jaundice</h2>
<p>Painless jaundice in an older adult is cancer until proven otherwise. The sequence below is what the shelf rewards.</p>
<ol class="sp-flow"><li><span>Confirm a cholestatic pattern<small>Raised direct bilirubin and alkaline phosphatase out of proportion to the aminotransferases.</small></span></li><li><span>Right upper quadrant ultrasound<small>Look for dilated bile ducts and stones. Dilated ducts without stones point to a distal obstruction.</small></span></li><li><span>Pancreatic-protocol CT for a distal obstruction<small>Multiphase CT shows the mass, its relation to the mesenteric vessels and any liver metastases, which decides resectability.</small></span></li><li><span>No mass on CT but high suspicion: endoscopic ultrasound<small>EUS finds small tumors that CT misses and allows fine-needle biopsy when tissue is needed.</small></span></li><li><span>Hilar stricture: MRI with MRCP, then ERCP<small>MRCP maps the ducts; ERCP adds brushings for cytology and a stent for drainage. This is the cholangiocarcinoma path.</small></span></li><li><span>Use CA 19-9 last<small>It supports the picture and tracks treatment response, but benign biliary obstruction also raises it.</small></span></li></ol>

<h2>The work-up of iron deficiency anemia in an older adult</h2>
<p>In a man or a postmenopausal woman, iron deficiency anemia means GI blood loss until proven otherwise. The 2020 AGA guideline sets the steps.</p>
<ol class="sp-flow"><li><span>Confirm iron deficiency<small>AGA uses a ferritin cutoff of 45 ng/mL to diagnose iron deficiency.</small></span></li><li><span>Bidirectional endoscopy<small>Upper endoscopy and colonoscopy for asymptomatic men and postmenopausal women with iron deficiency anemia.</small></span></li><li><span>Celiac serology before duodenal biopsy<small>In asymptomatic adults, AGA suggests noninvasive celiac testing first and biopsy only if it is positive.</small></span></li><li><span>Test for H. pylori and treat if positive<small>Noninvasive testing is suggested as part of the evaluation.</small></span></li></ol>
<p>Never accept diet or a low-grade cause as the explanation in this group without endoscopy. A right-sided colon cancer often presents with anemia and nothing else.</p>

<h2>Treatment pearls the shelf still asks</h2>
<ul>
<li>Advanced hepatocellular carcinoma: first-line systemic therapy is atezolizumab plus bevacizumab or durvalumab plus tremelimumab (AASLD 2023). Sorafenib is no longer the first-line answer.</li>
<li>Small HCC within transplant criteria in decompensated cirrhosis: liver transplant evaluation. Resection is for patients with preserved liver function.</li>
<li>Resectable pancreatic cancer: surgery with adjuvant chemotherapy (modified FOLFIRINOX for fit patients), or neoadjuvant therapy first. Offer germline genetic testing to every patient.</li>
<li>Low-grade gastric MALT lymphoma with H. pylori: eradication therapy first.</li>
<li>Colorectal cancer after resection: CEA is for surveillance, not for screening.</li>
</ul>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>70-year-old man, hemoglobin 9.8 g/dL, ferritin 6 ng/mL, no GI symptoms</td><td>Iron deficiency anemia from occult GI loss</td><td>Upper endoscopy and colonoscopy</td></tr>
<tr><td>Painless jaundice, palpable nontender gallbladder, dilated ducts without stones</td><td>Periampullary or pancreatic head mass</td><td>Pancreatic-protocol CT</td></tr>
<tr><td>CT negative, persistent obstruction and weight loss</td><td>Small pancreatic tumor</td><td>Endoscopic ultrasound</td></tr>
<tr><td>Recurrent superficial venous clots in different veins, weight loss</td><td>Trousseau syndrome</td><td>Look for an occult cancer, pancreatic first</td></tr>
<tr><td>Cirrhosis, new 2.5 cm nodule on ultrasound</td><td>Possible HCC</td><td>Multiphase CT or MRI</td></tr>
<tr><td>Streptococcus gallolyticus endocarditis</td><td>Colonic neoplasm</td><td>Colonoscopy</td></tr>
<tr><td>Ulcerative colitis, cholestatic labs, hilar stricture</td><td>Cholangiocarcinoma in PSC</td><td>MRCP, then ERCP with brushings</td></tr>
<tr><td>Early satiety, weight loss, hard left supraclavicular node</td><td>Gastric cancer</td><td>Upper endoscopy with biopsy</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Ordering CA 19-9, CEA or AFP to diagnose a cancer. Markers support imaging and track treatment; they do not replace a diagnostic test.</li>
<li>Choosing ERCP as the first test for painless jaundice. Imaging comes first; ERCP is for tissue, brushings or drainage.</li>
<li>Stopping at colonoscopy for iron deficiency anemia. Both the upper and lower GI tract are examined.</li>
<li>Biopsying a liver nodule that already meets imaging criteria for HCC.</li>
<li>Assuming no cirrhosis means no HCC risk. Hepatitis B can cause HCC in a noncirrhotic liver.</li>
<li>Listing sorafenib as first-line therapy for advanced HCC. Immunotherapy combinations replaced it.</li>
</ul>

<h2>Practice question</h2>
<p>A 67-year-old man comes to the physician because of yellow skin and dark urine for 2 weeks. He has lost 6 kg over 3 months without trying. He has no abdominal pain or fever. He has smoked 1 pack of cigarettes daily for 40 years and was diagnosed with type 2 diabetes 6 months ago. Temperature is 37.0 C. He is jaundiced. A nontender, distended gallbladder is palpable in the right upper quadrant. Total bilirubin is 9.2 mg/dL (direct 7.8 mg/dL), alkaline phosphatase 610 U/L, AST 88 U/L and ALT 102 U/L. Ultrasound shows dilated intrahepatic and extrahepatic bile ducts and a dilated pancreatic duct, with no gallstones.</p>
<p>Which of the following is the most appropriate next step in diagnosis?</p>
<ol type="A">
<li>Serum CA 19-9</li>
<li>Hepatobiliary iminodiacetic acid scan</li>
<li>Multiphase pancreatic-protocol CT of the abdomen</li>
<li>ERCP with biliary stent placement</li>
<li>Laparoscopic cholecystectomy</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: C.</strong> Painless jaundice, weight loss, new diabetes and a palpable nontender gallbladder with a dilated bile duct and pancreatic duct (the double duct sign) point to a pancreatic head cancer. Multiphase CT confirms the mass and stages it, including vascular involvement, which decides whether it can be resected.</p>
<p><strong>Why the others are wrong.</strong> A: CA 19-9 supports the diagnosis and is used for monitoring, but obstructive jaundice alone can raise it. B: a HIDA scan evaluates acute cholecystitis, not a painless obstruction. D: ERCP is for drainage or tissue once imaging defines the lesion; routine preoperative stenting is not the first step. E: the gallbladder is distended because of a distal obstruction, not gallbladder disease.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>First test for dysphagia with weight loss</strong> Upper endoscopy with biopsy.</li><li><strong>First test for painless jaundice with dilated ducts and no stones</strong> Pancreatic-protocol CT.</li><li><strong>CT negative but high suspicion for pancreatic cancer</strong> Endoscopic ultrasound.</li><li><strong>HCC on imaging</strong> Arterial enhancement plus washout; no biopsy needed.</li><li><strong>Iron deficiency anemia in an older adult</strong> Ferritin under 45 ng/mL, then EGD and colonoscopy.</li><li><strong>Advanced HCC first-line</strong> Atezolizumab plus bevacizumab, or durvalumab plus tremelimumab.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review the <a href="https://med-rise.com/board-review/-gi-cancer-pathways-medicine-shelf-step-2-ck">GI cancer progression pathways</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1053/j.gastro.2020.06.046">Ko CW, et al. AGA clinical practice guidelines on the gastrointestinal evaluation of iron deficiency anemia. Gastroenterology, 2020 (PubMed 32810434)</a></li>
<li><a href="https://doi.org/10.1001/jama.2021.13027">Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review. JAMA, 2021 (PubMed 34547082)</a></li>
<li><a href="https://doi.org/10.1097/HEP.0000000000000466">Singal AG, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology, 2023 (PubMed 37199193)</a></li>
<li><a href="https://doi.org/10.1002/hep.32771">Bowlus CL, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2023 (PubMed 36083140)</a></li>
<li><a href="https://doi.org/10.14309/ajg.0000000000001680">Shaheen NJ, et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. Am J Gastroenterol, 2022 (PubMed 35354777)</a></li>
<li><a href="https://doi.org/10.14309/ajg.0000000000002968">Chey WD, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol, 2024 (PubMed 39626064)</a></li>
<li><a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening">US Preventive Services Task Force. Colorectal cancer: screening. Final recommendation statement, 2021</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/gi-cancers-mind-map-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>GI on the NBME Medicine Shelf: Four Algorithms That Decide Most Questions</title><link>https://med-rise.com/board-review/-gi-system-mind-map-nbme-medicine-shelf</link><guid isPermaLink="true">https://med-rise.com/board-review/-gi-system-mind-map-nbme-medicine-shelf</guid><pubDate>Thu, 03 Apr 2025 23:13:58 -0500</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Guide</category><category>Board Review</category><description>Upper GI and variceal bleeding, acute pancreatitis, C. difficile and acute cholangitis as step-by-step algorithms, with the clue that changes each answer.</description><content:encoded><![CDATA[<p>GI is one of the largest content areas on the medicine shelf, and most of its management questions come from four presentations: a GI bleed, acute pancreatitis, C. difficile diarrhea and acute cholangitis. Each one has a fixed order of steps. The question tells you where the patient is in that order, and the answer is the next step, not the most aggressive one.</p>

<h2>Upper GI bleeding: the algorithm</h2>
<ol class="sp-flow"><li><span>Resuscitate first<small>Two large-bore IV lines and crystalloid. Transfuse red cells at a hemoglobin threshold of 7 g/dL (ACG 2021); a higher threshold is used with active cardiovascular disease.</small></span></li><li><span>Stratify risk<small>A Glasgow-Blatchford score of 0 or 1 identifies very-low-risk patients who can be discharged with outpatient follow-up.</small></span></li><li><span>Suspect varices in cirrhosis<small>Start a vasoactive drug (octreotide or terlipressin) and antibiotic prophylaxis, usually ceftriaxone, before endoscopy. Baveno VII uses a restrictive transfusion target of 7 to 8 g/dL.</small></span></li><li><span>Prepare the stomach<small>An erythromycin infusion before endoscopy improves the view. An IV PPI is reasonable while waiting but does not replace endoscopy.</small></span></li><li><span>Endoscopy within 24 hours<small>For varices, within 12 hours with band ligation. Ulcers with active bleeding or a nonbleeding visible vessel get endoscopic therapy; a clean base or flat spot does not.</small></span></li><li><span>After hemostasis of an ulcer<small>High-dose PPI continuously or intermittently for 3 days, then oral PPI twice daily through the first 2 weeks. Test for H. pylori and stop NSAIDs.</small></span></li><li><span>Rebleeding<small>Repeat endoscopy. If endoscopic therapy fails, transcatheter embolization, then surgery. For varices, high-risk patients (Child-Pugh C under 14 points, or B over 7 with active bleeding at endoscopy) get a preemptive TIPS within 72 hours.</small></span></li></ol>

<h2>Acute pancreatitis: the approach</h2>
<p>The diagnosis needs two of three: typical epigastric pain, lipase or amylase above 3 times the upper limit of normal, and imaging findings. With the first two, no CT is needed.</p>
<ol class="sp-flow"><li><span>Right upper quadrant ultrasound in every patient<small>Gallstones change the plan. Check triglycerides and calcium if there is no stone or alcohol history.</small></span></li><li><span>Moderate, goal-directed fluids<small>Lactated Ringer's at a moderate rate, adjusted to urine output, heart rate and BUN. Aggressive fluid loading increases fluid overload without improving outcomes.</small></span></li><li><span>Feed early<small>Oral feeding within 24 to 48 hours as tolerated. If the patient cannot eat, enteral nutrition is preferred over parenteral.</small></span></li><li><span>No prophylactic antibiotics<small>Antibiotics are for a documented infection, such as infected necrosis or cholangitis.</small></span></li><li><span>ERCP only for cholangitis<small>Urgent ERCP (within 24 hours) is for gallstone pancreatitis with cholangitis, not for every gallstone case.</small></span></li><li><span>Cholecystectomy before discharge<small>Mild gallstone pancreatitis: cholecystectomy during the same admission prevents recurrence.</small></span></li><li><span>CT only when the course is off track<small>Contrast CT after 48 to 72 hours if the patient does not improve, to look for necrosis. Infected necrosis is treated with antibiotics and delayed, minimally invasive drainage.</small></span></li></ol>

<h2>C. difficile infection: step by step</h2>
<ol class="sp-flow"><li><span>Test the right patient<small>Three or more unformed stools in 24 hours, no laxatives, and a risk factor such as recent antibiotics or hospitalization.</small></span></li><li><span>Grade severity<small>Severe: white count 15,000/mm³ or more, or creatinine above 1.5 mg/dL. Fulminant: hypotension or shock, ileus or megacolon.</small></span></li><li><span>First episode<small>Oral fidaxomicin for 10 days is preferred; oral vancomycin for 10 days is an acceptable alternative. Metronidazole is only for a nonsevere episode when neither is available.</small></span></li><li><span>Fulminant infection<small>Oral vancomycin 500 mg four times daily plus IV metronidazole, rectal vancomycin if there is ileus, and an early surgical consult.</small></span></li><li><span>Recurrence<small>Fidaxomicin, or a vancomycin taper and pulse. After two or more recurrences, fecal microbiota-based therapy. Bezlotoxumab, an option in the 2021 update, was discontinued in the United States in January 2025.</small></span></li></ol>

<h2>Acute cholangitis: the algorithm</h2>
<ol class="sp-flow"><li><span>Recognize it<small>Charcot triad: fever, right upper quadrant pain, jaundice. Reynolds pentad adds hypotension and confusion. The Tokyo criteria combine systemic inflammation, cholestatic labs and imaging showing dilated ducts or a cause.</small></span></li><li><span>Grade severity<small>Grade III (severe) means organ dysfunction. Grade II (moderate) needs any two of: abnormal white count, fever of 39 C or more, age 75 or older, bilirubin 5 mg/dL or more, low albumin.</small></span></li><li><span>Antibiotics and fluids now<small>Broad-spectrum IV antibiotics covering enteric gram-negative organisms, plus resuscitation.</small></span></li><li><span>Drain the bile duct<small>Severe: as soon as possible once the patient is supported. Moderate: early drainage. Mild: drainage if there is no response to antibiotics. ERCP is first-line; percutaneous transhepatic drainage if ERCP fails or is not possible.</small></span></li><li><span>Treat the cause<small>Remove the stone, and plan cholecystectomy for gallstone disease once the patient recovers.</small></span></li></ol>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Melena, hemoglobin 6.4 g/dL, no heart disease</td><td>Upper GI bleed below the threshold</td><td>Transfuse red cells, then endoscopy within 24 hours</td></tr>
<tr><td>Cirrhosis, ascites, hematemesis</td><td>Variceal bleed</td><td>Octreotide and ceftriaxone, then band ligation within 12 hours</td></tr>
<tr><td>Ulcer with a clean base on endoscopy</td><td>Low rebleeding risk</td><td>No endoscopic therapy; oral PPI and early feeding</td></tr>
<tr><td>Lipase 9 times normal, typical pain, no stones on ultrasound, no alcohol</td><td>Pancreatitis of unclear cause</td><td>Check triglycerides and calcium</td></tr>
<tr><td>Gallstone pancreatitis, improving, no cholangitis</td><td>Mild biliary pancreatitis</td><td>Cholecystectomy before discharge</td></tr>
<tr><td>Pancreatitis with fever on day 10 and gas in necrosis on CT</td><td>Infected necrosis</td><td>Carbapenem, delay drainage until walled off</td></tr>
<tr><td>Diarrhea after clindamycin, white count 22,000/mm³</td><td>Severe C. difficile</td><td>Oral fidaxomicin or vancomycin</td></tr>
<tr><td>C. difficile with hypotension and a distended, silent abdomen</td><td>Fulminant colitis with ileus</td><td>Oral and rectal vancomycin, IV metronidazole, surgical consult</td></tr>
<tr><td>Fever, jaundice, RUQ pain, then hypotension and confusion</td><td>Severe cholangitis</td><td>Antibiotics, resuscitation and urgent ERCP</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Transfusing to a hemoglobin of 10 g/dL in a GI bleed. Restrictive transfusion is the standard.</li>
<li>Skipping antibiotics in a cirrhotic patient with GI bleeding. Prophylaxis lowers infection, rebleeding and death.</li>
<li>Ordering CT on day 1 of pancreatitis when pain and lipase already make the diagnosis.</li>
<li>Choosing aggressive fluid boluses, prophylactic carbapenems or prolonged NPO status for pancreatitis.</li>
<li>Sending every gallstone pancreatitis to urgent ERCP. Only cholangitis or persistent obstruction justifies it.</li>
<li>Picking metronidazole for a severe C. difficile episode, or testing formed stool.</li>
<li>Waiting for antibiotics to work in a hypotensive patient with cholangitis. Drainage is the treatment.</li>
</ul>

<h2>Practice question</h2>
<p>A 46-year-old woman is admitted with severe epigastric pain radiating to the back that began 12 hours after a large meal. She does not drink alcohol. Temperature is 37.6 C, blood pressure 128/80 mm Hg and pulse 98/min. The abdomen is tender in the epigastrium without guarding. Lipase is 2,400 U/L. Total bilirubin is 1.1 mg/dL and alkaline phosphatase 118 U/L. Triglycerides are 160 mg/dL. Ultrasound shows multiple gallstones in the gallbladder and a common bile duct of 5 mm. She is treated with lactated Ringer's solution and analgesia. On hospital day 2, her pain has improved, she is hungry, and she has no fever.</p>
<p>Which of the following is the most appropriate next step in management?</p>
<ol type="A">
<li>Urgent ERCP with sphincterotomy</li>
<li>IV imipenem for 14 days</li>
<li>Keep her NPO and start parenteral nutrition</li>
<li>Contrast-enhanced CT of the abdomen</li>
<li>Start an oral diet and perform cholecystectomy during this admission</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: E.</strong> She has mild gallstone pancreatitis that is improving. Early oral feeding is safe and shortens the stay, and cholecystectomy during the same admission prevents recurrent biliary events.</p>
<p><strong>Why the others are wrong.</strong> A: she has no cholangitis and no persistent bile duct obstruction (normal bilirubin, normal duct size), so urgent ERCP adds risk without benefit. B: prophylactic antibiotics are not recommended in acute pancreatitis. C: prolonged fasting and parenteral nutrition are worse than early enteral feeding. D: she is improving; CT is for patients who fail to improve after 48 to 72 hours or when the diagnosis is uncertain.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>GI bleed transfusion threshold</strong> Hemoglobin 7 g/dL.</li><li><strong>Variceal bleed bundle</strong> Vasoactive drug, ceftriaxone, band ligation within 12 hours.</li><li><strong>Pancreatitis fluids</strong> Lactated Ringer's at a moderate, goal-directed rate.</li><li><strong>Pancreatitis ERCP</strong> Only with cholangitis or persistent obstruction.</li><li><strong>First C. difficile episode</strong> Fidaxomicin preferred, oral vancomycin acceptable.</li><li><strong>Severe cholangitis</strong> Antibiotics, resuscitation and biliary drainage as soon as possible.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review the <a href="https://med-rise.com/board-review/-gi-cancers-mind-map">GI cancers by organ</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.14309/ajg.0000000000001245">Laine L, et al. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol, 2021 (PubMed 33929377)</a></li>
<li><a href="https://doi.org/10.1016/j.jhep.2021.12.022">de Franchis R, et al. Baveno VII: renewing consensus in portal hypertension. J Hepatol, 2022 (PubMed 35120736)</a></li>
<li><a href="https://doi.org/10.14309/ajg.0000000000002645">Tenner S, et al. American College of Gastroenterology guidelines: management of acute pancreatitis. Am J Gastroenterol, 2024 (PubMed 38857482)</a></li>
<li><a href="https://doi.org/10.1093/cid/ciab549">Johnson S, et al. IDSA and SHEA 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis, 2021 (PubMed 34164674)</a></li>
<li><a href="https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1130">ASHP. Bezlotoxumab injection: discontinued. Drug shortage detail, 2025</a></li>
<li><a href="https://doi.org/10.1002/jhbp.512">Kiriyama S, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis. J Hepatobiliary Pancreat Sci, 2018 (PubMed 29032610)</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/gi-system-mind-map-nbme-medicine-shelf-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>Initial vs Best Diagnostic Test: The Pairs Step 2 CK Keeps Testing</title><link>https://med-rise.com/board-review/-clinical-pearls-initial-vs-best-diagnostic-test-high-yield-summary</link><guid isPermaLink="true">https://med-rise.com/board-review/-clinical-pearls-initial-vs-best-diagnostic-test-high-yield-summary</guid><pubDate>Tue, 01 Apr 2025 23:16:38 -0500</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Guide</category><category>Board Review</category><description>The first test and the confirmatory test for PE, endocarditis, HIT, celiac, H. pylori, adrenal disorders and more, and how to tell which one a question wants.</description><content:encoded><![CDATA[<p>Step 2 CK and the shelf exams test the same disease from two angles. "What is the most appropriate next step in diagnosis?" usually wants the first, cheapest or most sensitive test. "Which test is most likely to confirm the diagnosis?" wants the most accurate one. Many wrong answers are the right test at the wrong moment, so read the verb in the question before you read the options.</p>

<h2>The approach: which test the question wants</h2>
<ol class="sp-flow"><li><span>Read the lead-in<small>"Next step" or "initial" means the first test in the sequence. "Most accurate," "confirm" or "definitive" means the reference standard.</small></span></li><li><span>Check stability<small>An unstable patient gets the bedside test: echocardiography for suspected massive PE, TEE for suspected aortic dissection, ultrasound in trauma. Do not send a crashing patient to the scanner.</small></span></li><li><span>Weigh pretest probability<small>A sensitive test such as D-dimer rules a diagnosis out only when the probability is already low. High probability skips straight to imaging.</small></span></li><li><span>Screen with a sensitive test, confirm with a specific one<small>The adrenal disorders follow this pattern: a screening hormone test, then a confirmatory test, and only then imaging.</small></span></li><li><span>Prefer the noninvasive confirmation when it exists<small>Typical HCC on multiphase imaging needs no biopsy; a low 4Ts score needs no HIT assay.</small></span></li></ol>

<h2>The pairs</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Condition</th><th>Initial test</th><th>Best or confirmatory test</th><th>The detail that gets tested</th></tr></thead>
<tbody>
<tr><td>Pulmonary embolism, stable</td><td>Clinical probability (Wells or Geneva); D-dimer only if probability is low or intermediate</td><td>CT pulmonary angiography</td><td>V/Q scan if contrast is contraindicated; unstable patient gets bedside echocardiography</td></tr>
<tr><td>Acute aortic dissection</td><td>CT angiography in a stable patient</td><td>CT angiography; TEE if unstable</td><td>A normal chest radiograph does not exclude it</td></tr>
<tr><td>Infective endocarditis</td><td>Three sets of blood cultures before antibiotics, and transthoracic echocardiography</td><td>Transesophageal echocardiography</td><td>Go straight to TEE with a prosthetic valve or when TTE is negative and suspicion stays high</td></tr>
<tr><td>Heparin-induced thrombocytopenia</td><td>4Ts score</td><td>Anti-PF4/heparin immunoassay, then a functional assay such as the serotonin release assay</td><td>Low 4Ts score: no testing and no empiric treatment</td></tr>
<tr><td>Celiac disease</td><td>Tissue transglutaminase IgA with total IgA, on a gluten-containing diet</td><td>Duodenal biopsy</td><td>IgA deficiency gives a false-negative tTG-IgA; use deamidated gliadin IgG</td></tr>
<tr><td>H. pylori</td><td>Urea breath test or stool antigen</td><td>Biopsy-based testing when endoscopy is indicated</td><td>Serology cannot show active infection or confirm eradication</td></tr>
<tr><td>Pheochromocytoma</td><td>Plasma free or urine fractionated metanephrines</td><td>CT or MRI of the abdomen after biochemical confirmation</td><td>Imaging first finds incidentalomas, not answers</td></tr>
<tr><td>Primary aldosteronism</td><td>Plasma aldosterone to renin ratio</td><td>Confirmatory suppression test, then adrenal CT, then adrenal vein sampling before surgery</td><td>Spontaneous hypokalemia, undetectable renin and aldosterone above 20 ng/dL make confirmation unnecessary</td></tr>
<tr><td>Cushing syndrome</td><td>1 mg overnight dexamethasone test, late-night salivary cortisol or 24-hour urine free cortisol</td><td>A second abnormal test from that list, then ACTH to localize</td><td>Rule out exogenous glucocorticoids first</td></tr>
<tr><td>Acute cholangitis or a duct stone</td><td>Right upper quadrant ultrasound</td><td>MRCP to diagnose; ERCP to diagnose and treat</td><td>ERCP is not the first test when the diagnosis is uncertain</td></tr>
<tr><td>Acute pancreatitis</td><td>Lipase</td><td>Contrast CT only if the diagnosis is unclear or the patient fails to improve after 48 to 72 hours</td><td>Pain plus lipase above 3 times normal is enough</td></tr>
<tr><td>Hepatocellular carcinoma</td><td>Ultrasound with or without AFP for surveillance</td><td>Multiphase CT or MRI</td><td>Arterial enhancement with washout is diagnostic without biopsy</td></tr>
</tbody>
</table></div>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Pleuritic chest pain, Wells low, otherwise well</td><td>Low-probability PE</td><td>D-dimer</td></tr>
<tr><td>Same patient with a Wells score that makes PE likely</td><td>High-probability PE</td><td>CT pulmonary angiography; skip D-dimer</td></tr>
<tr><td>Hypotension, distended neck veins, dilated right ventricle on bedside echo</td><td>High-risk PE</td><td>Systemic thrombolysis without waiting for CT</td></tr>
<tr><td>Fever and a new murmur 4 months after aortic valve replacement</td><td>Prosthetic valve endocarditis</td><td>Blood cultures and TEE</td></tr>
<tr><td>Platelets fall by 60% on day 7 of heparin, new leg DVT</td><td>Intermediate-to-high 4Ts score</td><td>Stop heparin, start a non-heparin anticoagulant, send the PF4 assay</td></tr>
<tr><td>Iron deficiency, diarrhea, low tTG-IgA with low total IgA</td><td>Celiac disease masked by IgA deficiency</td><td>Deamidated gliadin IgG, then duodenal biopsy</td></tr>
<tr><td>Hypertension, hypokalemia, undetectable renin, aldosterone 30 ng/dL</td><td>Primary aldosteronism without the need for confirmation</td><td>Adrenal CT</td></tr>
<tr><td>Episodic headache, sweating, palpitations</td><td>Possible pheochromocytoma</td><td>Plasma free metanephrines</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Ordering a D-dimer when the clinical probability of PE is already high. A negative result would not change the plan.</li>
<li>Choosing CT of the adrenal glands before biochemical testing. Adrenal incidentalomas are common; the hormones decide whether the mass matters.</li>
<li>Stopping at a negative TTE in a patient with a prosthetic valve or persistent bacteremia.</li>
<li>Sending HIT antibodies when the 4Ts score is low.</li>
<li>Testing for celiac disease after the patient has already gone gluten-free, or forgetting total IgA.</li>
<li>Using H. pylori serology to confirm eradication.</li>
<li>Taking an unstable patient to CT for a dissection or a PE when a bedside study would answer the question.</li>
</ul>

<h2>Practice question</h2>
<p>A 54-year-old man is evaluated for hypertension that remains above target on lisinopril, amlodipine and chlorthalidone. He has muscle cramps. Blood pressure is 168/98 mm Hg. Serum potassium is 2.9 mEq/L before any potassium supplement, and serum bicarbonate is 31 mEq/L. Plasma aldosterone is 32 ng/dL, and plasma renin activity is below the detectable limit. Serum creatinine is normal.</p>
<p>Which of the following is the most appropriate next step?</p>
<ol type="A">
<li>Oral sodium loading test</li>
<li>CT of the adrenal glands</li>
<li>Adrenal vein sampling</li>
<li>Plasma free metanephrines</li>
<li>Bilateral adrenalectomy</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: B.</strong> Spontaneous hypokalemia, renin below the detection limit and aldosterone above 20 ng/dL establish primary aldosteronism without a confirmatory suppression test (Endocrine Society 2016). The next step is adrenal CT to look for an adenoma, carcinoma or bilateral hyperplasia before deciding on lateralization testing.</p>
<p><strong>Why the others are wrong.</strong> A: confirmatory testing adds nothing when the biochemistry is this clear. C: adrenal vein sampling comes after CT, in a patient who wants surgery, to show which side is producing aldosterone. D: nothing suggests pheochromocytoma. E: bilateral hyperplasia is treated medically with a mineralocorticoid receptor antagonist, not surgery.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>D-dimer</strong> Rules out PE only when clinical probability is low or intermediate.</li><li><strong>Suspected endocarditis with a prosthetic valve</strong> Blood cultures and TEE.</li><li><strong>HIT</strong> 4Ts score first; low score means no testing.</li><li><strong>Celiac</strong> tTG-IgA plus total IgA on gluten, then duodenal biopsy.</li><li><strong>Adrenal disorders</strong> Hormones first, imaging second.</li><li><strong>Unstable patient</strong> Bedside test (echocardiography or TEE), not the scanner.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review the <a href="https://med-rise.com/board-review/-gi-system-mind-map-nbme-medicine-shelf">GI algorithms for the medicine shelf</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1093/eurheartj/ehz405">Konstantinides SV, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J, 2020 (PubMed 31504429)</a></li>
<li><a href="https://doi.org/10.1161/CIR.0000000000001106">Isselbacher EM, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease. Circulation, 2022 (PubMed 36322642)</a></li>
<li><a href="https://doi.org/10.1093/cid/ciad271">Fowler VG, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases criteria for infective endocarditis. Clin Infect Dis, 2023 (PubMed 37138445)</a></li>
<li><a href="https://doi.org/10.1093/eurheartj/ehad193">Delgado V, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J, 2023 (PubMed 37622656)</a></li>
<li><a href="https://doi.org/10.1182/bloodadvances.2018024489">Cuker A, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv, 2018 (PubMed 30482768)</a></li>
<li><a href="https://doi.org/10.14309/ajg.0000000000002075">Rubio-Tapia A, et al. American College of Gastroenterology guidelines update: diagnosis and management of celiac disease. Am J Gastroenterol, 2023 (PubMed 36602836)</a></li>
<li><a href="https://doi.org/10.14309/ajg.0000000000002968">Chey WD, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol, 2024 (PubMed 39626064)</a></li>
<li><a href="https://doi.org/10.1210/jc.2014-1498">Lenders JW, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2014 (PubMed 24893135)</a></li>
<li><a href="https://doi.org/10.1210/jc.2015-4061">Funder JW, et al. The management of primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2016 (PubMed 26934393)</a></li>
<li><a href="https://doi.org/10.1210/jc.2008-0125">Nieman LK, et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2008 (PubMed 18334580)</a></li>
<li><a href="https://doi.org/10.1002/jhbp.512">Kiriyama S, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis. J Hepatobiliary Pancreat Sci, 2018 (PubMed 29032610)</a></li>
<li><a href="https://doi.org/10.14309/ajg.0000000000002645">Tenner S, et al. American College of Gastroenterology guidelines: management of acute pancreatitis. Am J Gastroenterol, 2024 (PubMed 38857482)</a></li>
<li><a href="https://doi.org/10.1097/HEP.0000000000000466">Singal AG, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology, 2023 (PubMed 37199193)</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/clinical-pearls-initial-vs-best-diagnostic-test-high-yield-s-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>Anticoagulants vs Antiplatelets vs Thrombolytics: Mechanisms, Uses and Reversal</title><link>https://med-rise.com/board-review/anticoagulants-vs-antiplatelets-vs-thrombolytics</link><guid isPermaLink="true">https://med-rise.com/board-review/anticoagulants-vs-antiplatelets-vs-thrombolytics</guid><pubDate>Sat, 29 Mar 2025 17:48:50 -0500</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Guide</category><category>Board Review</category><description>Where each antithrombotic class acts, when Step 2 CK expects each one, and how to reverse a bleed on warfarin, a DOAC, heparin or a thrombolytic.</description><content:encoded><![CDATA[<p>Antithrombotic questions on Step 2 CK come in three forms: pick the right class for the clot (arterial or venous, prevention or dissolution), spot the exception (mechanical valve, pregnancy, HIT), or reverse the drug in a bleeding patient. The rule underneath all three: antiplatelets for arterial clots, anticoagulants for venous clots and cardiac emboli, thrombolytics only to dissolve a clot that is causing harm right now.</p>

<h2>The pathway: where each drug class acts</h2>
<ol class="sp-path"><li><span>Platelet plug<small>Aspirin, P2Y12 inhibitors</small></span></li><li><span>Factor Xa<small>Apixaban, rivaroxaban, edoxaban, fondaparinux</small></span></li><li><span>Thrombin (IIa)<small>Dabigatran, argatroban, bivalirudin</small></span></li><li><span>Fibrin clot<small>Heparins and warfarin act upstream</small></span></li><li><span>Fibrinolysis<small>Alteplase, tenecteplase</small></span></li></ol>
<p>Aspirin blocks COX-1; clopidogrel, prasugrel and ticagrelor block the platelet P2Y12 receptor. Unfractionated heparin works through antithrombin on both thrombin and factor Xa, while LMWH acts mostly on Xa. Warfarin lowers the vitamin K-dependent factors II, VII, IX and X, and proteins C and S. Antiplatelets and anticoagulants prevent a clot from forming or growing; neither dissolves a clot that is already there. That is the job of the body's own fibrinolysis, or of a thrombolytic that converts plasminogen to plasmin.</p>

<h2>Which class for which clot</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Scenario</th><th>Class</th><th>First choice</th><th>The exception that gets tested</th></tr></thead>
<tbody>
<tr><td>Atrial fibrillation, CHA2DS2-VASc 2 or more in men, 3 or more in women</td><td>Anticoagulant</td><td>A DOAC over warfarin</td><td>Warfarin with a mechanical valve or moderate to severe mitral stenosis; aspirin alone is not stroke prevention</td></tr>
<tr><td>Deep vein thrombosis or pulmonary embolism</td><td>Anticoagulant</td><td>A DOAC, or LMWH bridged to warfarin</td><td>Pregnancy: LMWH; warfarin is teratogenic and DOACs are avoided</td></tr>
<tr><td>Mechanical heart valve</td><td>Anticoagulant</td><td>Warfarin</td><td>DOACs are harmful here. INR goal 2.5 for an aortic valve without risk factors, 3.0 for a mitral valve or an aortic valve with risk factors</td></tr>
<tr><td>Acute coronary syndrome</td><td>Antiplatelet plus anticoagulant</td><td>Aspirin, a P2Y12 inhibitor and a parenteral anticoagulant</td><td>Dual antiplatelet therapy continues after PCI, usually 12 months after ACS</td></tr>
<tr><td>STEMI when PCI cannot happen within 120 minutes</td><td>Thrombolytic plus antiplatelets and anticoagulant</td><td>Fibrinolytic within 30 minutes of arrival</td><td>Then transfer for angiography</td></tr>
<tr><td>Ischemic stroke within 4.5 hours with a disabling deficit</td><td>Thrombolytic</td><td>Tenecteplase or alteplase</td><td>Mild nondisabling stroke gets aspirin plus clopidogrel for 21 days instead</td></tr>
<tr><td>PE with hypotension</td><td>Thrombolytic</td><td>Systemic alteplase</td><td>Normotensive PE gets anticoagulation, even with right ventricular strain</td></tr>
<tr><td>Heparin-induced thrombocytopenia</td><td>Non-heparin anticoagulant</td><td>Argatroban, bivalirudin, fondaparinux or a DOAC</td><td>Stop all heparin, including flushes; no warfarin until platelets recover; no platelet transfusion</td></tr>
<tr><td>Stable coronary or peripheral artery disease, secondary stroke prevention</td><td>Antiplatelet</td><td>Aspirin or clopidogrel</td><td>Anticoagulants do not replace antiplatelets for arterial plaque</td></tr>
</tbody>
</table></div>

<h2>The bleeding algorithm on an anticoagulant</h2>
<p>Based on the 2020 ACC decision pathway for bleeding on oral anticoagulants, updated for the 2025 market change.</p>
<ol class="sp-flow"><li><span>Judge the bleed<small>Major bleeding means hemodynamic instability, a fall in hemoglobin of 2 g/dL or more, a need for 2 or more units of red cells, or a critical site such as intracranial bleeding.</small></span></li><li><span>Stop the drug and support the patient<small>Local measures, volume and red cells. Note the last dose time and kidney function, which set how long a DOAC lasts.</small></span></li><li><span>Warfarin<small>IV vitamin K 5 to 10 mg plus 4-factor prothrombin complex concentrate. Plasma only if PCC is unavailable.</small></span></li><li><span>Dabigatran<small>Idarucizumab 5 g IV. Dabigatran is also removed by hemodialysis.</small></span></li><li><span>Factor Xa inhibitors<small>4-factor PCC. Andexanet alfa was withdrawn from the US market in December 2025, so it is no longer the answer.</small></span></li><li><span>Heparin<small>Protamine for unfractionated heparin; protamine only partly reverses LMWH.</small></span></li><li><span>Restart<small>Once bleeding is controlled, weigh restarting: the reason for anticoagulation has not gone away.</small></span></li></ol>
<p>Antiplatelet drugs have no specific reversal agent. In spontaneous intracerebral hemorrhage in patients taking antiplatelets, platelet transfusion increased death or dependence in the PATCH trial and is not given routinely.</p>

<h2>Reversing a thrombolytic bleed: step by step</h2>
<p>Suspect symptomatic intracranial hemorrhage when headache, vomiting, a rising blood pressure or a worse neurologic exam appears within 24 hours of alteplase or tenecteplase.</p>
<ol class="sp-flow"><li><span>Stop the infusion<small>Stop alteplase, or a tenecteplase bolus if it is still being given.</small></span></li><li><span>Emergency noncontrast head CT<small>Draw CBC, PT and INR, aPTT, fibrinogen and a type and crossmatch at the same time.</small></span></li><li><span>Cryoprecipitate<small>10 units over 10 to 30 minutes, aiming for a fibrinogen of 150 mg/dL or more. Ten units raise fibrinogen by about 50 mg/dL.</small></span></li><li><span>Or an antifibrinolytic<small>Tranexamic acid 1,000 mg IV over 10 minutes, or aminocaproic acid 4 to 5 g over 1 hour, especially when blood products are declined or cryoprecipitate is not available quickly.</small></span></li><li><span>Call for help and control pressure<small>Hematology and neurosurgery consults, and supportive care including blood pressure, temperature and glucose control.</small></span></li></ol>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Intracranial bleed on apixaban taken 3 hours ago</td><td>Factor Xa inhibitor bleed</td><td>4-factor PCC</td></tr>
<tr><td>GI bleed with hypotension on dabigatran</td><td>Direct thrombin inhibitor bleed</td><td>Idarucizumab</td></tr>
<tr><td>INR 6.8 with a large retroperitoneal bleed</td><td>Warfarin-associated major bleed</td><td>IV vitamin K plus 4-factor PCC</td></tr>
<tr><td>Bleeding after a heparin bolus in the cath lab</td><td>Unfractionated heparin</td><td>Protamine</td></tr>
<tr><td>New aphasia worsens and vomiting starts during an alteplase infusion</td><td>Thrombolysis-related intracranial hemorrhage</td><td>Stop the infusion, emergency CT, cryoprecipitate</td></tr>
<tr><td>Platelets fall by half on day 6 of heparin, new DVT</td><td>Heparin-induced thrombocytopenia</td><td>Stop heparin, start argatroban or another non-heparin agent</td></tr>
<tr><td>Atrial fibrillation with a new mechanical mitral valve</td><td>Valve thrombosis risk</td><td>Warfarin, INR goal 3.0; not a DOAC</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Choosing andexanet alfa for a factor Xa inhibitor bleed. It left the US market in December 2025; 4-factor PCC is the answer.</li>
<li>Giving plasma before PCC for a warfarin bleed. PCC works faster and needs less volume.</li>
<li>Forgetting vitamin K with PCC. PCC wears off; vitamin K keeps the INR down.</li>
<li>Prescribing a DOAC for a mechanical valve or for VTE in pregnancy.</li>
<li>Giving aspirin alone for stroke prevention in atrial fibrillation.</li>
<li>Thrombolyzing a normotensive PE because the right ventricle looks strained.</li>
<li>Starting warfarin in acute HIT or transfusing platelets for it.</li>
</ul>

<h2>Practice question</h2>
<p>A 76-year-old woman is brought to the emergency department 90 minutes after the sudden onset of headache, left-sided weakness and vomiting. She takes apixaban 5 mg twice daily for atrial fibrillation; her last dose was 3 hours ago. Blood pressure is 182/96 mm Hg and pulse 88/min and irregular. She has a dense left hemiparesis. Noncontrast CT of the head shows a 28-mL right basal ganglia hemorrhage without intraventricular extension. Serum creatinine is 0.9 mg/dL, and the platelet count is 210,000/mm³.</p>
<p>In addition to blood pressure control, which of the following is the most appropriate treatment?</p>
<ol type="A">
<li>Andexanet alfa</li>
<li>Idarucizumab</li>
<li>Protamine sulfate</li>
<li>4-factor prothrombin complex concentrate</li>
<li>Platelet transfusion</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: D.</strong> She has an intracerebral hemorrhage on a factor Xa inhibitor taken within the last few hours. With andexanet alfa withdrawn from the US market in December 2025, 4-factor PCC is the reversal strategy.</p>
<p><strong>Why the others are wrong.</strong> A: no longer available in the United States. B: idarucizumab reverses dabigatran only. C: protamine reverses heparin, not apixaban. E: her platelet count is normal, and she takes no antiplatelet drug; platelet transfusion does not reverse apixaban.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>Class for an arterial clot, a venous clot or cardiac embolus, and a clot causing harm right now</strong> Antiplatelet, anticoagulant, thrombolytic.</li><li><strong>Warfarin bleed</strong> IV vitamin K plus 4-factor PCC.</li><li><strong>Dabigatran bleed</strong> Idarucizumab.</li><li><strong>Apixaban or rivaroxaban bleed</strong> 4-factor PCC (andexanet withdrawn in the US, December 2025).</li><li><strong>Thrombolytic intracranial bleed</strong> Stop the drug, CT, cryoprecipitate 10 units; tranexamic acid as the alternative.</li><li><strong>Mechanical valve</strong> Warfarin only, never a DOAC.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review the <a href="https://med-rise.com/board-review/acute-stroke-algorithm-neurology-shelf">acute stroke algorithm</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1016/j.jacc.2020.04.053">Tomaselli GF, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol, 2020 (PubMed 32680646)</a></li>
<li><a href="https://www.aabb.org/news-resources/news/article/2025/12/23/astrazeneca-withdraws-factor-xa-reversal-agent-from-u.s.-market">AABB News. AstraZeneca withdraws factor Xa reversal agent from US market. December 23, 2025</a></li>
<li><a href="https://doi.org/10.1161/STR.0000000000000513">Prabhakaran S, et al. 2026 guideline for the early management of patients with acute ischemic stroke. Stroke, 2026 (PubMed 41582814)</a></li>
<li><a href="https://doi.org/10.1161/CIR.0000000000001193">Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation, 2024 (PubMed 38033089)</a></li>
<li><a href="https://doi.org/10.1161/CIR.0000000000000923">Otto CM, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. Circulation, 2021 (PubMed 33332150)</a></li>
<li><a href="https://doi.org/10.1093/eurheartj/ehz405">Konstantinides SV, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J, 2020 (PubMed 31504429)</a></li>
<li><a href="https://doi.org/10.1182/bloodadvances.2018024489">Cuker A, et al. American Society of Hematology 2018 guidelines: heparin-induced thrombocytopenia. Blood Adv, 2018 (PubMed 30482768)</a></li>
<li><a href="https://doi.org/10.1016/S0140-6736(16)30392-0">Baharoglu MI, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH). Lancet, 2016 (PubMed 27178479)</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/anticoagulants-vs-antiplatelets-vs-thrombolytics-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>Prosthetic Valve Endocarditis on Step 2 CK: Empiric Antibiotics, TEE and When to Operate</title><link>https://med-rise.com/board-review/-cardio-question-empiric-antibiotics-in-prosthetic-valve-ie</link><guid isPermaLink="true">https://med-rise.com/board-review/-cardio-question-empiric-antibiotics-in-prosthetic-valve-ie</guid><pubDate>Fri, 28 Mar 2025 12:31:43 -0500</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Guide</category><category>Board Review</category><description>Why vancomycin, gentamicin and rifampin is the classic empiric regimen for prosthetic valve endocarditis, plus the TEE rule and the surgical triggers.</description><content:encoded><![CDATA[<p>A prosthetic valve endocarditis question gives a fever weeks to months after valve surgery, sometimes a new murmur, and asks for one of three things: the empiric antibiotics after blood cultures, the imaging test, or the reason to operate. The answers differ from native valve endocarditis because the organisms differ and because bacteria living on prosthetic material behave differently.</p>

<h2>Why the regimen looks different</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Timing after valve surgery</th><th>Usual organisms</th><th>Why it matters</th></tr></thead>
<tbody>
<tr><td>Early PVE, within about 1 year</td><td>Coagulase-negative staphylococci (S. epidermidis), S. aureus, gram-negative bacilli, fungi</td><td>Mostly acquired around the operation; methicillin resistance is common</td></tr>
<tr><td>Late PVE, after about 1 year</td><td>Similar to native valves: streptococci, S. aureus, enterococci, coagulase-negative staphylococci</td><td>Community sources such as the mouth, skin and gut</td></tr>
</tbody>
</table></div>
<p>Staphylococci form biofilm on sewing rings and leaflets. Vancomycin covers methicillin-resistant strains, gentamicin adds early synergy, and rifampin is the drug that penetrates biofilm on foreign material. That is the logic behind the classic empiric answer: <strong>vancomycin plus gentamicin plus rifampin</strong>. US references often add gram-negative coverage, such as cefepime, for early or healthcare-associated PVE.</p>

<h2>The work-up algorithm</h2>
<ol class="sp-flow"><li><span>Treat any fever with a prosthetic valve as endocarditis until proven otherwise<small>Do not start empiric oral antibiotics for a presumed minor infection before cultures.</small></span></li><li><span>Three sets of blood cultures from separate sites<small>Draw them before the first antibiotic dose. In a stable patient, a short delay for cultures is worth it; in septic shock, draw cultures and give antibiotics without waiting.</small></span></li><li><span>Go to TEE<small>Transthoracic echo misses many prosthetic valve vegetations and abscesses, so TEE is recommended for every patient with a prosthetic valve and suspected endocarditis.</small></span></li><li><span>Add PET/CT or cardiac CT when echo is unclear<small>The 2023 Duke-ISCVID criteria count abnormal FDG PET/CT uptake on a prosthetic valve (implanted more than 3 months earlier) and cardiac CT findings as major imaging criteria.</small></span></li><li><span>Start empiric therapy<small>Vancomycin plus gentamicin, with rifampin for staphylococcal infection on prosthetic material. Rifampin is usually started a few days after effective therapy, once bacteremia is clearing, to limit resistance.</small></span></li><li><span>Narrow to the organism<small>Methicillin-sensitive S. aureus: an antistaphylococcal penicillin plus rifampin, with gentamicin for the first 2 weeks. Methicillin-resistant staphylococci: vancomycin plus rifampin, also with gentamicin for the first 2 weeks. Treat PVE for at least 6 weeks.</small></span></li><li><span>Call the endocarditis team early<small>Cardiology, cardiac surgery and infectious diseases decide on surgery together.</small></span></li></ol>

<h2>When to operate</h2>
<ul>
<li><strong>Heart failure</strong> from valve dysfunction, dehiscence or a fistula. This is the strongest indication.</li>
<li><strong>Uncontrolled infection</strong>: a perivalvular abscess, heart block from extension into the conduction system, persistent bacteremia despite appropriate antibiotics, or fungal or multiresistant organisms.</li>
<li><strong>Organism</strong>: PVE caused by S. aureus or non-HACEK gram-negative bacteria is a reason to consider surgery.</li>
<li><strong>Embolic risk</strong>: a large vegetation (10 mm or more) with a prior embolic event.</li>
<li><strong>Early PVE</strong>: the 2023 ESC guideline supports surgery for PVE within 6 months of valve surgery, with a new valve and complete debridement.</li>
</ul>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Fever 2 months after mechanical aortic valve replacement, stable</td><td>Early PVE</td><td>Three sets of blood cultures, then empiric vancomycin, gentamicin and rifampin, and TEE</td></tr>
<tr><td>Blood cultures grow S. epidermidis in 3 of 3 sets with a prosthetic valve</td><td>True infection, not contamination</td><td>Vancomycin plus rifampin plus gentamicin</td></tr>
<tr><td>TTE normal, prosthetic valve, persistent bacteremia</td><td>Echo cannot rule out PVE</td><td>TEE</td></tr>
<tr><td>New PR prolongation in aortic PVE</td><td>Perivalvular (aortic root) abscess</td><td>TEE and urgent surgical evaluation</td></tr>
<tr><td>Dyspnea, crackles and new severe regurgitation across the prosthesis</td><td>Valve dysfunction with heart failure</td><td>Urgent surgery</td></tr>
<tr><td>Fever 4 years after valve surgery, viridans streptococci in cultures</td><td>Late PVE behaving like native valve IE</td><td>Penicillin or ceftriaxone for 6 weeks, with or without gentamicin for the first 2 weeks</td></tr>
<tr><td>Candida in blood cultures with a prosthetic valve</td><td>Fungal PVE</td><td>Antifungal therapy and surgery</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Choosing the native valve empiric regimen (vancomycin plus ceftriaxone, or ampicillin-sulbactam plus gentamicin) for early PVE.</li>
<li>Dismissing coagulase-negative staphylococci as a contaminant in a patient with a prosthetic valve when several culture sets are positive.</li>
<li>Accepting a negative TTE. With a prosthetic valve, TEE is the test.</li>
<li>Giving rifampin alone, or without an active partner drug. Resistance develops quickly.</li>
<li>Treating for 4 weeks. Prosthetic valve endocarditis gets at least 6 weeks.</li>
<li>Missing new heart block as a sign of abscess and a surgical indication.</li>
</ul>

<h2>Practice question</h2>
<p>A 68-year-old man comes to the emergency department because of fever, chills and fatigue for 5 days. Ten weeks ago, he underwent mechanical aortic valve replacement for aortic stenosis. Temperature is 38.9 C, blood pressure 124/72 mm Hg and pulse 104/min. A crisp mechanical closing click is heard, along with a new grade 2/6 diastolic murmur at the left sternal border. There are no stigmata of emboli. Leukocyte count is 15,800/mm³. Three sets of blood cultures are drawn from separate sites.</p>
<p>Which of the following is the most appropriate empiric antibiotic regimen?</p>
<ol type="A">
<li>Ceftriaxone plus gentamicin</li>
<li>Ampicillin-sulbactam plus gentamicin</li>
<li>Nafcillin alone</li>
<li>Vancomycin plus gentamicin plus rifampin</li>
<li>Vancomycin alone</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: D.</strong> Fever and a new regurgitant murmur 10 weeks after valve replacement point to early prosthetic valve endocarditis. The likely organisms are staphylococci, including methicillin-resistant coagulase-negative strains, growing in biofilm on prosthetic material. Vancomycin covers them, gentamicin adds synergy, and rifampin penetrates biofilm. Many protocols also add gram-negative coverage, such as cefepime, in early PVE. TEE should follow.</p>
<p><strong>Why the others are wrong.</strong> A and B: these target the streptococci and enterococci of community-acquired native valve disease and miss methicillin-resistant staphylococci. C: nafcillin misses methicillin-resistant strains, which are common in early PVE. E: vancomycin alone lacks the biofilm-active partner that prosthetic material needs.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>Early PVE organisms</strong> Coagulase-negative staphylococci and S. aureus.</li><li><strong>Classic empiric regimen</strong> Vancomycin plus gentamicin plus rifampin.</li><li><strong>Why rifampin</strong> It penetrates biofilm on prosthetic material; never use it alone.</li><li><strong>Imaging</strong> TEE for every suspected PVE; PET/CT or cardiac CT if echo is unclear.</li><li><strong>Duration</strong> At least 6 weeks.</li><li><strong>Strongest surgical indication</strong> Heart failure from valve dysfunction.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review <a href="https://med-rise.com/board-review/-clinical-pearls-initial-vs-best-diagnostic-test-high-yield-summary">initial vs best diagnostic tests</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1161/CIR.0000000000000296">Baddour LM, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. A scientific statement from the American Heart Association. Circulation, 2015 (PubMed 26373316)</a></li>
<li><a href="https://doi.org/10.1093/eurheartj/ehad193">Delgado V, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J, 2023 (PubMed 37622656)</a></li>
<li><a href="https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2023/08/29/20/49/2023-esc-guidelines-for-endocarditis-esc-2023">American College of Cardiology. 2023 ESC guidelines for management of endocarditis: key points, 2023</a></li>
<li><a href="https://doi.org/10.1093/cid/ciad271">Fowler VG, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases criteria for infective endocarditis. Clin Infect Dis, 2023 (PubMed 37138445)</a></li>
<li><a href="https://statpearls.com/point-of-care/21087">Infective endocarditis. StatPearls point-of-care review</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/cardio-question-empiric-antibiotics-in-prosthetic-valve-ie-photo.jpg" medium="image" type="image/jpeg"/></item><item><title>CABG vs PCI on Step 2 CK: The Revascularization Decision, Step by Step</title><link>https://med-rise.com/board-review/cabgvspci</link><guid isPermaLink="true">https://med-rise.com/board-review/cabgvspci</guid><pubDate>Fri, 28 Mar 2025 10:13:00 -0500</pubDate><dc:creator>MedRise (with AI assistance)</dc:creator><category>Guide</category><category>Board Review</category><description>When the 2021 and 2025 ACC/AHA guidelines favor bypass surgery over stenting: left main disease, diabetes, low ejection fraction, ACS and shock.</description><content:encoded><![CDATA[<p>A revascularization question gives a coronary angiogram in words (left main stenosis, three-vessel disease, a diabetic patient, an ejection fraction) and asks what comes next: bypass surgery, a stent, or no procedure at all. Three facts usually decide it: is this an acute coronary syndrome or stable disease, how complex is the anatomy, and does the patient have diabetes or a low ejection fraction.</p>

<h2>The revascularization algorithm</h2>
<ol class="sp-flow"><li><span>Acute or stable<small>STEMI needs reperfusion now: primary PCI of the culprit artery. Stable ischemic heart disease starts with guideline-directed medical therapy; the question is whether a procedure adds survival or symptom relief.</small></span></li><li><span>Left main disease<small>Significant left main stenosis: CABG is recommended to improve survival (class 1). PCI is a reasonable alternative in selected patients whose anatomy is of low to intermediate complexity (class 2a).</small></span></li><li><span>Low ejection fraction<small>Multivessel disease with LVEF of 35% or less: CABG improves survival (class 1), based mainly on the STICH extension.</small></span></li><li><span>Diabetes<small>Multivessel disease in a patient with diabetes who can have surgery: CABG with a left internal mammary artery graft to the LAD is preferred over PCI (class 1), based on FREEDOM. PCI is an option for poor surgical candidates.</small></span></li><li><span>Anatomic complexity<small>Complex multivessel disease (SYNTAX score above 33): CABG is reasonable for a survival benefit over PCI. With less complex anatomy, CABG and PCI give similar results, and the heart team decides with the patient.</small></span></li><li><span>Normal ejection fraction, no diabetes, no left main<small>Revascularization for survival is only class 2b in three-vessel disease with normal LVEF. It can reduce cardiac death, spontaneous MI and urgent revascularization (class 2a), and it relieves angina that persists on medical therapy.</small></span></li><li><span>One or two vessels, LAD spared, normal LVEF<small>PCI to improve survival is not recommended (class 3). Treat medically and revascularize for symptoms.</small></span></li></ol>
<p>The 2021 downgrade for three-vessel disease with normal LVEF was driven largely by the ISCHEMIA trial and remains disputed: the cardiac surgery societies (STS and AATS) did not endorse that recommendation, arguing that ISCHEMIA was weighted too heavily. Exam questions follow the guideline.</p>

<h2>The trials behind the answers</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Trial</th><th>Population</th><th>Result</th><th>What it changed</th></tr></thead>
<tbody>
<tr><td>FREEDOM (2012)</td><td>Diabetes with multivessel CAD</td><td>CABG lowered the combined rate of death, MI and stroke compared with drug-eluting stents, with more strokes after CABG</td><td>CABG is preferred in diabetic multivessel disease</td></tr>
<tr><td>STICH extension (2016)</td><td>Ischemic cardiomyopathy, LVEF 35% or less</td><td>CABG plus medical therapy lowered 10-year all-cause mortality compared with medical therapy alone</td><td>CABG for multivessel disease with low LVEF</td></tr>
<tr><td>ISCHEMIA (2020)</td><td>Stable CAD with moderate or severe ischemia, excluding left main disease and LVEF below 35%</td><td>An initial invasive strategy did not reduce ischemic events or death over a median of 3.2 years; angina improved</td><td>Medical therapy first for most stable patients</td></tr>
<tr><td>CULPRIT-SHOCK (2017)</td><td>Acute MI with cardiogenic shock and multivessel disease</td><td>Culprit-only PCI did better than immediate multivessel PCI</td><td>Routine non-culprit PCI in shock is harmful</td></tr>
</tbody>
</table></div>

<h2>Acute coronary syndromes</h2>
<ul>
<li><strong>STEMI</strong>: primary PCI of the culprit artery. If PCI cannot be done within 120 minutes, a fibrinolytic within 30 minutes, then transfer.</li>
<li><strong>STEMI with multivessel disease, hemodynamically stable</strong>: PCI of significant non-culprit lesions (complete revascularization), at the index procedure or staged, reduces cardiovascular death or MI.</li>
<li><strong>STEMI with cardiogenic shock</strong>: PCI of the culprit artery only. Routine PCI of non-culprit arteries at the same time is harmful (class 3).</li>
<li><strong>NSTE-ACS</strong>: invasive angiography; the same anatomy rules then apply. Left main or complex multivessel disease, especially with diabetes, points to CABG.</li>
</ul>

<h2>Clue in the stem, next best step</h2>
<div class="table-wrap"><table class="sp-table">
<thead><tr><th>Clue in the stem</th><th>What it points to</th><th>Next best step</th></tr></thead>
<tbody>
<tr><td>Stable angina, 80% left main stenosis, good surgical candidate</td><td>Left main disease</td><td>CABG</td></tr>
<tr><td>Type 2 diabetes, three-vessel disease including the proximal LAD</td><td>Diabetic multivessel disease</td><td>CABG with a LIMA graft to the LAD</td></tr>
<tr><td>Ischemic cardiomyopathy, LVEF 30%, multivessel disease</td><td>Low ejection fraction</td><td>CABG plus guideline-directed medical therapy</td></tr>
<tr><td>Single-vessel right coronary disease, normal LVEF, mild angina on one drug</td><td>Low-risk stable disease</td><td>Optimize medical therapy; PCI only for persistent symptoms</td></tr>
<tr><td>Inferior STEMI, transfer time to a PCI center 3 hours</td><td>PCI not available in time</td><td>Fibrinolysis within 30 minutes, then transfer</td></tr>
<tr><td>Anterior STEMI with shock, two other diseased arteries</td><td>Cardiogenic shock with multivessel disease</td><td>Culprit-only PCI</td></tr>
<tr><td>Stable STEMI patient after culprit PCI, 80% stenosis in another artery</td><td>Non-culprit disease</td><td>Staged or same-procedure PCI of that lesion</td></tr>
</tbody>
</table></div>

<h2>Where students lose points</h2>
<ul>
<li>Stenting multivessel disease in a patient with diabetes who can have surgery. CABG is preferred.</li>
<li>Sending every stable patient with a positive stress test to angiography. Medical therapy comes first unless the anatomy or ejection fraction changes the survival picture.</li>
<li>Stenting every narrowed artery during primary PCI in cardiogenic shock.</li>
<li>Forgetting the LIMA graft to the LAD, the part of CABG that carries its long-term benefit.</li>
<li>Answering PCI for left main disease in a good surgical candidate with complex anatomy.</li>
</ul>

<h2>Practice question</h2>
<p>A 61-year-old man with type 2 diabetes and hypertension has exertional chest pressure that has persisted for 4 months despite metoprolol, isosorbide mononitrate, aspirin and atorvastatin. HbA1c is 7.9%. A stress test showed a large area of anterior and lateral ischemia. Coronary angiography shows 85% stenosis of the proximal left anterior descending artery, 80% stenosis of the left circumflex artery and 75% stenosis of the right coronary artery; the left main is normal. Left ventricular ejection fraction is 50%. He has no other major illnesses and is a good surgical candidate.</p>
<p>Which of the following is the most appropriate management?</p>
<ol type="A">
<li>Continue medical therapy alone</li>
<li>PCI of the left anterior descending artery only</li>
<li>Multivessel PCI with drug-eluting stents</li>
<li>CABG with a left internal mammary artery graft to the LAD</li>
<li>Fibrinolytic therapy</li>
</ol>
<details class="sp-answer"><summary>Show the answer</summary>
<p><strong>Answer: D.</strong> He has diabetes, three-vessel disease involving the proximal LAD and angina that persists on medical therapy, and he can have surgery. CABG with a LIMA graft to the LAD is recommended over PCI in this group to reduce death and repeat revascularization, based on FREEDOM.</p>
<p><strong>Why the others are wrong.</strong> A: his angina persists despite good medical therapy, and his anatomy carries a survival argument for CABG. B: incomplete revascularization leaves two diseased arteries. C: multivessel PCI is the option for diabetic patients who are poor surgical candidates. E: fibrinolysis is for STEMI when PCI is not available in time, not for stable disease.</p>
</details>

<h2>60-second recall</h2><ul><li><strong>Left main disease</strong> CABG (class 1); PCI in selected low-complexity anatomy (class 2a).</li><li><strong>Diabetes with multivessel disease</strong> CABG with LIMA to LAD (FREEDOM).</li><li><strong>Multivessel disease with LVEF 35% or less</strong> CABG (STICH extension).</li><li><strong>Three-vessel disease with normal LVEF</strong> Survival benefit only class 2b (ISCHEMIA).</li><li><strong>STEMI with shock</strong> Culprit-only PCI.</li><li><strong>Stable STEMI with multivessel disease</strong> Complete revascularization.</li></ul>

<p>Next: browse every <a href="https://med-rise.com/board-review">Board Review</a> post, review <a href="https://med-rise.com/board-review/anticoagulants-vs-antiplatelets-vs-thrombolytics">anticoagulants vs antiplatelets vs thrombolytics</a>, or see <a href="https://med-rise.com/medicine/students/">MedRise for students</a>.</p>

<h2>Sources</h2>
<ol class="refs">
<li><a href="https://doi.org/10.1161/CIR.0000000000001038">Lawton JS, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. Circulation, 2022 (PubMed 34882435)</a></li>
<li><a href="https://www.acc.org/latest-in-cardiology/articles/2022/10/31/13/02/key-takeaways-from-the-2021-coronary-revascularization-guidelines">American College of Cardiology. Key takeaways from the 2021 coronary revascularization guidelines, 2022</a></li>
<li><a href="https://doi.org/10.1161/CIR.0000000000001309">Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. Circulation, 2025 (PubMed 40014670)</a></li>
<li><a href="https://doi.org/10.1056/NEJMoa1211585">Farkouh ME, et al. Strategies for multivessel revascularization in patients with diabetes (FREEDOM). N Engl J Med, 2012 (PubMed 23121323)</a></li>
<li><a href="https://doi.org/10.1056/NEJMoa1602001">Velazquez EJ, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy (STICH extension). N Engl J Med, 2016 (PubMed 27040723)</a></li>
<li><a href="https://doi.org/10.1056/NEJMoa1915922">Maron DJ, et al. Initial invasive or conservative strategy for stable coronary disease (ISCHEMIA). N Engl J Med, 2020 (PubMed 32227755)</a></li>
<li><a href="https://doi.org/10.1056/NEJMoa1710261">Thiele H, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock (CULPRIT-SHOCK). N Engl J Med, 2017 (PubMed 29083953)</a></li>
</ol>

<p><em>MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.</em></p>]]></content:encoded><media:content url="https://med-rise.com/images/shelf-prep/og/cabgvspci-photo.jpg" medium="image" type="image/jpeg"/></item></channel></rss>
